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resumo 
 
 
A doença de Alzheimer (DA) é uma desordem neurodegenerativa progressiva 
patologicamente caracterizada pela presença de placas de amilóide (placas 
senis) insolúveis e também pela presença de tranças neurofibrilhares,formadas 
pela proteína Tau hiperfosforiladada. O principal constituinte das placas senis 
é o peptídeo beta-amilóide (Aβ), que deriva do processamento proteolítico da 
proteína precursora de amilóide de Alzheimer (APP). Embora Aβ exista como 
um agregado pouco solúvel nas placas senis, ele é secretado pelas células 
como uma molécula solúvel. O Aβ “per se” pode afectar o metabolismo da 
APP. Alguns autores sugerem que o Aβ exerce o seu efeito alterando o 
processamento ou catabolismo da APP, outros sugerem que ele também induz 
a transcrição da APP, onde aumentando os níveis da APP pode estar a 
contribuir para a sua própria produção (mecanismo de “feedback” positivo). 
Assim sendo, torna-se difícil consolidar todas estas observações e identificar 
as potenciais funções fisiológicas do Aβ “in vivo”, ou as consequências da sua 
produção. Neste trabalho caracterizaram-se os efeitos do Aβ no metabolismo 
da APP. Os nossos estudos revelaram que um dos mecanismos induzidos 
pelo Aβ é a acumulação intracelular do fragmento neuroprotector sAPP 
(isAPPα) em estruturas com características vesiculares associadas ao 
citosqueleto. Estudos adicionais em culturas primárias revelaram que o Aβ 
estava a exercer o seu efeito ao nível da secreção vesicular, provavelmente 
interferindo com o transporte de APP/sAPP ao longo da rede do citosqueleto. 
Esta hipótese é sustentada pelo facto do Aβ estar a afectar a estabilidade e a 
polimerização de proteínas envolvidas na dinâmica do citosqueleto. 
Contrariamente a publicações anteriores o Aβ não induziu a transcrição da 
APP, na verdade em culturas primárias neuronais foi observado uma 
diminuição nos níveis de expressão da APP. Isto foi acompanhado por um 
aumento nos fragmentos C-terminais da APP (CTFs) e uma diminuição na 
localização nuclear do seu domínio intracelular (AICD), sugerindo alterações 
na sinalização nuclear da APP. O Aβ pode afectar outras vias de sinalização, 
particularmente alterando o balanço entre as actividades das proteínas cinases 
e fosfatases, o que pode ter consequências para o desenvolvimento da 
doença. Os dados obtidos indicam que o Aβ é capaz de inibir a actividade da 
proteína fosfatase1, a sua importância numa perspectiva de futuras terapias é 
discutida.  
Devido à relevância da agregação do Aβ para a sua toxicidade, a formação de 
complexos com proteínas que promovem a sua desagregação/degradação e o 
seu efeito no processamento da APP foi avaliado. Na presença destes 
complexos observou-se uma reversão da acumulação isAPP, demonstrando o 
potencial terapêutico destas proteínas como moduladores do metabolismo da 
APP. Este trabalho permitiu compreender melhor os mecanismos envolvidos 
nos efeitos do Aβ no processamento da APP e descobrir algumas moléculas 
que podem ser relevantes numa perspectiva de diagnóstico e terapia na DA. 
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abstract 
 
Alzheimer´s disease (AD) is a progressive neurodegenerative disorder 
pathologically characterized by the presence of extracellular deposition of 
insoluble amyloid plaques (senile plaques) and also by the appearance of 
neurofibrillary tangle-bearing neurons, mainly composed of 
hyperphosphorylated Tau protein. The major component of senile plaques is 
the amyloid-beta (Aβ) peptide, derived from proteolytic processing of the 
Alzheimer´s amyloid precursor protein (APP). Although Aβ exists as an 
aggregated, poorly soluble form in brain deposits, it is secreted from cells 
during normal metabolism as a soluble molecule. Aβ “per se” has been 
reported to affect APP metabolism, and while some authors suggest that it may 
exert its effects by altering APP processing/catabolism, others reported that it 
also induces APP transcription. This latter observation suggested a positive 
feedback mechanism resulting in increased APP levels, thus Aβ would 
stimulate its own production. Difficulties arise when trying to consolidate all 
these observations and to identify the potential “in vivo” physiological role of 
Aβ, or the consequences of its overproduction in AD. Hence, in this work we 
characterized the Aβ effects on APP metabolism. Our studies reveal that 
mechanistically Aβ leads to intracellular retention of the neuroprotective 
fragment (isAPPα) at vesicular-like densities associated with the cytoskeleton. 
Additional studies in primary neuronal cultures revealed that Aβ was exerting 
an inhibitory effect at the vesicular secretory level, probably by interfering with 
APP/sAPP transport along the cytoskeleton network. This hypothesis was 
supported by the fact that Aβ was affecting the stability and polymerization of 
proteins involved in cytoskeleton dynamics. Contrary to previous observations 
Aβ did not induce APP transcription. In fact for primary neuronal cultures we 
observed a decrease on APP expression levels. This was accompanied by an 
increase in APP C-terminal fragments (CTFs) and decreased APP intracellular 
domain (AICD) nuclear targeting, suggesting altered APP nuclear signaling. 
Aβ may affect other signaling cascades, for instance by altering the balance 
between kinase and phosphatase activities which may have consequences for 
the disease progression. Data obtained reveals that Aβ was able to inhibit 
protein phosphatase1 activity, and the importance of this for therapeutic 
approaches is discussed. 
Further, it is also known that Aβ aggregation state is associated with its 
neurotoxicity. Hence, Aβ complex formation with proteins that promote its 
disaggregation/clearance and its effect on APP processing was evaluated. 
These complexes reverse isAPP retention, thus demonstrating the therapeutic 
potential of these proteins as modulators of APP metabolism. The work in this 
thesis allowed for a better understanding of the molecular mechanisms 
underlying Aβ effects on APP metabolism and identified molecules relevant for 
diagnosis and therapy in AD. 
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OPENING REMARKS 
First described by the German pathologist Alois Alzheimer in 1906 (Alzheimer 1906), 
Alzheimer´s disease (AD) is a progressive neurodegenerative disorder that occurs 
predominantly in later life. The prevalence of the disease is below 1% in individuals aged 
60-64 years old but it rises abruptly with age, so that in people aged 75 years or older, 
prevalence is about 19% and up to 30% above 85 (Blennow et al. 2006; Lambert and 
Amouyel 2007). As life span is increasing there is the possibility that this elderly 
population may develop AD, which will constitute a major public-health problem. 
Therefore, it is of extreme importance to understand the basic nature of the disease, so 
that effective preventive procedures can be developed. The latest worldwide estimate of 
AD prevalence shows that 26.6 million people were living with the disease in 2006. 
Researchers predict that global prevalence will quadruple by 2050 to more than 100 
million, at which time 1 in 85 people worldwide will be living with the disease. 
AD is a progressive neurodegenerative dementia that invariably leads to a complete loss 
of all cognitive abilities and ultimately to death. Initially AD patients exhibit subtle memory 
failure which becomes more severe. The short-term memory begins to decline when the 
cells in the hippocampus degenerate. As the cerebral cortex (the outer layer of the brain) 
becomes affected, judgment declines, emotional outbursts may occur, and language is 
impaired. Progression of the disease leads to death of nerve cells and subsequent 
behavioural changes, such as wandering and agitation. Thus, in the later stages perception 
and orientation are affected as well as loss of personality and intellect to a level that 
influences daily activities. The ability to recognize faces and to communicate is completely 
lost in the final stages of the disease. Patients will eventually need constant care, complete 
dependency may last for years before the patient dies. The average length of time from 
diagnosis to death is 4 to 8 years, although neurodegeneration is estimated to start 20-30 
years before clinical symptoms become apparent (Bird 2007a). The overall lifetime risk of 
developing dementia is 10-12% (Goedert and Spillantini 2006). 
 
 
 
 
Aβ biology and its contribution to AD       Chapter I 
 
18       Centro Biologia Celular 
Universidade de Aveiro 
 
1.1 NEUROPATHOLOGICAL FEATURES OF AD 
AD is characterized by a variety of pathological features, including extracellular senile 
plaques and intracellular neurofibrillary tangles, synaptic loss, and brain atrophy (Selkoe 
2000; Hardy and Selkoe 2002; Forman et al. 2004). The characteristic brain atrophy and 
mass loss in AD patients is due to extensive neuronal damage and death. There is an 
overall shrinkage of brain tissue, with the most affected areas being the hippocampus, the 
cerebral cortex and amygdala, regions of the brain that play a major role in memory, 
cognition and behaviour. Widening of the sulcus and shrinkage of the gyrus, the well-
developed fold of the brain's outer layer, is evident. The ventricles, which are cavities or 
spaces in the brain that contain cerebrospinal fluid, are enlarged (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Normal versus Alzheimer´s brain. A. Brain volume reduction and atrophy characteristic of AD 
patients (right).  From www.cienciahoje.pt/index.php?oid=17362&op=all. B. Brain areas affected in AD patients. Images 
represent brain cross sections of a normal individual (left) and of an AD patient (right). The bottom three pictures 
represent brain shrinkage as AD continues to evolute. The arrows demonstrate shrinkage in the region of the brain 
associated with short term memories. Adapted from www.alzheimer.sk.ca/english/Just4Kids/alz_dis... 
Early   Middle      End 
Gyrus 
Sulcus 
Gyrus 
Sulcus 
Memory 
Language Language 
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Normal Alzheimer´s 
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The senile or neuritic plaques are mainly composed of Aβ (Allsop et al. 1983; Glenner 
and Wong 1984), while the neurofibrillary tangles (NFT) are intraneuronal bundles of 
paired helical filaments (PHF) consisting predominantly of hyperphosphorylated Tau 
protein (Goedert et al. 1992; Goedert et al. 1996) (Figure 2). While Aβ deposition is 
specific for AD, the NFTs are also seen in other degenerative disorders, but the 
coexistence of both lesions, along with cerebral atrophy and neuronal degeneration, are 
the conclusive hallmarks of the AD.  
 
 
 
 
 
 
 
 
                Senile plaques          NFT 
 
Figure 2. Signature lesions of AD. Plaques are extracellular deposits of Aβ surrounded by dystrophic neuritis, 
reactive astrocytes, and microglia, whereas neurofibrillary tangles (NFT) are intracellular aggregates composed of a 
hyperphosphorylated form of the microtubule-associated protein Tau. Bielschowsky silver stains (From 
www.neuropathologyweb.org/.../chapter9bAD.html). 
 
NFTs - Tangles occur at dystrophic neuritis (small dendrites and axons with degenerative 
changes), and are mainly found in the pyramidal regions of the amygdala, the hippocampus 
and the neocortex (Haroutunian et al. 1999; Oddo et al. 2003). NFTs consist of pyramidal 
cells filled with paired helical and straight filaments of aggregated hyperphosphorylated 
Tau. Tau is usually quite soluble and a key normal function of this protein is to bind to 
axonal microtubules to stabilize the axonal cytoskeleton framework. Tau is known to aid 
in cell microtubule assembly and stabilization, by promoting tubulin polymerization and 
reducing dynamic instability of the microtubule (Smith et al. 1996). This binding of Tau 
protein increases the rate of association at the end of the microtubule and decreases the 
rate of dissociation at the growing end (Goedert et al. 1997). It was also discovered that 
this protein can acts as a regulator of intracellular vesicles and organelle traffic, by 
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interacting with cytoskeletal proteins, such as actin which also aid in cytoskeletal 
maintenance and trafficking (Drewes et al. 1998; Drouet et al. 2000). The extent to which 
Tau promotes its activity depends on its phosphorylation state (Lindwall and Cole 1984), 
with abnormal hyperphosphorylation interfering with its normal biological function 
(Gustke et al. 1992; Alonso et al. 1994). Problems arise when Tau becomes 
hyperphosphorylated at serine and threonine residues of the protein by a still unclear 
mechanism (Tanaka et al. 2000). Hyperphosphorylated Tau protein loses its ability to bind 
tubulin and stabilize microtubule assembly (Drouet et al. 2000), leading to microtubule 
breakdown into PHFs and NFTs. Hence, abnormal Tau phosphorylation may contribute 
to the formation of NFTs resulting in neuronal degeneration (Higuchi et al. 2002b; 
Sorrentino and Bonavita 2007). 
 
Senile plaques - As already mentioned, another feature of AD brains are the neuritic 
plaques found distributed throughout the brain, but notably in the cerebral cortex and 
hippocampus of AD patients (Dickson 1997; Haroutunian et al. 1998). These plaques 
exhibit a central core of extracellular amyloid, surrounded of dystrophic neuritis, 
containing Tau aggregates (mostly in the straight filament form), and also reactive 
astrocytes and microglia, among other protein/peptides constituents. This central core is 
composed of aggregates of Aβ peptide of 40-43 amino acids (called Aβ1-40, Aβ1-42 and 
Aβ1-43). The Aβ1-40 peptides are most soluble and apparently less neurotoxic (majority of 
Aβ peptides), whereas the Aβ1-42 peptides are more hydrophobic (less soluble), and 
exhibit a higher potential for aggregation and neurotoxicity than does Aβ1-40. Although 
Aβ1-42 peptides are less prevalent, overall they predominate in the central core of the 
plaques (Jarrett and Lansbury 1992; Jarrett et al. 1993). Aβ deposition occurs as 
oligomeric, protofibrilar, amylospheroid and fibrillar forms (Kuo et al. 1996; Lambert et al. 
1998; Hartley et al. 1999; Walsh et al. 1999; Hoshi et al. 2003). The term “soluble Aβ” is 
generally applied either to newly generated, cell secreted Aβ, or to the fraction of tissue 
Aβ that is taken into the aqueous phase of a non-detergent-containing extraction buffer. 
“Misfolded” and “aggregated” Aβ are the terms used to describe very early, non-specific 
changes in Aβ folding states or solubility states, respectively. ”Oligomeric” Aβ refers to 
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peptide assemblies with limited stoichiometry (e.g. dimmers, trimers, etc.), while 
protofibrils (PFs) are structures of intermediates preceding biologically inert amyloid 
fibrils that are found in plaques. The term “Aβ-derived diffusible ligand” (ADDLs) is also 
applied to pre-protofibrillar intermediates (Figure 3). Indeed, oligomers, PFs and ADDLs 
are believed to be the Aβ assembly states with the most potent toxicity, being therefore 
the mediators of Aβ induced neurotoxicity (Klein et al. 2001; Kayed et al. 2004). The final 
assemblies, named fibrils, are the basic insoluble building blocks of the amyloid plaques. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Different assembly (biophysical) states of Aβ. The assembled forms obtained from incubation with 
synthetic Aβ are highly sensitive to preparation and incubation. Widely different proportions of insoluble fibrils (A), 
soluble PFs (B), and oligomers (C), also known as ADDLs are revealed by atomic force microscopy. Scale bars: 200 nm. 
(Adapted from Gandy, 2005).  
 
It has been hypothesized that the most dangerous Aβ form may be smaller groups of a 
“few pieces”, rather than the large plaques themselves. The small clumps are suggested to 
synapse signal and possibly trigger immune system inflammation. 
In addition to neuritic plaques, Aβ is also found in diffuse, non-fibrillar deposits, known as 
diffuse plaques, without accompanying dystrophic neuritis. Although these plaques may be 
found sometimes in large numbers in old, non-demented persons, and therefore not 
associated with dementia, they may also represent an early stage of AD plaques. 
Consistently, these plaques contain predominantly Aβ1-42 and small levels of Aβ1-43 rather 
than Aβ1-40 (Gowing et al. 1994; Iwatsubo et al. 1994; Iizuka et al. 1995; Iwatsubo et al. 
1995; Lemere et al. 1996). 
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Amyloid and NFTs - The unequivocal fact that both senile plaques and NFT are 
consistently found in the early-stages of the disease and increase as a function of disease 
severity have led a number of researchers to postulate a role for Aβ and Tau 
abnormalities in the pathogenesis of AD. Although it remains inconclusive whether Aβ or 
Tau initiates AD pathology, several evidences demonstrated that altered Aβ metabolism 
plays an essential role. Consistently, evidence points to amyloid deposition preceding and 
precipitating the formation of NFTs in some patients, with Aβ preceding Tau aggregation. 
In agreement with this, Tau deposition in transgenic mice is influenced by Aβ (Lewis et al. 
2001; Oddo et al. 2003). Further, in young Down’s syndrome patients, Aβ deposits exist 
in the absence of NFTs, notably in areas of the brain most affected by AD (Iwatsubo et al. 
1995; Leverenz and Raskind 1998; Gouras et al. 2000). On the other hand, a number of 
Tau mutations result in familial forms of non-AD neurodegenerative dementia (Higuchi et 
al. 2002a), and neuropathological investigations of AD brains have indicated that 
filamentous Tau aggregates are more closely related to neuronal loss than Aβ plaques 
(Arriagada et al. 1992; Cummings and Cotman 1995; Gomez-Isla et al. 1996). By inducing 
Tau abnormalities, which promote disruption of neuronal structure and function leading 
to neuronal death, Aβ peptide may be placed in the centre of a molecular cascade of 
events that contributes to AD pathogenesis. 
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1.2 AD CLINICAL DIAGNOSIS 
AD is usually diagnosed only after clinical symptoms, such as memory loss and confusion, 
become apparent, symptoms that in most cases develop after Aβ begins to accumulate in 
the brain, and even then a diagnosis cannot be conclusive. Indeed, AD can only be 
diagnosed with entire certainty by examining post-mortem brain. Nowadays physicians 
can use brain imaging such as MRI (magnetic ressonance imaging) techniques, alongside 
with developed cognitive tests in order to identify and document specific changes in the 
brain as early as possible. More recently, neuroimaging techniques, such as PET (positron 
emission tomography) have been developed (Figure 4). Using PET, an Alzheimer's-
predicting 18F-2-Fluoro-2deoxy-D-glucose (FDG)-PET scan, scientists can visualize and 
measure brain metabolic activity  and try to predict future AD development (Mosconi 
2005). Further, it is also possible to visualize Aβ inside the brain before the disease 
becomes debilitating, by using a chemical, named Pittsburgh Compound-B, or PIB for 
short, a novel PET biomarker. PIB can enter the brain in living humans, bind to the beta-
amyloid plaques, and be detected by PET (Klunk et al. 2004). This compound can help 
determine the efficacy of anti-amyloid drug therapies in clinical trials, and in the future, it 
may also be used as a diagnostic agent for AD. The development of molecular imaging 
agents for AD is critically important in early diagnosis, neuropathogenesis studies and 
treatment of AD.  
 
 
 
 
 
 
 
 
FDG 
 
 
Figure 4. PET an Alzheimer´s predicting technique. FDG-PET (left) and PIB-PET (right) images show the 
regional distribution of the rate of glucose metabolism and of the amount of Aβ petide in AD brains, respectively. FDG-
PET scans show the decline in metabolic activity in an Alzheimer’s brain (AD) compared to a normal brain (Control). 
Because active neurons have a very high metabolic rate, FDG uptake is high in brains of healthy subjects, especially in 
the cortex. In contrast, FDG uptake in AD is greatly diminished, especially in the temporal and parietal regions of the 
brain. From www.researchmagazine.uga.edu/.../ra_slime2.htm and http://www.sciencedaily.com/releases/2004/01/040122084019.htm. 
Control   AD                                  
FDG-PET 
 MR              PIB-PET                      PIB-PET              MR                                  
 Control   AD                                  
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1.3 AD SPORADIC AND GENETIC RISK FACTORS 
Several pathogenic mechanisms that underlie the changes observed in AD have been 
extensively studied, including Aβ aggregation and deposition with plaque development, tau 
hyperphosphorylation with tangle formation, neurovascular dysfunction, and other 
mechanisms such as cell-cycle abnormalities, inflammatory processes, mitochondrial 
dysfunction, and oxidative stress. However to date, none of the known mechanisms alone 
are sufficient to explain all the biochemical and pathological alterations observed in AD. 
Nonetheless, the cause-and-effect relationship between Aβ deposition and AD pathology 
is once again strongly supported by the discovery of genetic mutations that are causative 
of familiar AD. Indeed, all identified mutations greatly alter the metabolic processing of 
Alzheimer´s amyloid precursor protein (APP) and Aβ production, resulting in decreased 
clearance and increased accumulation of fibrillary Aβ in the brain (Hardy and Selkoe 2002; 
Tsubuki et al. 2003). 
From an etiological perspective AD forms have been characterized as sporadic or familial 
AD (FAD). FAD is considered when more that one person in a family has been affected, 
while sporadic refers to AD cases when no other cases in close family have been seen. 
Approximately 5% of all AD cases are associated to the familial form, with the remainder 
being sporadic (Bird 2007a). AD is further divided into early-onset (denotes onset of 
disease before age 65) and late-onset (denotes age onset after age 65). Most of the 
sporadic AD cases, which represent the vast majority, are late-onset. In most cases, AD is 
a complex multifactorial disease resulting from the interaction of several factors, principal 
genetic but also environmental. 
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1.3.1 Genetics of AD 
From a genetic standpoint, AD is a heterogeneous disorder, with a number of genes that 
may increase the risk of developing the disease. The most well-established genetics link is 
in familial early-onset AD cases. Although these only represent a small percentage of all 
AD cases, their molecular and genetic study allows for improved knowledge about the 
etiology of the more abundant sporadic forms, since increased Aβ production and 
accumulation is a common feature in all cases.  
 
Genes implicated in familial disease  
Three genetic loci have been linked to early onset inherited forms of the disease namely 
genes encoding for APP located on chromosome 21, presenilin-1 (PS1) on chromosome 
14 and presenilin-2 (PS2) on chromosome 1 (reviewed in Marambaud and Robakis, 2005). 
The APP gene encodes the APP which is normally cleaved to form Aβ. Within the APP 
gene twenty-three locations carrying mutations have been identified, however these only 
explain around 5-10% of familial early-onset cases (Bird 2007b). Although some of them 
are directly linked to AD, others are associated with cerebral haemorrhages (Figure 5 and 
see www.alzforum.org/res/com/mut/app). The first APP mutation discovered was Glu693 
to Gln (“Dutch” mutation) within the Aβ sequence (Hardy and Allsop 1991). Synthetic 
peptides containing this mutation were shown to have high propensity to aggregate 
(Wisniewski et al. 1991; Clements et al. 1993). Subsequently, some families with early 
onset AD were found to have pathogenic mutations at APP Val717, resulting in a change 
from Val717 to Ile, Gly or Phe (Chartier-Harlin et al. 1991; Goate et al. 1991; Murrell et al. 
1991). This mutation was called the “London” mutation. The “Swedish” double mutation 
(Lys/Met670 to Asn/Leu, on the immediate Aβ N-terminus) results in secretion of larger 
amounts of total Aβ (Citron et al. 1992; Mullan et al. 1992; Cai et al. 1993). A more 
recently discovered pathogenic mutation, named the APP “Arctic” mutation (Glu693 to 
Gly), leads to decreased Aβ1-40/1-42 levels in plasma and in cells conditioned media, but as a 
consequence a higher tendency of Aβ to aggregate. In fact, Aβ in the Arctic mutation, 
forms protofibrils at a much higher rate and in larger quantities than wild-type Aβ 
(Nilsberth et al. 2001). These mutations, all lye near or within the Aβ domain, result in 
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APP being more efficiently processed by secretases, thus generating increased amounts of 
Aβ that is more likely to form plaques (Citron et al. 1992; Cai et al. 1993; Haass et al. 
1995; Goedert and Spillantini 2006), thereby promoting amyloidogenesis.  
Further, the level of APP being expressed also appears to be an important aspect. For 
instance, in Down’s Syndrome, caused by trissomy of chromosome 21, there is an extra 
copy of the APP gene. These individuals show increased levels of Aβ and invariably 
develop plaques and tangles in their brains, with clinical dementia in many cases before 
the age of 50 (Tanzi et al. 1987; Selkoe 1997; Esler and Wolfe 2001).  
 
 
 
 
Figure 5. APP mutations lying near or in the Aβ domain. Location of the mutations within the fragment 
665-723 of APP is highlighted with a circle in the corresponding amino acid sequence (APP770 isoform numbering). 
The most frequent Aβ peptides (Aβ1-40 and Aβ1-42) extend from position 672 to amino acid 711 (for Aβ1-40) or 713 
(for Aβ1-42). Mutations indicated in green produce Alzheimer disease phenotypes; mutations notated in blue are 
primarily associated with cerebral amyloid angiopathy phenotypes. Mutations depicted in gray produce neither 
phenotype. Dutch mutation, the first APP mutation discovered, at position 22 of Aβ is highlighted in red. The gray 
box, spanning from positions 700 to 723, represents the location of the single transmembrane domain of APP. 
Adapted from www.nature.com/.../n9/fig_tab/nn0904-902_F1.html. 
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Mutations in the highly homologous PS1 and PS2 genes account for most cases of familial 
AD (Levy-Lahad et al. 1995; Sherrington et al. 1995). A total of 142 mutations have been 
found for PS1 in 281 families (www.alzforum.org/res/com/mut/pre/table1.asp), which 
represents the gene with highest number of pathogenic mutations for AD. For PS2 10 
mutations have been found in 16 families (www.alzforum.org/res/com/mut/pre/table2.asp). 
These genes encode for proteins that are involved in the normal cleavage of the APP 
protein, and mutations on these genes will result in increased Aβ1-42 production (Citron 
et al. 1997; Xia et al. 1997; De Strooper et al. 1998). In particular, PS1 participates in the 
catalytic core of γ-secretase complex and its mutations induce relative amounts of AβX-42 
peptides (Wolfe et al. 1999). Some PS2 mutations, like those of PS1, were functionally 
associated with increased production of AβX-42 peptides, while others did not modify 
either AβX-40 or AβX-42 peptide production (reviewed in Lambert and Amouyel, 2007). 
 
Genes implicated in sporadic disease 
Inheritance of ε4 allele of apolipoprotein E (APOE ε4) represents the greatest genetic risk 
factor in sporadic AD (Corder et al. 1993; Poirier 1994; Raber et al. 2004; Goedert and 
Spillantini 2006), although its mode of action in AD progression is unknown. The APOE ε4 
allele appears to operate mainly by modifying age onset (Meyer et al. 1998; Xiong et al. 
2005), with each allele copy lowering the age of onset by almost 10 years, suggesting that 
APOE ε4 association with AD may be related to longer disease duration in these cases 
(Basun et al. 1995). Further, there is no well described molecular mechanism underlying 
APOE ε4 as an increased risk factor for AD. It is known that APOE acts as a cholesterol 
transporter in the brain, with APOE ε4 being less efficient than the other variants in 
recycling membrane lipids and neuronal repair (Poirier 1994). On the other hand, APOE is 
essential for Aβ deposition, promoting Aβ aggregation and plaque formation (Holtzman et 
al. 2000; Holtzman 2001), possibly by acting as a pathological chaperone that binds to Aβ. 
Further, other genetic susceptibility factors have been proposed. Polymorphisms on genes 
encoding several proteins, including α2-macroglobulin, angiotensin I converting enzyme, 
Fe65 (Chapman et al. 1998; Alvarez et al. 1999; Kovacs 2000; Lambert et al. 2000), as well 
as some mitochondrial genetic polymorphisms (reviewed in Zhu et al. 2004) have been 
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associated with the disease. More recently, new susceptibility loci for late AD have been 
identified on chromosome 1, 9, 10, 12, and 13 (Bertram and Tanzi 2004). These risk 
factor genes are likely to affect one or more of the known pathogenic mechanisms (i.e. 
altered Aβ production, increased Aβ aggregation and inflammatory responses) which will 
result in decreased Aβ degradation/clearance and ultimately in neurodegeneration. 
 
Genetic screening of AD 
Genetic testing for the mutations associated with both familial and sporadic AD are 
available, although the circumstances under which testing is recommended differ. If there 
is suspicion of familial early-onset AD, genetic testing to detect gene mutations can and 
should be performed to identify the disease causing mutation and the molecular lesion 
(Bird 2007b). For APOE, and although a large number of patients with sporadic late-onset 
AD have at least one allele APOE ε4, the association of the mutation with the 
development of the disease is not strong enough to recommend that APOE genotyping be 
used as a predictive test in asymptomatic individuals. Instead APOE genotyping is most 
useful as an adjunct diagnostic test in individuals exhibiting symptoms of progressive 
dementia (Xiong et al. 2005; Bird 2007a). 
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1.3.2  Non-genetic factors contributing to sporadic AD 
For AD sporadic forms, besides aging, which is the most obvious risk factor, 
epidemiological studies have proposed several other putative contributing factors. Some 
can be linked to decreased reserve brain capacity (including reduced brain size and 
number of neurons and their synaptic and dendritic arborisation) due to for instance 
brain injury, low educational and occupational attainment, low mental ability in early life, 
and reduced mental and physical activity during late life (Mayeux 2003; Mortimer et al. 
2003; Jellinger 2004). Other risk factors are associated with vascular disease, including 
hypertension, hypercholesterolemia, atherosclerosis, coronary heart disease, smoking, 
obesity and diabetes (Mayeux 2003). Nonetheless is not clear if these are true causal risk 
factors that lead to the pathological features of the disease, or whether they induce 
cerebrovascular pathology that will add to the clinically silent disease pathology beyond 
the threshold for dementia. Evidence suggests that dietary intake of antioxidants, such as 
vitamin C and E; homocysteine-related vitamins (vitamin B12 and folate); unsaturated fatty 
acids; and also moderate alcohol intake, especially wine, could reduce the risk for AD 
(Luchsinger et al. 2007), but data so far does not support the recommendation of any 
specific diet for the prevention of AD. Although many environmental factors may increase 
the risk of developing sporadic AD, this form of the disease has been shown to have a 
significant genetic background.  
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1.4  A CENTRAL ROLE FOR Aβ IN AD NEURODEGENERATION 
The association of the pathogenic mutations with alterations in APP processing pathways 
that relatively increase Aβ1-42 production, together with the in vitro and in vivo observations 
of Aβ−induced neurotoxicity (for review see Canevari at al. 2004 and Smith et al. 2006) 
sustain that this peptide is at the heart of the disease process. These findings have lead to 
the proposal of the amyloid cascade hypothesis, which has been the basis of several 
research activities that have significantly contributed to the understanding of the 
molecular basis of AD (reviewed in Hardy 2006). In the cascade theory, Aβ is the central 
trigger for the pathological changes observed in AD brains, such as synapse loss, 
activation of inflammatory processes, the induction of NFTs and, ultimately, neuronal 
death. Therefore, all factors that can contribute to altered APP processing/metabolism 
resulting in increased Aβ production and/or aggregation, like APP and presinilin 
mutations, APOE ε4 allele, Trissomia 21, oxidative stress, environmental factors, and even 
normal aging will contribute to AD progression. 
 At the molecular cascade level diffuse amyloid deposits progress over time and eventually 
become neuritic plaques. One hypothesis is that deposition of Aβ1-42 may form a 
“precipitation core” to which soluble Aβ1-40 could aggregate, in an AD-specific process. 
The in vivo evolution of Aβ deposition and aggregation may trigger an oxidative 
inflammatory response that can be initiated due to the release of reactive oxygen 
intermediates, nitric oxide and inflammatory cytokines by activated microglia (Lukiw and 
Bazan 2000; Butterfield et al. 2001; Eikelenboom et al. 2008). Some of these pro-
inflammatory molecules may be locally toxic to neuronal processes in the vicinity of 
amyloid plaques. Further, the relative overproduction of this peptide may lead, first to 
neurofibrillary degeneration and then to neuronal death (Hardy 1997).  
The unequivocal involvement of Aβ in AD neurodegenerative process is summarized in 
the following figure.  
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Figure 6. Aβ involvement in the AD neurodegenerative process: the amyloid cascade 
hypothesis. It is likely that during the disease process the balance between Aβ production and Aβ catabolism 
is altered, which results in increased Aβ production/accumulation. Adapted from 
http://www.alzforum.org/res/adh/cur/knowntheamyloidcascade.asp. 
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Nonetheless, this hypothesis, often considered a dogma, has some limitations and other 
pathophysiological mechanisms, not necessarily exclusive, are still under study. These 
include, for example alterations in cell trafficking (Naruse et al. 1998) or neuronal calcium 
homeostasis induced by mutant presenilins (Schneider et al. 2001), and also oxidative 
stress (reviewed in Chauhan and Chauhan 2006 and Hamel et al. 2008). Corroborating 
the latter hypothesis is the observation that genetic mutations in AD have lead to 
increased cellular vulnerability to oxidative stress and apoptotic insults. It is still unclear 
whether mutations result in Aβ deposition that then cause oxidative stress, or whether 
mutations cause oxidative stress that result in Aβ deposition. Indeed, while some studies 
demonstrated that Aβ can directly cause oxidative stress others shows that the reverse is 
also true. Obviously, whether Aβ is the culprit, as argued by the amyloid cascade, or just 
a promoter factor that may culminate in neuronal death needs to be further investigated 
to advance our understanding and contribute to the design of efficacious therapeutics for 
this disease. 
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1.5  ALZHEIMER´S AMYLOID PRECURSOR PROTEIN (APP) 
1.5.1 APP gene family and alternatively spliced isoforms 
Aβ is constitutively secreted by both neuronal and non-neuronal mammalian cells into the 
extracellular fluid (Selkoe 1994b) and arises from the proteolytic processing of APP, an 
integral transmembrane glycoprotein containing a membrane-spanning domain towards its 
carboxyl-terminus (Kang et al. 1987). The mammalian APP superfamily comprises APP 
and APP-like proteins, known as APLP1 and APLP2 (Sprecher et al. 1993; Wasco et al. 
1993), of which APLP2 is the nearest relative (50% of homology). These three related 
proteins are well-conserved in evolution, functionally and structurally related, and share 
similar functions (Bayer et al. 1999; Coulson et al. 2000). The mammalian APP family 
members are type I integral membrane proteins that have relatively large extracellular 
domains and short intracellular domains. Of note is that APLP1 and APLP2 share 
homology at the amino acid sequence, domain structure and protein organization with 
APP, but lack the Aβ domain. Other known members of the APP superfamily are non-
mammalian and include APPL in Drosophila (Rosen et al. 1989; Luo et al. 1992), APL-1 in 
C. elegans (Daigle and Li 1993) and an APP homologue protein in Xenopus (Okado and 
Okamoto 1992). 
APP is encoded by a gene on chromosome 21 (21q21.3) and contains 18 exons (GenBank 
accession number D87675), with the Aβ sequence occurring between exons 16 and 17. 
Alternative post-transcriptional splicing of exons 7, 8 and 15 of the APP mRNA (Neve et 
al. 1988; Palmert et al. 1988; Koo et al. 1990b; Ohgami et al. 1993a; Sandbrink et al. 
1994b) produces different isoforms of this protein ranging from 365-770 amino acid 
residues that differ in size extracellularly, but share the same cytoplasmic, 
transmembranar and Aβ peptide sequences. At least eight isoforms of APP have been 
described (Figure 7), numbered according to their length in amino acids: L-677, 695, L-
696, 714, L-733, 751, L-752, 770 (Kitaguchi et al. 1988; Ponte et al. 1988).  
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Figure 7. APP isoforms resulting from alternative splicing of the APP gene. Alternatively spliced exons 
are indicated in colour: dark blue, exon 7; light blue, exon 8; orange, exon 15. The Aβ sequence lying in exon 16 
and 17 is indicated in red. Adapted from Sandbrink et al. 1994b. 
 
APP is ubiquitously expressed in mammalian cells with a broad tissue distribution (Tanzi 
et al. 1987; Neve et al. 1988; Tanzi et al. 1988; Weidemann et al. 1989; Golde et al. 1990; 
Sisodia and Price 1995). Analysis of APP mRNA expression levels revealed that APP can 
be detected in almost all tissues examined, as well as in cultured cells. The tissue-specific 
pattern of APP mRNA splicing was studied by RT-PCR analysis (Sandbrink et al. 1994a). 
The less abundant L-APP isoforms, lacking exon 15, are mainly expressed in leukocyte 
cells, such as T-lymphocytes, macrophages and microglial cells. They are also ubiquitously 
expressed in rat tissues, including brain, but not in neurons (Ohgami et al. 1993b; 
Sandbrink et al. 1994b).  
The three major isoforms expressed were found to be 695, 751 and 770 amino acids 
(APP695, APP751 and APP770, respectively). While the 751- and 770- amino acid spliced 
isoforms are predominantly expressed in peripheral tissues, the 695 is the APP isoform 
predominantly produced in the mammalian brain with the 695:751:770 mRNA ratios 
APP 770 
APP 751 
APP L-752 
APP L-733 
APP 714 
APP 695 
APP L-696 
1      2       3      4        5          6         7      8     9    10    11      12     13       14     15  16     17     18 
APP L-677 
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being approximately 20:10:1 (Neve et al. 1988; Konig et al. 1989; Tanaka et al. 1989; 
Kang and Muller-Hill 1990). The exon 7-containing isoforms also predominate in cultured 
astrocytes (Gray and Patel 1993a; Gray and Patel 1993b; Rohan de Silva et al. 1997), with 
the 695:751:770 ratio being 1:4:2 (Gray and Patel 1993a; Gray and Patel 1993b). APP695, 
lacking exon 7 and 8, is most highly expressed in neurons, representing 95% of total 
neuronal APP (Tanzi et al. 1987; Weidemann et al. 1989; LeBlanc et al. 1991), and is 
therefore often referred to as the “cerebral” or “neuronal” isoform. Due to APP695 
predominance in the brain and CNS (Neve et al. 1988; Tanzi et al. 1993), this isoform has 
received considerable attention in AD research. Additional studies have indicated that 
alternative splicing of exons 7 and 8 changes in brain during aging and with AD, but 
results obtained are still inconsistent and controversial to consider altered alternative 
splicing as an AD risk factor (Sandbrink et al. 1994a; Rockenstein et al. 1995; Moir et al. 
1998; Panegyres et al. 2000).  
  
1.5.2 APP functional domains 
The APP exon 7 encodes a 56 amino acid (aa) Kunitz-type serine protease inhibitor (KPI) 
domain, which inhibits proteases, such as trypsin or plasmin, and blood coagulation 
factors (Van Nostrand and Cunningham 1987; Kitaguchi et al. 1988; Ponte et al. 1988; 
Tanzi et al. 1988; Wagner et al. 1992) and thus may regulate the degradation of APP 
(Edelberg and Wei 1996). Exon 8 encodes a 19 aa domain with homologies to the MRC 
OX-2 antigen found on the surface of neurons and certain cells involved in the immune 
response such as thymocytes (Clark et al. 1985). Besides KPI and OX-2, several other 
structural domains have been identified within APP (Figure 8 and Reinhard et al. 2005). 
Several heparin-binding domains (Small et al. 1994), a collagen-binding site (Beher et al. 
1996), an integrin-binding motif (amino acid sequence RHDS, Ghiso et al. 1992) and N-
linked carbohydrate attachment sites (Weidemann et al. 1989) were also found in this 
region. Consistently, APP has been shown to bind heparin (Mok et al. 1997), collagen 
(Beher et al. 1996), and laminin (Kibbey et al. 1993). Additionally, two subdomains (328-
332 and 444-612) were presumed to have a neuroprotective function, including the 
“RERMS” sequence with putative growth-promoting properties (Ninomiya et al. 1993). 
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The APP ectodomain also contains binding-sites for metals such as zinc (Bush et al. 1993; 
Bush et al. 1994) and copper (Hesse et al. 1994; Multhaup et al. 1996; Barnham et al. 
2003) in the APP N-terminal but also within the Aβ domain. The C-terminus can be 
cleaved to release the APP intracellular domain (AICD). Almost all known APP binding 
proteins bind at its C-terminus, and specifically at one of two APP domains: YTSI and 
YENPTY. The latter is highly conserved from nematodes to humans, and has been shown 
to be responsible for several protein-protein interactions. Several intracellular proteins 
have been shown to bind to this domain including Fe65 (a phosphotyrosine binding 
domain-containing protein), X11 also known as LIN-10 or MINT (Munc-18-interacting 
protein), Dab1 (disabled homolog 1) and JIP-1b. Interacting proteins for YTSI domain 
included APP-BP1 (APP-binding protein 1), the microtubule associated protein PAT1 
(protein interacting with APP tail 1), and kinesin-I (an axonal transport protein) (De 
Strooper and Annaert 2000; Van Gassen et al. 2000; King and Scott Turner 2004). 
Another domain, VTPEER, has not been implicated so far in APP binding to other 
proteins, but it includes a G0 binding sequence. These intracellular domains can be 
classified according to their attributed functions and are thought to be involved in 
regulating APP rate of secretion, endocytosis, and Aβ production (Ando et al. 1999; Iijima 
et al. 2000; Mueller et al. 2000; Ando et al. 2001; Sabo et al. 2001; Roncarati et al. 2002). 
 
 
 
 
 
 
Figure 8. APP functional domains. Yellow, signal peptide (1-17); light blue, heparin-binding domains (28-123; 174-
185; 391-412); brown, copper-binding domain (135-155); violet, zinc-binding domain (181-188); pink, KPI domain; grey, 
OX-2 domain; “RERMS”, putative growth-promoting motif (403-407); orange, gelateinase A (matrix metalloproteinase) 
inhibitor (407-417); green, collagen-binding site (523-540); red, Aβ; “RHDS”, integrin-binding motif (aa 5-8 of Aβ); 
heparin-binding motif “VHHQK” (aa 12-16 of Aβ); dark Blue, APP intracellular domain (AICD) which include YTSI, 
YENPTY, VTPEER. APP770 isoform numbering. TM, transmembrane domain. 
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1.5.3  Putative functions for APP and APP cleaved fragments 
The overall physiological function of APP has not yet been definitively determined but due 
to the structures and the specific characteristics of its domains several APP putative 
functions have been attributed and considered valid. These include cell surface receptor, 
cell adhesion molecule, precursor to growth factor and regulator of neuronal copper 
homeostasis. Besides that, other functions arise from many in vitro and in vivo studies 
which evaluated the involvement of APP and APP fragments resulting from APP 
processing (see section 1.5.4). These include neurotoxicity, neuritic outgrowth, 
synaptogenesis, involvement in learning and memory processes, and in cell signaling (for 
review see Zheng and Koo 2006; Senechal et al. 2006; Reinhard et al. 2005). 
 
APP as a receptor molecule 
Due to the type I integral membrane structure and due to it binding site to G0 protein, via 
the intracellular tail, it has been suggested that APP might function as a cell surface G-
protein coupled receptor (Kang et al. 1987; Okamoto et al. 1995). G0 is a major GTP 
binding protein in brain involved in signal transduction cascades, such as adenylyl cyclase 
(Carter and Medzihradsky 1993), phospholipase C (Moriarty et al. 1990), voltage-
dependent calcium channels (Hescheler et al. 1987) and pathways for apoptosis 
(Giambarella et al. 1997). Therefore, the activation of APP may contribute to one or 
more of these cascades, although the exact downstream mechanisms involving G0 
activation or inhibition by APP are unknown. Additionally, the analogy of the secondary 
structures and proteolytic processing profile between APP and Notch is also consistent 
with APP functioning as a cell surface receptor similar to Notch (Selkoe and Kopan 2003). 
Fibrillar forms of Aβ were reported to bind cell surface APP (Lorenzo et al. 2000), and 
Nogo-66 receptor was also shown to interact with the APP ectodomain, interaction 
which affects Aβ production (Park et al. 2006). Further evidence came from the Ho and 
Sudhof (2004) study, which demonstrated that the APP extracellular domain binds to 
F-spondin, a neuronally secreted glycoprotein, and that this interaction regulates APP 
cleavage and subsequent Aβ production and downstream signaling. More recently, Ma et 
al. (2008) identified TAG1 (a GPI-linked recognition molecule of CNS) as a functional 
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ligand for APP, and suggested that this TAG1–APP signaling pathway was involved in the 
modulation of neurogenesis.  
 
APP involvement in cell adhesion  
Convincing data places APP as a CAM (cell adhesion molecule) and SAM (subtrate 
adhesion molecule). Neuronal CAMs play an important role in neuronal plasticity and 
thus learning and memory processes may be closely linked to CAM function and any 
disruption in CAM interactions may have potential neuropathological consequences 
(Cotman et al. 1998). Cell surface APP has been described to enhance neuronal cell 
adhesion and neurite outgrowth (Breen et al. 1991). APP possesses several ectodomains 
(Figure 8) that promote binding to specific substrates such as heparin, collagen and 
laminin (extracellular matrix components), supporting its role in cell-substratum adhesion. 
The same sequences have been shown to be involved in cell-cell interactions. “RHDS” 
motif (Figure 8) within the Aβ sequence appears to also promote cell adhesion. In 
particular, cell surface APP has been recently reported to trans-interact with other APP 
(or APLP) molecules by homo- or hetero-dimer formation at the surface of adjacent cells, 
and that these trans-dimerizations promote trans-cellular adhesion in vivo (Soba et al. 
2005). Furthermore, down-regulation of APP using antisense oligonucleotides also 
reduced neuronal adhesion to specific substrata, and APP overexpression in the neuronal-
like B103 cells led to more rapid cellular adhesion (Schubert et al. 1993). Moreover, 
fibroblasts from FAD patients that were observed to have down-regulated APP mRNA 
levels, presented decreased cellular adhesiveness (Ueda et al. 1989), and Hep-1 cells 
expressing an APP FAD mutant cDNA also exhibited decreased cell adhesion properties 
(Kusiak et al. 2001).  
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APP and cell motility regulation  
Via its intracellular domain APP can bind several proteins, including the adapter protein 
Fe65. The latter binds a second protein, MENA, which is a cytoskeletal protein expressed 
in active actin remodelling areas such as axonal growth cones. In H4 neuroglioma and 
MDCK cells, Fe65 has been found associated with MENA in active actin areas. The 
functional role of this ternary complex was documented in non-neuronal cells, in which 
co-expression of APP and Fe65 drastically increases cell motility, and this process appears 
to be partially dependent on the MENA/actin complex (Sabo et al. 2001). Subsequent 
analysis from the same group showed that in primary neurons, the APP and Fe65 complex 
is localized to the dynamic adhesion sites (actin-rich sites) in the growth cone (Sabo et al. 
2003). Taken together these data supports a role for APP/Fe65 complex in cell motility 
and growth cone dynamics.  
 
APP and sAPPα have a role in neurite outgrowth and synaptogenesis 
This function is probably the most consistent and well documented since several 
overexpression and downregulation studies have addressed this issue. Neurotrophic and 
synaptogenic roles have been attributed to both APP and sAPPα (APP secreted fragment 
resulting from α-secretase cleavage, see section 1.5.4). As such APP may exert these 
activities in both an autocrine and a paracrine mode. APP is expressed at neuronal 
synapses and exhibits widespread expression in vesicular structures of cell bodies, axons 
and dendrites. It undergoes rapid anterograde transport and is targeted to the synaptic 
sites (Koo et al. 1990a; Sisodia et al. 1993; Yamazaki et al. 1995). During neuronal 
maturation and development APP expression has been described to be upregulated (Hung 
et al. 1992; Bibel et al. 2004), and correlated with periods of intense neuritic outgrowth 
and synaptogenesis (Loffler and Huber 1992; Moya et al. 1994). Moreover, cultured 
hippocampal neurons derived from APP knockout (KO) mice exhibit both reduced 
viability and neuritic outgrowth (Perez et al. 1997). Other studies directly demonstrated 
the importance of sAPPα (lacking APP C-terminal domain) in these functions. In vivo 
application of sAPPα causes neurite outgrowth in cultured fibroblasts (Saitoh et al. 1989; 
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Bhasin et al. 1991), PC12 cells (Milward et al. 1992), cortical and hippocampal neuronal 
cells (Araki et al. 1991; Qiu et al. 1995; Ohsawa et al. 1997) and human neuroblastoma 
cell lines (Wang et al. 2004). More recently, studies in mice overexpressing ADAM-10 (a 
secretase involved in APP cleavage to sAPPα) and perfused with exogenous sAPPα, were 
shown to present neurotrophic effects on cortical synaptogenesis (Bell et al. 2008). Of 
interest, the pentapeptide sequence “RERMS” located C-terminal to the KPI and OX-2 
domains (Figure 8) was identified as the site responsible for the growth-promoting 
trophic role of sAPP (Ninomiya et al. 1993). Infusion of this peptide or sAPP into brain 
animals resulted in improved memory and increased synaptic density (Roch et al. 1994; 
Meziane et al. 1998). Further, neurotrophic and neuroprotective effects are induced by 
sAPPα approximately 100 times more strongly than by sAPPβ (resulting upon APP 
cleavage by β-secretase, section 1.5.4). Indeed, Li and colleagues (1997) showed that 
sAPPβ lowered neurite outgrowth below control levels. Although the conserved regions 
of both proteins contain domains that have been associated with these functional effects 
(such as “RERMS” region), the difference between these sAPP effects seems to subsist in 
their C-terminal region, where sAPPα contain 17 more aminoacids. This region of sAPPα 
contains a heparin-binding domain (“VHHQK” residues 12-16 of Aβ), that is lacking in 
sAPPβ, and appears to play a key role in mediating the neurotrophic effects (Furukawa et 
al. 1996). 
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APP, sAPP and Aβ functions in memory  
APP appears to have an important role in the regulation of synaptic structure and 
neuronal function. Sequence-specific antibodies were used to block protein function and 
antisense oligonucleotides to prevent APP translation. APP association with improving 
memory was supported by studies were infusion of “RERMS” sequence rescued amnesia 
that was induced by anti-APP antibodies (Mileusnic et al. 2000). Additionally, 
intraventricular injection of anti-N-terminal APP antibodies (for example delivery of the 
22C11 antibody targeting the N-terminal part of APP) in rat, close to the training period, 
has been shown to result in an impairment of rat memory in a passive avoidance task 
(Doyle et al. 1990; Huber et al. 1993; Gschwind et al. 1996; Turner et al. 2003). In the 
case of APP-null mutations, mice show a variety of alterations in neuronal structure and 
function, including gliosis, decreased neocortical and hippocampal levels of synaptophysin, 
reduced dendritic length in hippocampal neurons, reduced survival of cultured neurons 
and impaired long-term potentiation (LTP) (Perez et al., 1997; Dawson et al., 1999; 
Chapman et al., 1999; Seabrook et al., 1999; but see Phinney et al., 1999). However these 
effects could also be due to the loss of the neurotrophic sAPPα fragment. Consistently, 
exposure of hippocampal slices to sAPPα results in raising the threshold for long term 
depression (LTD) but facilitating LTP (Ishida et al. 1997) thus changing synaptic efficacy. 
Since memories are believed to be stored within synapses, LTP and its opposing process, 
LTD, are widely considered the major cellular mechanisms underlie learning and memory 
(Cooke and Bliss 2006).  
Contrary to APP or sAPPα effects, Aβ peptide has been associated with synaptic 
dysfunction and inhibition of LTP (Cullen et al. 1997; Lambert et al. 1998; Hsia et al. 1999; 
Walsh et al. 2002a; Raymond et al. 2003; Turner et al. 2003), although downstream 
mechanisms are not well understood. Further, studies in transgenic mice models of AD 
have shown that Aβ immunization reduces plaque deposition and improves cognitive 
function (Bard et al. 2000; Lombardo et al. 2003; Oddo et al. 2004; Brendza et al. 2005; 
Buttini et al. 2005). All these data strengthen a role for APP and APP proteolytic 
fragments in learning and memory processes. 
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APP and sAPP involvement in brain repair and neuroprotection 
Several studies have provided evidence that APP plays a role in the repair of adult brain 
following trauma. In fact, APP has been reported to be upregulated in response to 
neuronal injury and damage (Siman et al. 1989; Gentleman et al. 1993; Struble et al. 1998). 
Up-regulation of APP in response to neuronal injury appears to promote axonal 
arborization (Leyssen et al. 2005). Perez et al. (1997) showed that APP-deficient neurons 
exhibited shorter axons and branching processes. These effects were rescued when 
hippocampal neurons from APP-deficient mice were co-cultured with wild-type 
astrocytes, suggesting that APP contribute to axon and dendritic outgrowth and 
arborization. Consistent with a possible role for APP in axonal repair mechanisms, 
following traumatic brain injury in vivo administration of sAPPα has been shown to 
improve functional outcome and to reduce neuronal apoptosis and axonal injury 
(Thornton et al. 2006).  
Metal ions such as copper are essential in brain, since it is an essential cofactor of 
oxidoreductive enzymes, including superoxide dismutase that is involved in cellular 
protection induced by oxidative stress. APP structure harbours several metal-binding 
domains for copper (Figure 8), in agreement with an APP involvement in the transport of 
this metal into the brain. Studies using APP KO mice have shown increased copper levels 
in the cerebral cortex, supporting a possible physiological role for APP in modulating 
copper neuronal homeostasis in vivo (White et al. 1999; Bayer and Multhaup 2005; 
Inestrosa et al. 2005; Maynard et al. 2005).  
sAPP secreted fragment has also been implicated in neuroprotection (reviewed in 
Mattson 1997), including against Aβ effects and induced apoptosis. Stimulation of sAPPα 
secretion results in protective effects against Aβ-induced neurotoxicity (Levites et al. 
2003). Also, in human keratinocytes, Wehner and colleagues (2004) have shown that at a 
nanomolar range sAPPα was able to protect these cells against induced apoptosis. 
Further, sAPPα was shown to increase expression levels of several neuroprotective genes 
and protect against Aβ induced-tau phosphorylation and neuronal death (Stein et al. 
2004). Further, the APP N-terminal heparin binding domain was also reported to display a 
neuroprotective function (Small et al. 1999). Hence, it is clearly evident that 
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sAPPα fragments play a key role in neuroprotection and factors contributing to its 
decreased production or secretion will result in neuronal toxicity and death. 
 
Aβ and CTF contribution to neurotoxicity and apoptosis 
Several authors suggest that Aβ is at the heart of AD being either directly or indirectly 
responsible for the pathological mechanisms and altered cellular responses that culminate 
in the disease (Figure 6). This theory is supported by several studies where Aβ was 
shown to be toxic to various cultured cell types (Walsh et al. 2002b; Smith et al. 2006), 
and also to have long-term effects when injected directly into the brain (McKee et al. 
1998). Of note is that Aβ is found in a variety of forms and aggregation states which affect 
its neurotoxic properties. Soluble oligomeric forms can produce sub-toxic effects on 
neuronal function (Klein et al. 2001; Walsh and Selkoe 2004), and the more extensively 
aggregated forms (fibrilar Aβ) have also been show to be potent neurotoxins able to 
impair neuronal function (Selkoe 1994a; Klein 2002). Both forms are usually present at 
the same time in brain, making it difficult to evaluate the effects of plaques and oligomers 
independently. Hence, debate arises regarding which Aβ state is more toxic, the soluble 
or the more aggregated one (Lue et al. 1999; Watson et al. 2005). Although initial fibrilar 
amyloid aggregates were considered the main neurotoxic forms, currently it is proposed 
that soluble olygomeric pools may be more important in synaptic dysfunction and 
consequent memory loss (Lue et al. 1999; McLean et al. 1999). It has been reported that 
gross amyloid deposition, although contributing to AD pathology, may be less toxic and, 
at least initially, does not impair memory (Walsh and Selkoe 2004; Lesne et al. 2008). 
Mechanisms underlying Aβ toxicity include mitochondrial dysfunction (reviewed in Chen 
and Yan 2007), disruption of calcium homeostasis, altered energy metabolism, and 
production of reactive oxygen species (ROS) that results in increased oxidative stress 
(reviewed in Chauhan and Chauhan 2006 and Hamel et al. 2008). Oxidative stress, 
induced by Aβ or other factors, can trigger apoptosis associated events, activating 
caspases or increasing expression of apoptotic related proteins. Concordantly, it has been 
demonstrated that Aβ1-42 is toxic to human neurons through activation of p53 and Bax 
proapoptotic pathway (Zhang et al. 2002; Ohyagi et al. 2005).  
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Other potential mechanisms may contribute to neurotoxicity, including secretase cleavage 
to release both CTFs and AICD (section 1.5.4). CTFs have been associated with impaired 
calcium homeostasis and learning and memory through blocking LTP and overexpression 
of CTFs has the potential to elicit neurodegeneration in vivo (Sato et al. 1997; Kim et al. 
2004; Chang and Suh 2005).  
 
Signal transduction and AICD transcriptional regulation  
Several groups have suggested the generation of signaling proteins by “regulated 
intramembrane proteolysis” (RIP) as a new paradigm of signal transduction. RIP occurs 
when a transmembrane protein is cleaved within the transmembrane domain, releasing an 
intracellular fragment that can act directly in the nucleus to activate gene expression. This 
occurs in two steps. Cleavage of the protein outside the membrane (usually in response 
to ligand binding) results in a conformational change, which in turn triggers a second 
intramembrane cleavage event that releases an active cytoplasmic fragment. The latter is 
able to translocate to the nucleus and activate gene expression (Ebinu and Yankner 2002). 
Consistently, following intramembranous γ-secretase cleavage, the APP intracellular 
domain (AICD) is released into the cytoplasm and tends to relocalize to the nucleus 
(Cupers et al. 2001b; Kimberly et al. 2001; Kinoshita et al. 2002) where it can function as 
a transcriptional regulator. AICD is very labile but it can be stabilized by the adaptor 
protein Fe65 (Kimberly et al. 2001). Additionally, Cao and Sudhof (2001) demonstrated 
that Fe65 can bind to a transcriptionally relevant protein, Tip60, which is a histone 
deacetylase enzyme that is involved in regulating chromosome structure and consequent 
gene expression (Kimura and Horikoshi 1998).  
AICD is shown to form a transcriptionally active complex presumably in the nucleus 
together with Fe65 and Tip60 (Cao and Sudhof 2001), although AICD can bind Tip60, 
apparently independently of Fe65 (Kinoshita et al. 2002) also inducing gene expression. 
However, the nature of how AICD leads to activation of signaling pathways is unclear. 
More Recently, Cao and Sudhof (2004) showed that nuclear translocation of AICD is not 
required but may be indirect through Fe65 (Figure 9).  
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Figure 9. Cao and Sudhof proposed model for APP transcriptional activation. 
From Cao and Sudhof 2004. 
 
In this model the proposed AICD role in the transactivation process consists in activating 
Fe65, via conformational changes, for nuclear binding with Tip60. AICD binding to Fe65 at 
its PTB2 domain would disrupt Fe65 PTB2-WW intradomain binding, thus altering Fe65 
initially closed conformation. The “primed” Fe65 open conformation will make available 
the Fe65 WW domain for its transactivator role upon nuclear translocation. Hass and 
Yankner (2005) also reported that AICD production is not required for the nuclear 
signaling activity as it proceeds normally even in the presence of γ-secretase/PS inhibitor 
treatment. 
Finally, while some authors documented that the proposed signaling activity is executed 
by Fe65 and that APP is not required (Yang et al. 2006), others suggest that 
phosphorylation of APP at threonine 668 (Thr668, located in the 667VTPEER672 APP motif) 
residue is required for Fe65-dependent gene transactivation (Nakaya and Suzuki 2006). In 
the latter study phosphorylation of APP liberated membrane-bound Fe65 allowing it to be 
translocated into the nucleus where it up-regulates gene transactivation, while AICD 
nuclear translocation does not required phosphorylation of this APP residue. Therefore, 
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phosphorylation of APP, but not AICD, modulates Fe65-dependent gene transactivation 
by AICD by regulating Fe65 intracellular localization. 
Despite the controversy around the potential nuclear signaling activity, the trans-
activating role of the APP/Tip60/Fe65 complex has been well documented, at least in 
overexpressing systems. Several downstream targets for AICD dependent gene regulation 
have been identified including, neprilysin, a neuronal endopeptidase with Aβ degrading 
activity (Pardossi-Piquard et al. 2005); KAI1, a tumor suppressor gene also thought to be 
involved in membrane receptor function regulation; glycogen synthase kinase-3β (GSK3β), 
a kinase involved in Tau phosphorylation; Tip60; BACE, a secretase involved in APP 
processing; APP itself (reviewed in von Rotz et al., 2004); and alpha2-actin and transgelin, 
known to be involved in the organization and dynamics of actin cytoskeleton (Muller et al. 
2007). A different AICD-containing complex, with Fe65 and the ternary complex 
CP2/LSF/LBP1, was also found to promote the expression of the GSK-3β (Kim et al. 
2003). The regulation of both alpha2-actin and transgelin genes appears to be of relevance 
since cytoskeleton organization changes have been reported in AD brains (Pollak et al. 
2003), but this will be further discussed. AICD transcriptional up-regulation of neprilysin, 
APP and BACE is of particular interest because it suggests that AICD release may regulate 
Aβ degradation (by increasing neprilysin expression) or production, in the latter case 
either by increasing APP substrate for secretases or by increasing amyloidogenic 
processing of APP by BACE (Kerr and Small 2005).  
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Aβ physiological concentration and physiological function 
During the disease process the balance between Aβ production and Aβ catabolism is 
altered which results in increased Aβ accumulation and aggregation and subsequent 
neurotoxicity and neuronal death in specific brains areas. In AD brains soluble and 
insoluble Aβ1-40 and Aβ1-42 concentrations were in general drastically increased, by 100-fold 
in superior frontal gyrus (thought to contribute to cognitive functions and memory) and 
by more than 50-fold in entorhinal cortex (important memory center in brain), when 
compared to non-demented patients (Lue et al. 1999). For instance, in entorhinal cortex 
insoluble Aβ1-40 concentrations were around 0.8 µg/g for the non-demented (ND) group 
versus 53.7 µg/g for the AD group, and insoluble Aβ1-42 concentrations were 8.3 µg/g 
versus 117.3 µg/g, respectively. Concentrations of soluble Aβ1-40 forms were around 1.9 
pg/g in ND and 66.5 pg/g in AD cases, while for Aβ1-42 they were 0 pg/g and 15.5 pg/g, 
respectively. In the same study CSF concentrations obtained for ND was 232.4 pg/ml and 
162.9 pg/ml for AD. Consistently, in AD CSF soluble Aβ42/40 ratio is decreased probably 
reflecting amyloid accumulation in brain blood vessels (Pirttila et al. 1996; Hock et al. 
1998; Wiltfang et al. 2007).  
Despite its altered production and accumulation in AD, Aβ is a naturally occurring 
peptide produced at low levels during normal APP metabolism (Haass et al. 1992), not 
only in CSF but also in brain. These data suggest that it may play a role in normal cell 
function, that may differ from it neurotoxic effects when is levels are elevated in AD. 
These peptides form a heterogeneous group of 38–43 amino acids in length, whereby 
Aβ1–40 clearly predominates. Under physiological conditions, the fraction of Aβ1-42 is only 
10% of the total fraction (Haass et al. 1992b; Seubert et al. 1992). 
Aβ is likely to have an important physiological role given that in primary neuronal cultures 
inhibition of endogenous Aβ production by secretase inhibitors induced neuronal 
apoptosis, and co-incubation of Aβ1-40 with these inhibitors prevented this apoptotic effect 
(Plant et al. 2003). This effect appears to be neuron-specific since a variety of non-
neuronal cells were unaffected by the same treatments. Some neurotrophic properties 
have also been attributed to this peptide (Tanimukai et al. 2002; Atwood et al. 2003).  
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Further, several lines of evidence indicate that Aβ may play a role in controlling synaptic 
plasticity. Kamenetz et al. (2003) showed that neuronal activity modulates the formation 
and secretion of Aβ peptides in neurons that overexpress APP. In turn, Aβ selectively 
depresses excitatory synaptic transmission onto neurons that overexpress APP. Hence, at 
physiological levels of APP, Aβ may provide a negative feedback. Without such 
depression, synaptic activity could become excessive, leading to excitotoxicity (reviewed 
in Pearson and Peers 2006). The underlying mechanisms still have to be clarified but it 
may involve inhibition of NMDA receptor mediated currents (Chen et al. 2002) or 
altered K+ channel expression (Kamenetz et al. 2003). K+ channels activity have been 
implicated in neuronal survival or death, in part because they govern excitability and 
hence the excitotoxicity of released glutamate, but also because cellular [K+] is a key 
determinant in apoptosis (Yu 2003). It would be predictable from these findings that APP 
KO transgenic animals show severe neurological deficits and lethality, but this is not the 
case. APP-null mice show reduced branching of dendrites and fewer synaptic buttons but 
no reduction in neuronal number despite an absence of Aβ (Dawson et al. 1999).  
Despite these in vivo observations, cell culture findings provided compelling evidence for 
an Aβ role in neuronal survival, at least at physiological levels. Hence, Aβ should not be 
regarded as a mere toxic factor that should be eradicated in order to avoid dementia. 
Therefore it is of extreme importance to understand the molecular mechanism 
underlying Aβ effects not only at physiological low levels but also at higher levels, in 
attempt to prevent Aβ neurotoxic and apoptotic effects.  
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1.5.4 APP proteolytic processing and Aβ genesis 
APP metabolism is complex and can occur via several pathways (Nitsch et al. 1994; 
Checler 1995; Buxbaum and Greengard 1996; Selkoe et al. 1996) which have not been 
fully elucidated. In its simplest form APP processing can be described as occurring at least 
via two distinct pathways which differ in the proteases involved and in the resulting 
fragments generated (Figure 10 and Figure 11). These pathways are often referred as the 
non-amyloidogenic and the amyloidogenic pathways; the former precludes Aβ formation 
and the latter gives rise to the amyloidogenic peptide (Small and McLean 1999; Nunan and 
Small 2000; Sabo et al. 2001). APP proteolytic cleavage involves catalytic activity of three 
proteinases, termed α-, β- or γ-secretases, at specific sites (Esler and Wolfe 2001).  
In the non-amyloidogenic pathway cleavage by α-secretase within the Aβ domain (Lys16, 
also corresponding to α-site in Figure 11) results in the release of nearly the entire 
ectodomain, yielding a 612 amino acid long soluble APP derivate, sAPPα (Esch et al. 1990; 
Busciglio et al. 1993), and generation of membrane-associated 83 amino acid long C-
terminal fragment (CTFα, with ~10 KDa). The latter is in turn processed by the γ-
secretase to generate the so-called P3 peptide (3 KDa) and the APP intracellular domain 
(AICD, also referred to CTFγ). Alternatively, in the APP amyloidogenic pathway β-
secretase cleavage (Figure 10) also results in the formation of a 595 amino acid long N-
terminal fragment which is released from membrane (sAPPβ) and a membrane-bound 99 
amino acid long C-terminal derivative (named CTFβ with ~12 KDa). Following 
extracellular cleavage CTFβ is processed by γ-secretase within transmembrane domain, 
releasing the Aβ peptide and generating the 59/57 amino acid long AICD (with ~4 KDa). 
Of note is that γ-secretase cleavage may generate different Aβ species. CTFβ may be 
processed by γ-secretase (Younkin 1998; Xu et al. 2002) to generate predominantly Aβ1-40 
(~90%) or Aβ1-42 (~10%) peptides (Haass et al. 1992b; Seubert et al. 1992). Aβ species 
spanning from 1-38 to 1-43 amino acids long can also be produced, with fragments 
appearing to be more amyloidogenic with increasing length. 
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Figure 10. Schematic diagram of APP proteolytic processing. In its simplest form APP processing 
occurs via two distinct proteolytic pathways. One is known as the non-amyloidogenic pathway (left), precludes 
Aβ formation and involves sequential α- and γ-sectarese cleavage. The other is known as the amyloidogenic 
pathway (right) because it gives rise to Aβ production and involves β- and γ-secretase cleavage.  TM, 
transmembrane domain. Aβ domain is highlighted in red. 
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Sequence analysis of the AICD fragment showed that γ-secretase cleaves APP at an 
additional site (ε-site) (Sastre et al. 2001), a few amino acids downstream of the γ-site 
(Figure 11). Even though both cleavages are independent, they may occur nearly 
simultaneously (for review Selkoe and Kopan 2003), with the ε-site cleavage thought to 
occur for better AICD membranar release. Simultaneous γ- and ε-cleavages yield a 50 
amino acid long AICD peptide, making it difficult to know which AICD peptide (C59/57 
or C50) is physiologically functional (Selkoe and Kopan 2003). Nonetheless, evidence 
points to the C50 AICD as the physiologically functional peptide (von Rotz et al., 2004). 
 
 
 
 
 
 
 
 
 
Figure 11. APP secretases cleavage sites. α-secretase cleavage precludes Aβ formation while sequential β-
secretase and γ-secretase leads to the production of 38-43 amino acid long Aβ peptides (depending where γ-secretase 
cleavage occurs). The major secretase cleavage sites for APP are: Met596 for β-secretase, Lys612 for α-secretase, and 
Val636 (γ-site) and Leu645 (ε-site) for γ-secretase (APP695 isoform numbering). Aβ is highlighted in red and 
transmembrane domain defined by the two lightly lines. 
 
Additional reports have revealed that APP can also be proteolytic processed at it C-
terminus by caspases, like caspase-3 (Gervais et al. 1999), caspase-6 and -8 (Pellegrini et 
al. 1999), or caspase-9 (Lu et al. 2000). The target residue for the caspase-directed APP 
cleavage is Asp664 (Gervais et al. 1999; Weidemann et al. 1999; Zambrano et al. 2004). 
The resultant C-terminus C31 peptide is a potent inducer of apoptosis, and this cleavage 
was shown to reduce APP internalization but to have varying effects on the secreted 
levels of Aβ (Pellegrini et al. 1999; Lu et al. 2000; Soriano et al. 2001).  
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APP Secretases  
Considerable work has been dedicated to identifying all the secretases involved in these 
pathways in an attempt to understand how secretase activities, APP processing and 
subsequent Aβ production may be regulated (for review see Nunan and Small 2000).  
 
Likely candidates for α-secretase activity include several zinc metalloproteinases such as 
tumor necrosis factor α converting enzyme (TACE/ADAM17), ADAM9 (MCD9), 
ADAM10, which can cleave APP at the α-secretase site located within the Aβ domain 
(reviewed in Allison et al. 2003 and Marks and Berg 2008), thus precluding generation of 
intact Aβ. The aspartyl protease BACE2 has also been reported to have α-secretase like 
activity by efficiently cleaving APP within Aβ (Phe19 and Phe20) (Yan et al. 2001). All these 
candidates have inherent α-secretase activity or are thought to be somehow involved in 
the regulation of α-secretase (Sabo et al. 1999). While the cleavage is constitutive and 
therefore depends on an enzyme that is active at all times, it can also be increased by 
substances that activate protein kinase C (PKC), such as metabotropic glutamate receptor 
agonists (Kirazov et al. 1997; Nitsch et al. 1997; Nakaya and Suzuki 2006) and phorbol 
ester activation (Buxbaum et al. 1990; Caporaso et al. 1992; da Cruz e Silva et al. 1993; 
Gabuzda et al. 1993; Marambaud et al. 1997). TACE ability to cleave APP constitutively 
was demonstrated using TAPI-1 inibitor in HEK293 cells, which lead to decrease sAPPα 
release (Slack et al. 2001). Further, TACE KO mice showed deficiencies in sAPPα 
secretion supporting that it may also cleave APP (Buxbaum et al. 1998; Merlos-Suarez et 
al. 1998). This data is in agreement with Checler et al. (2005) data who observed that 90-
95% of sAPPα production was due to TACE activity in fibroblasts. Nitric oxide, a 
retrograde messenger in synaptic transmission, activates TACE in vitro and α-secretase in 
vivo (Zhang et al. 2000), consistent with TACE α-secretase activity and additionally 
supporting the APP ectodomain as a modulator of synaptic plasticity. Co-transfection of 
APP with ADAM10 or MDC9 results in increased (constitutive and regulated) sAPPα 
secretion. ADAM10 cleaves in vitro the Aβ peptide at the Lys16-Leu17 bond (corresponding 
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to α-site in Figure 11, APP695 isoform numbering), and the Flemish mutation Ala
21-Gly 
reduces this cleavage (Lammich et al. 1999). 
 
The major neuronal β-secretase is a transmembrane aspartyl protease, termed BACE1 
(also termed Asp2 or memapsin2) for β-site APP cleaving enzyme expressed in neuronal 
tissues (Vassar et al. 1999; Yan et al. 1999; Bennett et al. 2000a; Vassar 2004). This 
aspartic proteinase is generated as a proenzyme, whose activation is mediated by furin or 
a furin-like enzyme immediately before full maturation (N-glycosilation) and trafficking 
trough the Golgi (Bennett et al. 2000b; Capell et al. 2000; Huse et al. 2000). β-secretase 
cleaves APP at the N-terminal side of Asp1 of the Aβ sequence (also corresponding to β-
site in Figure 11, APP695 isoform numbering). It has been demonstrated that this APP 
cleavage occurs at positions 1 and 11, since cells overexpressing BACE1 exhibited an 
increase in secreted levels of Aβ1-40/42, and Aβ11-40/42 (Vassar et al. 1999). The former is the 
major cleavage site for β-secretase cleavage. Consistently with the β-secretase activity of 
BACE1, this membrane-anchored enzyme was reported to cleave APP carrying the FAD 
Swedish double mutation 10-fold more efficiently than wild-type APP (Yan et al. 1999). 
Furthermore, BACE1 KO mice showed a decrease in Aβ production and in β-cleavage 
(Cai et al. 2001; Luo et al. 2001), but given that rat were phenotypically normal (Roberds 
et al. 2001) it was proposed that inhibition of the β-site secretase pathway is not toxic 
and could be of therapeutic value. It was also recently demonstrated that in vivo BACE1 
inhibition lead to a decrease in brain Aβ1-40 and Aβ1-42 levels, with a concomitant increase 
in sAPPα levels, without affecting neuregulin processing (Sankaranarayanan et al. 2008). 
In humans, BACE2 has also been reported to cleave APP at Aβ position 1, however only 
BACE1 is significantly expressed in brain (Bennett et al. 2000a). Carboxypeptidase B was 
another β-secretase candidate identified by Matsumoto et al. (2000), which in contrast to 
BACE enzymes lacks a transmembrane domain. Carboxypeptidase B is a soluble enzyme 
located in the cytosol of various neurons and some microglial cells, especially in the 
hippocampus. In vitro or when overexpressed in cells it leads to increased CTFβ levels. 
Additional research may identify novel functions for this enzyme, since it is the only 
putative APP secretase that does not appear to be membrane-bound. 
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The γ-secretase activity is primarily executed by a multicomponent complex that 
contains at least 4 core components, including presenilin (PS1 or PS2), nicastrin, anterior 
pharynx defective 1 (APH1) and presenilin enhancer (PEN2) (Figure 12) (De Strooper 
2003; Capell et al. 2005; Gandy 2005). The simultaneous expression of these components 
in yeast, an organism that lacks any endogenous γ-secretase activity, results in the 
reconstitution of γ-secretase complex formation and activity, demonstrating that the 4 
membrane proteins are the core components of the complex (Edbauer et al. 2003). 
 
 
 
 
 
 
 
 
Figure 12. Topology of the 4 components that comprise the high molecular weight γ-secretase complex. 
Black bar represents the cleavage site for processing of the zymogen form of PS1 into the amino and carboxyterminal 
fragments that self associate and form the active enzyme (from Gandy 2005).  
 
The γ-secretase complex is responsible for cleaving APP at the C-terminus of the Aβ 
fragment, a site which is located within the APP transmembrane domain (reviewed in 
Wolfe et al. 1999). This γ-secretase complex has also been responsible for cleaving the 
Notch protein, a well known signal transducer, at its intramembranous sequence 
(Berezovska et al. 2000; Selkoe and Kopan 2003). In an identical manner both Notch and 
APP apparently need proteolytic cleavage of the extracellular domain to become a 
substrate for γ-secretase (Mumm et al. 2000; Struhl and Adachi 2000; Berezovska et al. 
2001).  
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The presenilins (PS) appear to provide the active core of the protease. Two mammalian 
homologs, PS1 and PS2, exist. The PS1 and PS2 are integral membrane proteins 
possessing at least eight putative transmembrane domains, expressed initially as full-length 
proteins that are thought to be inactive (Thinakaran et al. 1996). Two aspartate residues 
(Asp257 and Asp385) located in transmembrane domains 6 and 7, respectively are essential 
for the catalytic activity of the protease. Cleavage between these transmembrane domains 
yields a C-terminal fragment and an N-terminal fragment, which remain associated with 
each other in a multiprotein complex of high molecular weight (minimal 200-250 kDa) 
(Kimberly et al. 2003). PS1 and PS2 are not found in the same complexes, but their tissue 
specific expression profiles can overlap (Saura et al. 1999). PS1 appears to be more 
responsible for CTF cleavage than PS2 (Herreman et al. 1999). Accordingly, PS1 KO mice 
have markedly reduced γ-secretase activity (De Strooper et al. 1998) as denoted by a 
lowered amount of Aβ and P3 production, consistent with membrane accumulation of the 
CTFs arising from APP β and α cleavage. In double KO mice for PS1 and PS2 γ-secretase 
activity was shown to be even more reduced (Donoviel et al. 1999; Herreman et al. 
1999). Of note, in PS1/PS2 double KO mice there is a lack of Aβ1-42, but not of Aβ1-40, 
production in the early secretory pathway (Wilson et al. 2002), suggesting that there 
might be several γ-secretase enzymes with different selectivity for producing Aβ1-40 and 
Aβ1-42 (Wolfe and Haass 2001).  
Another component of γ-secretase is nicastrin, which also affects the complex’s enzymatic 
activity (Esler et al. 2000). This protein interacts with C-terminal fragments of APP and 
PS1 and PS2 (Yu et al. 2000). Nicastrin has four conserved cysteine residues near its 
extracellular N-terminus (Leem et al. 2002) and mutations in these residues lead to 
enhanced Aβ secretion, while deletion of the same region prevents Aβ secretion (Yu et 
al. 2000). Noticeably, it has been demonstrated that nicastrin trafficking and post-
translational processing is affected in presenilin double KO mice, which provide evidence 
that presenilin is responsible for directing assembly of the γ-secretase complex (Leem et 
al. 2002). 
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The other proteins identified as γ-secretase complex components were APH-1 and 
PEN-2 (Francis et al. 2002; Steiner et al. 2002; for review De Strooper 2003). Recent 
reports provide evidence that the γ-secretase complex is formed as an APH/immature 
nicastrin complex at the ER, which is further matured at the Golgi. At the Golgi, 
APH/nicastrin first bind to PS, stabilizing the unstable and readily degraded PS pool, and 
following binding of PEN-2. PS endoproteolysis (called PS maturation) is required for the 
γ-secretase complex to become active (Kim and Sisodia 2005). Although the catalytic 
activity of γ-secretase complex resides in the 2 aspartate residues of PS1, the 4 proteins 
participate in the regulation of each other´s activation and/or maturation associated with 
the active γ-secretase complex (Table 1), and are required to reconstitute γ-secretase in 
mammalian cells (Kimberly and Wolfe 2003) and in yeast (Edbauer et al. 2003). 
 
 
Table 1. γ-secretase complex members 
 
 
C. elegans components and mammalian homologs, and functions of the different γ-secretase components. (From De 
Strooper et al. 2003). 
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1.5.5 APP trafficking 
APP processing events occur in various organelles during it normal secretory pathway and 
also at the cell surface. In both neuronal and non-neuronal cells, APP is known to be 
transported via the secretory pathway, a continuum transport in separate membrane-
enclosed organelles that ultimately reach the cell surface. Throughout this secretory 
transport, post-translational modifications of the newly synthesized APP proteins may 
occur as well, which may influence APP cleavage and Aβ production. 
 
APP subcellular trafficking and maturation  
APP post-translational modifications include N- and O-linked glycosylation and tyrosine 
sulfation (Weidemann et al. 1989; Oltersdorf et al. 1990). In its mature form APP is both 
N- and O-glycosylated (Weidemann et al. 1989), while in its immature form APP is N-
glycosylated only. Although APP N-glycosylation occurs at the endoplasmatic reticulum 
(ER) more carbohydrate chains can be further processed in the cis-Golgi, and thus 
immature N-glycated APP can be found in both subcellular organelles (Tomita et al. 
1998). Nascent and immature APP can be degraded to a high degree by the proteasome, 
probably via the smooth ER (Yang et al. 1998; Kouchi et al. 1999), but if not degraded, 
APP maturation by O-glycosylation and tyrosyl-sulfation will occur while moving through 
the trans-Golgi network (TGN) (Weidemann et al. 1989) (Figure 13). Even though O-
glycosylation does not depend on correct APP N-glycosylation to occur, it is a 
subsequent process since it occurs at the TGN (Pahlsson and Spitalnik 1996). Mature APP 
(N-, O-glycated and sulfated) is therefore located in compartments from the trans-Golgi 
to the plasma membrane (Tomita et al. 1998). 
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Figure 13.  Post-translational modifications of APP along the classical secretory pathway. APP is 
subjected to N-glycosylation in the ER, O-glycosylation, tyrosyl sulfatation and sialylation in the Golgi apparatus, 
and then reaches the plasma membrane. N, Nucleus; ER, Endoplasmic reticulum; PM, Plasma membrane. 
(Adapted from Suzuki et al. 2006). 
 
Maturation of metabolic labelled APP cell-associated proteins reached maximum intensity 
after 30 min of chase (Peraus et al. 1997). The pool of TGN mature APP in SH-SY5Y 
cells, takes 30 to 45 min to reach the plasma membrane (Cai et al. 2003). Alterations in 
the glycosylation state of APP have been reported to decrease secretion of the 
neuroprotective sAPPα (for review see Georgopoulou et al. 2001). Pahlsson et al. (1996) 
showed that APP N-glycosylation play a key role in APP biosynthesis and secretion. 
Additional, the majority of APP cleavage by secretases occurs after O-glycosylation, as 
shown by Tomita et al. (1998). In this report mutant APP defective in O-glycosylation 
accumulated in subcellular ER compartments and exhibited decreased cleavage to CTFα 
or to Aβ1-40/1-42. Recently was described that APP sialylation enhanced extracellular levels 
of Aβ (Nakagawa et al. 2006). These data are in accordance with protein maturation 
playing a key role in APP processing and function.  
 
 
 
 
O-glycosylation 
Tyrosyl sulfatation 
Sialylation 
N-glycosylation 
 
PM 
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In neurons, and due to their unique cell morphology with a long axon and a rich dendritic 
arbour, an elaborated protein trafficking exists enabling targeting of proteins to their 
designated compartments, or to be transported back (retrograde transport) to cell 
bodies. Protein processing and modifications are known to take place during the transit in 
axons and in dendrites. APP was detected in both pre- and post-synaptic sites, in the 
axoplasm of myelinated and unmyelinated nerve fibres, within vesicular structures in 
axonal, dendritic and synaptic compartments, as well as on the surface of axons and 
dendrites (Schubert et al. 1991; Ferreira et al. 1993; Allinquant et al. 1994; Caporaso et al. 
1994; Simons et al. 1995). Presynaptically targeted full-length APP (and APLP2) occurs in 
its mature form (syalated and N- and O-glycosylated) (Lyckman et al. 1998).  
Neuronal APP is transported in axons via fast anterograde transport machinery (Koo et 
al. 1990, Ferreira et al. 1993, Kaether et al. 2000), a process that requires direct or 
indirect association of APP with kinesin light chain (KLC) subunit, a component of kinesin-
1 molecular motors (Kamal et al. 2000; Inomata et al. 2003; Matsuda et al. 2003; Lazarov 
et al. 2005) (see also section 1.6.1 and Figure 18). 
 Once at the cell surface APP can undergo two pathways (Figure 14): APP can be cleaved 
or undergo endocytosis if unprocessed, being retrogradely transported as a holoprotein 
from axonal synaptic compartments to neuronal cell bodies and dendrites (Simons et al. 
1995; Yamazaki et al. 1995). In the endocytic pathway, APP can be recycled back to the 
membrane, by retrograde delivery to the TGN, or it can be incorporated into secondary 
endosomes, which will target APP to complete degradation at the lysosomes or to be 
recycled back to the TGN/Golgi (Tagawa et al. 1993; Koo et al. 1996; Yamazaki et al. 
1996). 
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APP processing during its intracellular trafficking  
During its trafficking trough the different subcellular organelles besides maturating, APP 
can be proteolytic cleaved giving rise to the different APP fragments. Although most cell 
types appear to possess the same basic mechanisms for APP metabolism the relative 
contribution of the different pathways varies significantly, particularly between neurons 
and non-neuronal cell lines (Hartmann 1999). As already mentioned the majority of the 
APP cleavages occur after complete maturation of the protein, although some immature 
APP may also be cleaved by secretases at a low rate in the ER or the cis-Golgi subcellular 
compartments. Mature APP is processed rapidly (turnover of ~30-45 min) as it is 
transported to or from the cell surface via the secretory or endocytic pathways, 
respectively (Sambamurti et al. 1992; Kuentzel et al. 1993; Koo et al. 1996; Yamazaki et al. 
1996; Cook et al. 1997; Hartmann et al. 1997). Further, only small amounts of APP were 
detected at the cell surface when compared to the total cellular pool (Kuentzel et al. 
1993). This is due to rapid removal of cell surface APP, whose half-life was reported to be 
 
Figure 14. APP trafficking through the cellular secretory and endocytic pathways in 
neurons. APP domains are indicated in colours: pink, cytoplasmic domain; violet, Aβ domain; green, 
ectodomain (Gouras 2001). 
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less than 10 min (Lai et al. 1995), either by APP proteolytic cleavage or endocytosis. 
Approximately 30% of surface APP is cleaved to sAPP and secreted (Lai et al. 1995; Koo 
et al. 1996), while the remaining cell surface CTFs may be cleaved by γ-secretase locally, 
or in the endocytic pathway in endosomes, or further degraded in lysosomes (Tagawa et 
al. 1993; Mathews et al. 2002; Kaether et al. 2006). Both cell surface CTF cleavage 
product and unprocessed full-length APP are re-internalized via coated pits and vesicles 
by receptor-mediated endocytosis (Yamazaki et al. 1996). If endocytosed the half-life of 
internalized APP was estimated to be ∼30 min (Koo et al. 1996), with a pool of 
endosomal APP being delivered to lysosomes. 
 
Intracellular sites for Aβ precluding formation pathway  
The intracellular sites for non-amyloidogenic APP cleavage are in aggrement with the 
subcellular organelles where the recently described α-secretases are localized and active. 
The α-secretases are synthesized as preproteins (Schlondorff et al. 2000; Anders et al. 
2001) which turn into active proteolytic enzymes by cleavage of their inhibitory 
prodomain in late Golgi compartments, where they are thought to reside (Lammich et al. 
1999; Tousseyn et al. 2006). The mature active form of TACE has been detected at the 
cell surface but also intracellularly, where it was mainly localized in a perinuclear 
compartment (for review, see Hooper and Turner 2002). The putative α-secretase, the 
ADAM10, was described to occur at the cell surface, nevertheless it was abundantly 
present in the Golgi apparatus and possibly in transport vesicles destinated to go to cell 
surface (Lammich et al. 1999; Gutwein et al. 2003).  
APP processing by the non-amyloidogenic pathway has been described to occur 
intracellularly during its transport through the secretory pathway, before reaching the cell 
membrane.  Several reports suggested that CTFα products were intracellularly detected 
before the appearance of sAPPα in the medium (Sambamurti et al. 1992; De Strooper et 
al. 1993; Kuentzel et al. 1993). APP cleavage by α-secretase was demonstrated to occur 
locally either in the trans-Golgi apparatus or in post-TGN vesicles (Sambamurti et al. 
1992; Kuentzel et al. 1993). Additionally, in mice memory improvement models where α-
secretase was up-regulated, it was observed that regulated α-secretase cleavage of APP 
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occurred mainly during its transport from the TGN to the plasma membrane (Sisodia 
1992; Lammich et al. 1999). The pool of full-length mature APP that reaches the cell 
surface may locally undergo cleavage by α-secretase, living embayed to membrane the 
resulting CTFα (Sisodia 1992; Nordstedt et al. 1993; Koo and Squazzo 1994; Roberts et 
al. 1994; Parvathy et al. 1999). A more recent report demonstrated that α-secretase 
activities may also occur in the endoplasmic reticulum of a non-neuronal cell line (Shin et 
al. 2005). Nevertheless, it is known that the greater part of APP cleavage occurs after 
complete maturation and thus it is of reasonable consensus that the TGN/Golgi APP pool 
is the primarily source for α-secretase cleavage (Jolly-Tornetta and Wolf 2000; Hooper 
and Turner 2002).  
The ratio between plasma membrane and intracellular α-secretase cleavage appears to be 
cell-specific. In fact, in N2a neuroblastoma cells (De Strooper et al. 1992; De Strooper et 
al. 1993), PC12 cells (Sambamurti et al. 1992), neuroblastoma H4 cells (Kuentzel et al. 
1993), CHO cells (Jolly-Tornetta and Wolf 2000), the majority of APP cleavage to sAPPα 
was shown to occur intracellularly at the TGN or in post-TGN vesicles (probably just 
after sulfate incorporation), while in neurons α-secretase cleavage was reported to occur 
mainly at the cell surface (Parvathy et al. 1999). Additionally, in neuronal cells sAPPα may 
also be generated and released at synaptic terminals (McLaughlin and Breen 1999).  
 
Intracellular sites for Aβ generating pathway 
The major protease with known APP β-secretase activity is BACE1. The latter is 
expressed initially as a pro-enzyme and is cleaved after exiting the ER (Vassar et al., 1999). 
BACE1 is located intracellularly at the Golgi, TGN, and secretory vesicles, at the cell 
surface and in endosomes (Huse et al., 2000). This is in accordance with different pools of 
the secretase complexes regulating Aβ production and being present both at the plasma 
membrane and within the endocytic pathway. These intracellular localizations of β-
secretase are in fact consistent with sites previously associated with Aβ production. 
Figure 15 illustrates the possible Aβ generating pathways. 
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Figure 15. Three pathways leading to Aβ production. Aβ peptide is highlighted in red. ER, endoplasmic 
reticulum. (Adapted from Wilson et al. 1999). 
 
Early on, it was suggested that most of the amyloidogenic β-cleavage events occurred in 
an endosomal compartment, following internalization of APP from the plasma membrane, 
leading to the generation of a large part of Aβ peptides in the endocytic pathway (Haass 
et al. 1992a; Haass et al. 1992b; Shoji et al. 1992; Peraus et al. 1997). This is corroborated 
by studies where mutations in the APP 682YENPTY687 domain notably impair APP 
endocytosis and at the same time decrease Aβ levels (Perez et al. 1999). Additional 
studies identified that the secretory compartments ER and Golgi complex are also 
involved in Aβ generation (Cook et al. 1997; Hartmann et al. 1997; Tomita et al. 1998). In 
accordance with the last observations, Xia (2001) have reported that Aβ fragments can 
also be generated in the late Golgi compartment and packaged into post-TGN vesicles 
destined for extracellular secretion, during the APP secretory pathway. This Aβ 
production seems to occur at the TGN and does not need post-TGN vesicle formation 
(Xu et al. 1997).  
Even though some authors defend that the γ-secretase complex is still not formed or 
active in the ER compartment (Kaether et al. 2006), it was reported that in neuronal cells 
Aβ42 can also be produced inside this subcellular compartment (Cook et al. 1997; 
Aβ biology and its contribution to AD       Chapter I 
 
64       Centro Biologia Celular 
Universidade de Aveiro 
 
Hartmann et al. 1997; Xia et al. 1998; Greenfield et al. 1999; Xia 2001). This pathway is 
considerably reduced in other cell types and consequently production of the Aβ species is 
also reduced (Wild-Bode et al. 1997; Skovronsky et al. 1998; Xia et al. 1998).  Further, 
Chyung et al (1997) showed that β-secretase activity could be detected in neuronal but 
not in non-neuronal cells. Neurons exhibit higher levels of β-secretase activity (Busciglio 
et al. 1993; Simons et al. 1996) resulting in a higher Aβ/P3 ratio.  Hence it is reasonable to 
deduce that Aβ production plays an important role in determining neuronal phenotype, 
particularly intracellular Aβ. This is well exemplified during the differentiation process of 
NT2 cells (human tetracarcinoma cells) into neurons (NTN2). One week following 
differentiation these cells exhibit soluble Aβ levels of 26fmol/mg and secrete 
53fmolAβ/ml/24hr; at six weeks values rise to 44fmol/mg of soluble Aβ and secrete 
266fmolAβ/ml/24hr (Turner et al. 1996).  
 
Intracellular sites for γ-secretase cleavage 
Evidently, the intracellular localization of the γ-secretase complex is consistent with the 
described intracellular sites for CTF cleavage and P3 or Aβ production. Presenilins were 
described to be predominantly localized to the ER, where it may also co-localize with 
nicastrin (Yu et al. 2000), and early Golgi (Kovacs et al. 1996), and in limited quantities at 
locations such as endosomes and plasma membrane (Weidemann et al. 1997; Xia et al. 
1997). Interestingly, efficient γ-secretase cleavage of APP seems to occur in compartments 
that contain small amounts of PS1, while little γ-secretase activity is observed in 
compartments where abundant PS1 is residing (Cupers et al. 2001a). Hence, the main 
subcellular γ-secretase activity locations described for γ-secretase cleavage are the 
endosomes and the plasma membrane (Weidemann et al. 1997; Xia et al. 1997; Kaether 
et al. 2006). Mature nicastrin, PS1 and APP were found co-localized in the LAMP-1 
positive endosome membranes, where an acidic γ-secretase activity was also present 
(Pasternak et al. 2003), suggesting a role of the the lysosomal/endosomal system in the 
generation of Aβ. More recently, Kaether et al. (2006) demonstrated that by blocking 
selective transport steps along the secretory pathway the main subcellular locations of 
AICD generation are the plasma membrane and the endocytic compartments. 
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1.6 INVOLVEMENT OF THE CYTOSKELETON NETWORK IN ALZHEIMER´S DISEASE 
The cytoskeleton is a system of filaments found in the cytoplasm of cells that is 
responsible for the maintenance of and changes in cell shape, cell locomotion, movement 
of various elements within the cytoplasm, integration of the major cytoplasmic organelles, 
cell division, chromosomal organization and movement, and cell-cell or cell-surface 
adhesion. The primary cytoskeletons of eukaryotic cells are composed of microtubules 
(composed of α/β-tubulin heterodimers), actin and intermediate filaments (Figure 16). 
However, the presence of this system of filaments in all cells is extremely diverse in 
structure and cytoplasmic distribution. 
 
 
 
 
 
 
 
Figure 16. Eukaryotic cytoskeleton. Actin 
in red, tubulin in green, and nuclei in blue. 
From www.answers.com/topic/cytoskeleton. 
 
Both microtubules and actin have important roles in the secretory and endocytic 
pathways (reviewed in Vliet et al. 2003 and Lanzetti et al. 2007). Unlike actin filaments and 
microtubules, intermediate filaments are the least understood part of the cytoskeleton 
(for review see Godsel et al. 2008). Nonetheless, intermediate filaments interact with 
microtubules contributing to cell shape maintenance (Chang and Goldman 2004) and 
appear to play an important role in astrocyte directional mobility of vesicles (Potokar et 
al. 2007). Therefore, alterations in the dynamics of the cytoskeleton components will 
ultimately lead to cytoskeleton organization abnormalities and defects in related 
processes, which have in fact been associated with several neurodegenerative disorders, 
including AD (Pollak et al. 2003). 
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1.6.1 Microtubule network in APP axonal transport 
In neuronal cells the cytoskeleton consists of actin filaments, microtubules and 
neurofilaments (Figure 17).  
 
 
 
 
 
 
 
 
 
Figure 17. Neuronal cytoskeleton. 
Microtubules in green and actin in red. From 
http://neurobio.drexel.edu/GalloWeb/The%20
Neuronal%20Cytoskeleton.htm. 
 
The long neuritis and axonal processes constitute a challenge to the movement of 
proteins, vesicles and organelles between presynaptic sites and cell bodies. To overcome 
this challenge specialized transport machinery exists, consisting of cytoskeletal motor 
proteins that generate directed movement along cytoskeletal tracks. 
Microtubules are the major tracks or “highways” along which motor proteins generate 
long-distance efficient axonal transport (Kreutzberg 1969; Kamal et al. 2000). Fast 
anterogade transport machinery, and axonal terminals are dependent on axoplasmic flow, 
a function that requires intact microtubules and motor proteins such as kinesin, dynein 
and dynamin. Evidence suggests that dynein may be the major motor protein powering 
microtubule retrograde transport, and that kinesin motor proteins are involved in 
anterograde axonal transport (for review see Stokin and Goldstein 2006). In fact it has 
been reported that kinesin molecular motor proteins are responsible for many of the 
major microtubule-dependent transport pathways in neuronal and non-neuronal cells 
(Goldstein 2001). The microtubule motor complex kinesin-I comprise two components: 
kinesin heavy chains (KHC) that have ATP- and microtubule-binding motifs essential for 
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vesicle transport, and kinesin light chains (KLC). KLC associates with KHC and tethers 
membrane vesicles containing proteins to be transported axonally from the neuronal 
soma to nerve terminals (Hirokawa et al. 1998). 
The transport system is crucial to maintaining neuronal viability and differentiation, and 
failure of axonal transport may play a role in the development or progression of 
neurological diseases, including AD. Indeed, AD brains generally exhibit severe 
perturbations of several neurotransmitors and widespread synaptic and neuronal loss in 
specific brain areas. These changes are accompanied by severe disruption of the axonal as 
well as dendritic cytoskeleton, which suggests failed axonal transport as a contributing 
factor in the progression of the disease (Stokin and Goldstein 2006). 
Many proteins associated with AD pathogenesis (including APP, BACE, PS1, nicastrin, 
Aph-1, synuclein and tau) have been observed in the axonal compartment of neurons, 
with many of them found at presynaptic terminal (Iwai et al. 1995; Beher et al. 1999; 
Capell et al. 2002; Siman and Salidas 2004). Therefore, transport is almost certainly 
necessary to deliver these proteins to their final destination (Koo et al. 1990a). APP 
axonal anterograde transport is proposed to be mediated by functional interaction 
between APP and the kinesin light chain (KLC) subunit, a component of kinesin-1 
transport machinery (Kamal et al. 2000; Kamal et al. 2001). Nonetheless, recent evidence 
is consistent with the view that APP/KLC interaction may be enhanced/mediated through 
JIP-1, an adaptor protein member of JNK-interacting protein family known to interact 
with both KLC and APP (Taru et al. 2002; Inomata et al. 2003; Matsuda et al. 2003; 
Lazarov et al. 2005) (Figure 18).  
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Figure 18.  APP axonal anterograde transport and the kinesin motor protein. A. Association of APP with the 
kinesin-I motor. APP binds to KLC through an association with JIP-1b, but does not bind to KLC directly. Thus, APP 
serves as a cargo-receptor via JIP-1b. B. Anterograde transport of APP vesicles and metabolism of APP. APP is subjected 
to cleavage during axonal transport (1), on the plasma membrane (2), or in the endocytotic cycle (3), generating 
neurotoxic Aβ. (Adapted from Suzuki et al. 2006). 
 
In mouse, kinesin-1 reduction enhances de development of axonal defects, increases 
aberrant Aβ generation, and enhances amyloid deposition (Gunawardena and Goldstein 
2001; Stokin et al. 2005). Also, antisense treatment with oligonucleotides against KHC 
slows down APP axonal transport and increases the frequency of directional changes 
(Kaether et al. 2000). More recently, Stokin et al. (2005) observed axonal swellings 
containing motor proteins and vesicular elements in the brain of mouse models and 
patients with AD, and disturbed axonal transport resulted in increased Aβ generation.  
Interestingly, Aβ per se is sufficient to induce formation of axonal abnormalities (Pike et al. 
1992) and may directly contribute to the impairments in the axonal transport (Kasa et al. 
2000; Hiruma et al. 2003). Whether Aβ is a consequence or a cause of altered axonal 
transport is still unclear. The fact is that alterations in microtubule network will ultimately 
result in altered APP axonal transport and increased Aβ production and aggregation, the 
latter being intimately associated with AD neurodegeneration. 
 
 
 
 
 
PM 
 
B 
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  Microtubule acetylation and neuronal transport 
Key post-translational modifications of microtubules (PTM) may dictate microtubule 
dynamics and recruitment of microtubule associated proteins, microtubule stability and 
function (reviewed in Bloom, 2004). Several PTM of microtubules have been described 
including acetylation, polyglutamylation and tyrosination/detyrosination, all were shown to 
be reversible (reviewed in Bulinski, 2007 and Hammond et al., 2008). Although tubulin 
acetylation is not necessary for cell and organism survival, it is known that acetylation 
leads to microtubule stability. Further, recent work has suggested that α-tubulin 
acetylation plays a positive role in motor-based trafficking in mammals (Reed et al. 2006; 
Bulinski 2007; Dompierre et al. 2007). Of note, hyperacetylation of microtubules in 
neuronal cells using inhibitors of histone deacetylase 6 caused increased recruitment of 
the cytoplasmic motors dynein and kinesin-1 to microtubules and enhanced transport of 
brain derived neurotrophic factor vesicles (Dompierre et al. 2007). 
Reed at al. (2006) showed that microtubule acetylation is sufficient to increase kinesin-
mediated transport of JIP-1-containing vesicles to the tips of neurites (Figure 19, bold 
arrows), while detyrosination and poly-glutamylation appeared to have a smaller impact 
on transport (Figure 19, light arrows). 
  
 
 
 
 
 
Figure 19. Microtubules post-translational 
processes in neurons. Neurons undergo multiple 
reversible post-translational modifications including 
acetylation, detyrosination and poly-glutamylation. 
Although microtubules in the same process actually 
carry multiple modifications, in the figure they are 
only shown to have one type of modification per 
process for simplicity’s sake. Increased acetylation of 
all microtubules in hippocampal neurons was sufficient 
to target JIP-1 to neurite tips. Adapted from Bulinski, 
2007. 
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Althought, the cellular functions of PTMs have only recently begun to be revealed, the 
data suggest that these modifications can affect microtubule dynamics. PTMs can influence 
the stability and/or structure of microtubule assemblies, either directly by affecting tubulin 
modification on microtubule structure, or indirectly by influencing the recruitment of 
microtubule-associated proteins, such as molecular motor proteins. In the case of motor-
dependent transport it is possible that the PTMs serve as “road signs” to direct polarized 
trafficking such as axonal/dendritic trafficking in neuronal cells. It is also possible that 
PTMs simply mark stable microtubules for preferential transport, indicating to molecular 
motors the desirable microtubule track.  
 
1.6.2 The role of actin remodelling in AD 
  Actin and the dendritic cytoskeleton 
As already mentioned, AD is characterized by a progressive loss in the number of 
dendritic spines, as well as by alterations in the synaptic efficacy and damage at the 
synaptic terminal (Lippa et al. 1992; Masliah 1995), where decreased cortical synapse 
density correlates with cognitive decline in patients (Terry et al. 1991; DeKosky et al. 
1996). These changes are accompanied by a severe disruption of the axonal as well as 
dendritic cytoskeleton, and culminate in alterations in axonal transport. The regulation of 
actin dynamics is considered to be the main mechanism underlying morphological changes 
in dendritic spines (Halpain 2000; Matus et al. 2000), and these pathological actin-induced 
alterations have been associated with an actin polymerized conformation (F-actin). Actin-
depolymerizing factor (ADF) and cofilin are actin-binding proteins that critically control 
actin filament dynamics and reorganization by severing and depolymerizing actin filaments 
(Bamburg and Wiggan 2002). An imbalance in actin dynamics has been associated to the 
formation of cofilin-actin rods (Minamide et al. 2000), which are inclusion-like structures 
present in hippocampal and cortical neurons of post-mortem AD brain thought to 
mediate neurodegeneration. These rod-like inclusions are specially found in Alzheimer´s 
brain areas surrounding the amyloid plaque, supporting the idea that Aβ peptide may play 
a role in the imbalance of actin dynamics (Maloney et al. 2005). Further, under stress 
conditions induced by Aβ1-42 it was reported that cofilin becomes active 
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(dephosphorylated) and forms actin rods. Surprisingly, however, in hippocampal neurons 
treated with high concentrations of Aβ1-40 cofilin undergoes phosphorylation 
(inactivation), leading to dystrophic morphological changes, including accumulation of 
pretangle phosphorylated tau (Maloney and Bamburg 2007). Aβ per se has also been 
described to affect and accumulate in synapses (Takahashi et al. 2004), and this 
phosphorylation dependent regulation of cofilin by different Aβ peptides may provide a 
mechanistic explanation for the synaptic loss and plaque propagation in AD.  
In agreement with these Aβ effects on actin dynamics it was recently reported that Aβ1-42 
could increase actin polymerization by increasing activity of Rac/Cdc42 Rho GTPases in 
hippocampal neurons (Mendoza-Naranjo et al. 2007). The Rho family of small GTPases 
(Rho, Rac and Cdc42) are regulators of F-actin polymerization (Bishop and Hall 2000), 
acting as molecular switches by cycling between an inactive GDP-bound state and an 
active GTP-bound state. This system has also been implicated in the maintenance and 
reorganization of dendritic structures (Luo 2000; Nakayama et al. 2000). Rac1 and Cdc42 
promote polymerization at the leading edge, orchestrating the formation of lamellipodia 
and membrane ruffles (Ridley et al. 1992), as well as peripheral actin microspikes and 
filopodia (Kozma et al. 1995; Nobes and Hall 1995).  
A preceding study also demonstrated that Rac activation inhibits the formation of both 
dendritic spines and synapses (Zhang et al. 2003), and up-regulation of Rac/Cdc42 was 
observed in AD cases in comparison with an age-matched controls (Zhu et al. 2000). 
Further, Aβ was reported to destabilize Ca2+ regulation, and an increase in intracellular 
Ca2+ induces membrane translocation and activation of Rac, an event dependent on the 
activation of conventional protein kinase C (PKC) (Price et al. 2003). These results point 
to the actin cytoskeleton as a target for Aβ-induced neurodegeneration in AD. 
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The actin cytoskeleton in exocytosis of secretory vesicles 
In neurons and endocrine cells, exocytosis of neurotrasnsmitters or hormones containing 
vesicles occurs upon specific stimuli. Exocytosis controls cell surface expansion and 
protein secretion by fusing secretory vesicles with the PM. These trafficking processes 
require actin remodelling, which is strictly regulated by time and localization in the 
process of membrane trafficking and provides the forces for movement.  
In neurons, adrenal chromaffin cells and their tumor derived PC12 cells, synaptic 
vesicles/granules are organized in two pools: the reserve pool (RP) and the readily 
releasable pool (RRP) (Sudhof 2004; Dillon and Goda 2005). The RRP constitutes vesicles 
docked at the active zone, which are primed to undergo membrane fusion, whereas the 
RP is a cluster of vesicles present distally from the active zone. The traffick between these 
two pools is subjected to a fine regulation by the actin cytoskeleton. Actin was reported 
to act as a scaffold to impede vesicle dispersion. Indeed, in adrenal chromaffin cells, 
fodrin, an actin crosslinking protein, stabilizes the cortical actin network (below PM) and 
entraps secretory granules in the subplasmalemmal cytoskeleton severing as a reservoir 
for exocytotic demand (Aunis and Bader 1988; Malacombe et al. 2006). Additionally, the 
diverse effects of actin depolymerization on RP indicate that regulation of RP becomes 
dependent on actin under conditions when the RRP is depleted by stimulation (Dillon and 
Goda 2005). Actin depolymerization by cytochalasin D depletes vesicles in RP after high-
frequency stimulation at neuromuscular junction (Kuromi and Kidokoro 1998), suggesting 
that the F-actin network serves to maintain a vesicle storage pool.  
In the role of actin network in the docking and fusion process, it has been reported that 
actin depolymerization is required at docking stage to the PM, whereas actin 
polymerization is required at the stage of fusion to the PM (reviewed in Noda and Sasaki 
2008). Nonetheless, actin remodeling in the docking and fusion processes are not fully 
understood. 
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It has been proposed that in the process of exocytosis actin may act into two distinct 
modes. Actin may provide a track that guides the movement of vesicles to the targeted 
PM domain, or cortical actin network forms a physical barrier that prevents exocytosis. In 
the delivery of synaptic vesicles to the active zone, evidence supports the first model in 
which actin polimerization plays a facilitator role in vesicle recruitment. For instance, actin 
depolymerization by latrunculin A delays vesicle recruitment at the Calyx of Held synapse 
(Sakaba and Neher 2003). Actin filaments may actively participate in the vesicle transport 
or it may serve as a track for the motor protein myosin to penetrate the actin cortical 
barrier, promoting actin-driven transport (reviewed in Noda and Sasaki, 2008). In the 
translocation of secretory granules in neuroendocrine cells, stabilization of actin inhibits 
exocytosis whereas actin depolymerization enhanced exocytosis, supporting the actin 
barrier model (Malacombe et al. 2006). Early on studies reported that under resting 
conditions, the actin cytoskeleton, prevented secretory granules from reaching their 
exocytic destination (Burgoyne and Cheek 1987; Aunis and Bader 1988; Trifaro and Vitale 
1993). In PC12 cells the disruption of actin filaments by latrunculin increases granule 
motility (Ng et al. 2002; Desnos et al. 2003). Nonetheless, several reports showed a 
biphasic effect of actin on the exocytotic process. For instance, exocytosis in PC12 is 
promoted at low doses of latrunculin but inhibited at high concentrations (Gasman et al. 
2004). These biphasic effects of actin depolymerization indicate the requirement of a 
minimal actin structure for exocytosis. The mechanisms regulating the actin barrier 
appear to be dependent on RhoA GTPase. RohA activation by G0 or overexpression of 
constitutively RhoA mutant stabilizes the peripheral actin filaments and inhibits exocytosis 
in stimulated cells (Gasman et al. 1997; Frantz et al. 2002; Bader et al. 2004).  
Aβ itself is suspected to be associated with alterations in the exocytic pathway. Uemura 
and Greenlee (2001) reported that Aβ contribute to decrease neuronal glucose uptake by 
preventing exocytosis in hippocampal neurons. Neuronal glucose uptake is regulated by 
SNARE complex-dependent docking and fusion of GLUT3 vesicles with the plasma 
membrane, and Aβ25-35 decreased glucose uptake by inhibiting fusion of these vesicles with 
the PM.  
All these findings implicate Aβ in altered axonal transport but also in actin dynamics, 
which suggests the existence of an interplay between altered axonal transport, damage 
signaling, synaptic and neuronal loss and the Aβ peptide in the progression of AD.  
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1.7 CURRENT AND FUTURE THERAPEUTIC APPROACHES IN ALZHEIMER´S DISEASE 
A number of clinical trials are currently in progress based on different therapeutic 
strategies and they should indicate which of these approaches will be efficacious for 
treatment of AD (reviewed in Klafki et al. 2006 and Wang et al. 2008). Since the 
predominant hypothesis to explain AD pathogenesis is the “amyloid cascade”, several 
novel and promising current and future strategies are specifically targeting Aβ production 
and clearance.  
 
1.7.1 Current strategies to ameliorate AD symptoms 
Considerable efforts have been directed toward seeking or developing a variety of 
therapeutic strategies that seem to be able to produce modest symptomatic 
improvements in AD patients (reviewed in Cummings 2004), some of which will be 
herein discussed. At present, none of the available medications appear to be able to cure 
AD or to stop the disease progression. Current medications that have passed FDA 
approval for treatment of AD include acetylcholinesterase (AChE) inhibitors, for mild and 
moderate cases, and memantine, an NMDA-receptor antagonist for the treatment of 
moderate to severe Alzheimer´s dementia (Blennow et al. 2006; Hodges 2006; Klafki et 
al. 2006). 
The “cholinergic hypothesis of AD” postulates that destruction of cholinergic neurons 
and the resulting deficit in central cholinergic transmission contributes substantially to the 
characteristic cognitive and non-cognitive symptoms observed in AD patients (Bartus et 
al. 1982; Cummings and Back 1998). Cholinergic neurons are the nerve cells that 
synthesize and release acetylcholine, an important neurotransmitter associated with 
neurological functions. When acetylcholine levels drop memory and other brain functions 
are affected. Impairment or loss of cholinergic neurons in the basal forebrain leads to a 
significant reduction in the level of acetylcholine and decrease activity in both AChE (the 
enzyme that degrades acetylcholine in the synaptic cleft) and choline acetyltransferase 
(the enzyme that synthesizes acetylcholine). Reductions in the activities of the latter 
enzymes were reported in brain tissues from AD patients (Bowen et al. 1976; Perry et al. 
1977) and suggested a selective destruction of cholinergic neurons. This hypothesis 
Aβ biology and its contribution to AD   Chapter I 
 
Centro Biologia Celular  75 
Universidade de Aveiro 
 
provides the rational for the development of the AChE inhibitors for AD therapy. 
Inhibition of AChE leads to an increase in the acetylcholine concentration in the synaptic 
cleft which is expected to enhance cholinergic transmission and ameliorate cholinergic 
deficit. Three different cholinesterase inhibitors, namely donepezil, galantamine and 
rivastigmine are commonly used for AD treatment. The former are selective inhibitors of 
AChE, while the latter also inhibits butyrylcholinesterase (BChE), which accounts for 
~10% of the cholinesterase activity in normal human brain and appears to be 
predominantly associated with glia (Scarpini et al. 2003). Therefore, these drugs have 
been used to prevent the level of acetylcholine from dropping acutely in the brain. 
Alternative approaches aimed to prevent glutamate-mediated neurotoxicity. It is believed 
that the neurotransmitter glutamate and NMDA receptors have crucial roles for memory 
and learning processes in brain. Glutamate represents the main excitatory 
neurotransmitter in the CNS and a physiological level of glutamate-receptor activity is 
essential for normal brain function (Kornhuber and Weller 1997). Excess glutamate is 
detrimental to neurons due to its overstimulation on NMDA receptors which is believed 
to play a role in neuronal death observed in AD (Hynd et al. 2004). Memantine that is an 
uncompetitive NMDA receptor antagonist can protect neurons from the cytotoxicity 
elicited by glutamate via partially blocking NMDA receptors. This drug was reported to 
have a beneficial effect on cognitive function and function decline in patients with 
moderated to severe AD. The positive clinical results of memantine monotherapy and the 
observation that memantine does not interact in vitro with the AChE inhibitors donepezil 
or galantamine (Wenk et al. 2000), suggested that the clinical combination therapy of 
memantine with cholinesterase inhibitors may be of therapeutic value.  
Other potential treatments currently under investigation include vitamin E (antioxidant), 
Ginkgo biloba and Huperzine A (anti-inflammatory and anti-oxidant drug), calcium channel 
blockers, cholesterol lowering drugs, non-steroid anti-inflammatory drugs (NSAID) and 
metal interactions.  
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1.7.2 Therapeutic strategies targeting Aβ peptide  
As mentioned above, the prevalent hypothesis to explain the mechanisms leading to AD is 
the “amyloid cascade hypothesis”, which sates that Aβ plays a central role in the 
pathogenesis of the disease (Figure 6). It is believed that Aβ accumulation (in particular 
Aβ1-42) initiates a cascade of events that ultimately leads to neuronal dysfunction, 
neurodegeneration and dementia (for review see Hardy 2006). Therefore, an enormous 
therapeutic effort is directed towards developing drugs that reduce Aβ burden or toxicity 
by inhibiting secretase cleavage, Aβ aggregation, Aβ toxicity, Aβ metal interactions or by 
promoting Aβ clearance. The steady levels of Aβ are determined by the balance between 
its production or clearance (Figure 20, for review see Wang et al., 2006). Dysfunction in 
Aβ clearance is crucial for the accumulation of Aβ in AD brains. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Mechanisms of Aβ clearance. The transport of Aβ across the blood–brain barrier (BBB) is mainly 
mediated by receptors [i.e. receptor for advanced glycation end products (RAGE) and lipoprotein receptor-related 
protein (LRP)] on endothelial cells. Aβ in the extra- and intra-cellular space can be degraded by enzymes [i.e. neprilysin 
and insulin-degrading enzyme (IDE)]. Peripheral anti-Aβ antibodies and Aβ-binding substances are able to enter the 
brain at low levels, where they prevent Aβ aggregation and resolve Aβ fibrils. By binding to peripheral Aβ they also act 
as a peripheral sink to promote the efflux of Aβ from the brain and disrupt the Aβ equilibrium between the brain and 
the blood, resulting in the clearance of Aβ from the brain. These mechanisms of Aβ clearance become potential targets 
for drug development in Alzheimer’s disease. (From Wang et al., 2006). 
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Modulation of Aβ production by affecting secretase activity 
Aβ peptide arise from proteolytic processing of APP by β- and γ-secretases, which places 
these two enzymes as prime targets in the active search for small molecule compounds 
that can reduce Aβ production by affecting one of these secretases. BACE1 KO mice 
were reported to produce only very small amounts Aβ confirming that BACE1 represents 
the primary β-secretase in vivo. For β-secretase the identification of specific small 
molecule inhibitors suitable for drug development appears to be difficult (Citron 2004a) 
because the size and the shape of the active site of this aspartyl protease presents a 
considerable challenge in the design of potent inhibitors that can also achieve good brain 
penetration.  
In the case of γ-secretase, the situation is more complex, because its active site is 
intramembranous, and because PS requires additional membrane proteins for proteolytic 
activity. The γ-secretase inhibitor (LY450139) was reported to reduce Aβ levels in plasma 
but not in CSF at concentrations that did not produce significant side effects (Siemers et 
al. 2005). Another major concern regarding the therapeutic usefulness of γ-secretase 
inhibition and potential side effects comes from the identification of other γ-secretase 
substrates, including Notch 1 (De Strooper 2003). Nonetheless, the finding that certain 
NSAIDs can preferentially reduce the generation of the highly amiloidogenic species Aβ1-42 
without affecting Notch cleavage (Weggen et al. 2001), indicates the existence of a γ-
secretase modulating mechanism which may be a potential drug target to modulate Aβ1−42 
production. 
Cleavage of APP by α-secretase prevents Aβ production, and can be stimulated by 
muscarinic acetylcholine-receptor agonists (Wolf et al. 1995). The M1 muscarinic 
acetylcholine-receptor agonist (AF267B) was reported to ameliorate cognitive deficit and 
reduce both amyloid and tau pathologies in mice (Caccamo et al. 2006). 
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Inhibition of Aβ aggregation  
There has been some disagreement regarding the exact structure of the aggregated 
species which are associated with toxicity. It is unclear if the Aβ species responsible for 
toxicity are the protofibrils (intermediate species observed during the formation of 
mature amyloid fibrils), the slowly sedimenting Aβ diffusible non-fibrillar species, some of 
other low molecular intermediates or spherical aggregates. Nonetheless, it is certain that 
the toxicity is associated with peptide structures that are part of an aggregation pathway 
associated with amyloid fibril formation (Wang et al. 2008). Therefore, preventing the 
formation of the presumed toxic oligomeric/fibril aggregates of Aβ by small molecules 
represents a promising approach for the development of novel therapeutic strategies for 
treating AD. Several biomolecules, such as proteins, proteoglycans, lipids, metals, among 
others have been reported to be associated with amyloid plaques in AD brains (Table 2). 
While it is possible that some of these physiologically relevant molecules may be related 
to secondary events in amyloid deposition, several proteins have been described to bind 
Aβ peptide both in vitro and in vivo thus regulating its aggregation and neurotoxicity, either 
by preventing Aβ fibril formation or by contributing to it fibril degradation.  
A Canadian company (Neurochem Inc) has completed a Phase II clinical trial of their 
glycosaminoglycan mimetic Alzhemed that has been designed to bind Aβ peptides and 
thereby inhibits formation of Aβ aggregates. A Phase III trial was subsequently planned 
(reviewed in Citron 2004).  
Metal ions like Cu2+ and Zn2+ may be involved in the mediation of Aβ aggregation and 
toxicity (Atwood et al. 1998). Cherny and colleagues (2001) showed a significant decrease 
in brain Aβ deposition in APP-transgenic mice after 9 weeks treatment with clioquinol (an 
antibiotic and Cu/Zn chelator that crosses the blood-brain barrier).  
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Table 2. Aβ-binding proteins found in amyloid plaques. 
Modulator Aβ secondary 
structure 
Effect on Aβ 
aggregation 
Aβ interaction 
domain 
Plasma proteins 
 Albumin  n/d ↓  1-28 
α1-antitrypsin  n/d ↓  11-28 
IgG  n/d ↓ n/d 
IgA  n/d ↓ n/d 
α1-antichymotrypsin  random  
 ↑/↓  11-28, 29-42 
α2-macroglobulin random  ↓  11-28 
Serum amyloid A  n/d ↑  1-28 
        
Glicosaminoglycans 
 Heparan sulfate β-sheet  ↑ 13-16 
Keratan sulfate β-sheet  ↑ n/d 
Dermatan sulfate β-sheet  ↑ n/d 
Chondroitin sulfate  β-sheet  ↑ 13-16 
        
Apolipoproteins 
 ApoE  β-sheet  ↑/↓  29-42 
ApoJ  β-sheet  ↑/↓  29-42 
ApoA-1  n/d ↓ n/d 
        
Acetylcholinesterase  n/d ↑ n/d 
        
Base membrane components 
 Laminin  n/d ↓ n/d 
Entactin  random  ↓ n/d 
        
Phospholipids 
 Phosphatidylserine  random  ↑  29-42 
Phosphotidylinositol β-sheet  ↑  29-42 
Phosphotidylcholine random  no change  n/d 
Phosphotidylethanolamine random  no change  n/d 
Phosphatidic acid random  ↑  29-42 
Inositol stereoisomers α-helix 
stabilize small 
aggregates 
n/d 
        
Metals 
 Zn2+ β-sheet  ↑ His13, His14 
Cu2+  β-sheet  ↑ His13 
Fe3+  β-sheet  ↑ His 13 
  
n/d – not definned 
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Another potential therapeutic approach to inhibiting Aβ aggregation is the use of peptidic 
inhibitors, consisting of shorter peptide fragments (KLVFF, GVVIN, RVVIA), which have 
been employed to prevent Aβ fibrillogenesis/aggregation. Due to their marked affinity for 
Aβ or critical involvement in Aβ aggregation, these shorter peptide fragments are able to 
interact with Aβ molecules, change Aβ structure and thus prevent the process of 
assembly (reviewed in Wang et al., 2008). 
 
Promoting Aβ clearance via Aβ−binding substances  
Penetration of Aβ-binding substances into the brain provides a chance of inhibiting the 
aggregation of soluble Aβ and/or resolution of Aβ fibrils. This would shift brain 
equilibrium of soluble and aggregated Aβ species towards soluble ones and finally facilitate 
Aβ clearance. Aβ-binding substances may sequester plasma Aβ, leading to Aβ clearance 
by promoting a net efflux of a rapidly mobilized soluble Aβ pool (peripheral sink 
hyphothesis, Figure 20). Peripheral treatment with gelsolin or GM1, an agent that has high 
affinity for Aβ, reduced the level of the peptide in the brain probably because of a 
peripheral action (Matsuoka et al. 2003). Another Aβ-binding substance, enoxaparin (a 
low-molecular-weight heparin), when administrated peripherally, lowered the number of 
cortical Aβ deposits and the total Aβ1-40 concentration, possible by either impeding Aβ 
fibril formation or by sequestering the plasma Aβ peripherally (Bergamaschini et al. 2004). 
 
Promoting Aβ clearance via up-regulation of Aβ degrading enzymes  
Enhancement of Aβ-degradation enzymes represents a novel therapeutic strategy for the 
prevention and treatment of AD (Eckman and Eckman 2005). Gene transfer of both 
neprilysin and IDE reduces the accumulation of Aβ in the brain of AD animal models 
(Leissring et al. 2003; Marr et al. 2003; Iwata et al. 2004). Further, it has been reported 
that Aβ degradation by IDE can be enhanced by a small synthetic peptide substrate, 
without affecting the activity of this enzyme towards insulin (Song and Hersh 2005). 
Somatostatin can also regulate brain Aβ metabolism by up-regulating neprilysin. Aging 
induce downregulation of somatostatin expression, suggesting that somatostatin receptor 
Aβ biology and its contribution to AD   Chapter I 
 
Centro Biologia Celular  81 
Universidade de Aveiro 
 
agonist may be useful in the prevention and treatment of AD. Neprilysin gene promoters 
can be transactivated by AICD (Pardossi-Piquard et al. 2005), which provides a potential 
physiological mode of modulate Aβ levels. Nevertheless, it should be considered that up-
regulation of these Aβ degrading enzymes may also affect the physiological functions of 
other endogenous substrates, such as neuropeptides. 
 
Promoting Aβ clearance via Aβ immunotherapy  
Immunological approaches aim to reduce Aβ load in the brain by either active or passive 
immunization (for review see Wang et al. 2006). Two general approaches have been 
studied in AD mouse models: active vaccination with Aβ or fragments thereof and passive 
infusions of monoclonal antibodies. Both have worked well to clear plaques and lower Aβ 
levels in mice, and they have decreased neuritic dystrophy and even ameliorated learning 
deficits in these models. For instance, Bard et al. (2000) and co-workers, using peripheral 
antibody administration provided direct evidence that Aβ antibodies are sufficient to 
reduce amyloid deposition. These approaches have shown concomitant improvement in 
neuritic dystrophy and cognitive deficits in animal models (Schenk et al. 1999; Dodart et 
al. 2002; Bard et al. 2003; Wilcock et al. 2004; Billings et al. 2005; Maier et al. 2006).  
Anti-Aβ therapy represents the most advanced disease-modifying attempt so far, in terms 
of experience in humans. The first clinical trials of Aβ1-42 immunotherapy, also suggest that 
the active immunization with Aβ peptide is therapeutically effective, as demonstrated by 
eliciting amyloid plaque clearance, reduction in dystrophic neurites or reactive astrocytes 
compared with immunized controls. There is also decreased CSF tau levels and 
diminuished cognitive decline in patients (Lombardo et al. 2003; Nicoll et al. 2003; Ferrer 
et al. 2004; Oddo et al. 2004; Brendza et al. 2005; Gilman et al. 2005; Masliah et al. 2005). 
However, Aβ immunotherapy using aggregated Aβ1-42 as antigen, had to be stopped in 
Phase II due to the developement of autoimmune meningoencephalitis in a significant 
number of patients. The condition appeared to be caused primarily by the infiltration of 
autoreactive T-lymphocytes into the brain in response to active immunization (Nicoll et 
al. 2003; Ferrer et al. 2004). T-lymphocytes are activated by T-cell epitopes mapped to 
Aβ25-42, which is separated from the dominant B-cell epitopes identified in Aβ1-15 
Aβ biology and its contribution to AD       Chapter I 
 
82       Centro Biologia Celular 
Universidade de Aveiro 
 
(Monsonego et al. 2003).  Currently, these findings concerning the adverse effects are 
being considered for the development of alternative approaches in order to avoid the 
unwanted T-cell response induced by Aβ peptide.  Recent studies indicate that new 
vaccines composed of parts of the Aβ molecules, excluding the epitope that might 
provoke abnormal T-cell reactions are under development. Present findings indicate that 
immunization with Aβ1-15 is effective at generating anti-Aβ antibodies in the absence of T-
cell response and leads to reduction of cerebral-plaque Aβ burden and cognitive deficits 
in AD animal models (Agadjanyan et al. 2005; Maier et al. 2006). Antibodies generated 
against N-terminal of Aβ are able to inhibit Aβ fibrillogenesis and cytotoxicity, 
disaggregate pre-existing Aβ fibrils, and are most effective in clearance of amyloid plaque 
(McLaurin et al. 2002; Bard et al. 2003; Bussiere et al. 2004; Horikoshi et al. 2004). 
Recent data from the clinical Phase IIa study suggests that the predominant antibodies 
generated after immunization with Aβ42 (AN1792) are primarily N-terminal (1–8) specific, 
independent of the presence of meningoencephalitis seen in a subset of immunized 
patients (Lee et al. 2005). These preclinical and clinical data provide the basis for an 
improvement of immunization antigens by selecting epitopes, eliciting beneficial immune 
response and avoiding a potentially deleterious cellular immune response. If these novel 
approaches will exhibit the expected safety profile, Aβ immunotherapy holds promise as a 
disease modifying AD therapy.  
Nonetheless, and since AD is multifactorial disorder beside Aβ production/clearance 
other therapeutic targets have been addressed, being the identification of the various 
mechanisms associated with pathology critical for the development of potent disease 
modifying drugs.  
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1.8 AIM OF THE THESIS  
AD is characterized neuropathologically by the presence of amyloid plaques, 
neurofibrillary tangles, synaptic loss and consequent neurodegeneration. APP can be 
cleaved to give rise to different fragments, including the neuroprotective sAPPα fragment 
and the neurotoxic Aβ peptide (a major constituent of amyloid plaques). The disclosure 
of the molecular mechanisms triggered by Aβ is crucial to understanding AD 
pathogenesis, as well normal APP function and processing. Aβ itself has been suggested to 
have an effect on APP metabolism, potentially affecting the balance of APP proteolytic 
fragments produced. Aβ-induced alterations on APP metabolism have been the focus of 
previous attention, although the data reported are controversial. While some authors 
suggested that Aβ exerts its effect solely on APP catabolism/proteolytic cleavage, others 
report that it also induces APP transcriptional activation.  
The main aims of this thesis were to further characterize the Aβ-induced alterations on 
APP metabolism and to clarify the molecular mechanisms underlying Aβ function and 
neurotoxicity. The following specific objectives were addressed: 
- the use of different model systems to study the effect of Aβ in terms of APP 
processing and expression; 
 
- monitorization of the intracellular redistribution of APP protelolytic fragments in 
response to Aβ; 
 
- evaluation of the nature of the identified intracellular sAPP accumulation in 
response to Aβ; 
 
- monitorization of the nuclear targeting of proteolytic fragments, given the well 
documented role of APP as a signal transduction molecule; 
 
- evaluation of the aggregation state of the Aβ peptide and its impact on 
neurotoxicity and APP processing; 
 
- the effect of Aβ on signaling proteins, namely protein phosphatase 1, given the 
central role of signaling cascades in neuronal systems. 
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Chapter Outline 
Aβ accumulation and deposition into amyloid plaques has been reported to be involved in 
the sequential events ultimately leading to the typical AD neurodegeneration. The Aβ 
peptide results from proteolytic processing of APP and thus factors contributing to 
altered APP processing will potentially lead to an imbalance in the generation of APP 
proteolytic fragments. This is of major importance if we consider the variety of functions 
described for both APP and APP fragments, namely sAPPα, which has a neuroprotective 
role. Aβ is produced in natural occurring conditions, particularly in neuronal cells, and so 
it is postulated that it might have a physiological function. Therefore several studies have 
been designed in an attempt to better understand the Aβ-mediated effects and 
consequently contribute to the understanding of the basis of the disease. However, Aβ 
has been reported to have inconsistent effects on APP metabolism, which may contribute 
to Alzheimer´s associated neurotoxicity.  While some authors reported that Aβ leads to 
intracellular APP accumulation by inducing APP expression level, others link this 
observation with inhibition of APP catabolic/secretory processing (Le et al. 1995; Schmitt 
et al. 1997; Moreno-Flores et al. 1998; Carlson et al. 2000). The increase of APP 
transcription may suggest a possible positive feedback mechanism whereby Aβ can induce 
its own production.  In terms of secretion, different data has been obtained, with Aβ 
having either an inhibitory or no effect on sAPP secretion, depending on the cell type 
analysed. For instance, Carlson et al. (2000) reported both inhibition in medium secreted 
sAPP and a concomitant accumulation of mature APP in human glioma cells exposed to 
Aβ1-40 peptide. Interestingly, Aβ25-35 induces cytoskeletal rearrangements in cultures 
astrocytes (Salinero et al. 1997). Mendoza-Naranjo (2007) showed that Aβ1-42 was able to 
stimulate F-actin polymerization, indicating that Aβ may interfere with cytoskeletal 
network. 
 
 
 
 
Aβ biology and its contribution to AD   Chapter II 
 
120       Centro Biologia Celular 
Universidade de Aveiro 
 
In this chapter Aβ-mediated effects on APP metabolism were addressed, in an attempt to 
elucidate the molecular mechanisms induced by Aβ and its potential relevance to AD. 
Experiments were carried out either in non-neuronal, neuronal-like and neuronal cells for 
comparative purposes. Results revealed that several cellular responses were induced 
upon exposure to the Aβ toxic peptide. Alterations could be detected in the processing 
of APP, and mechanistically an accumulation of the neuroprotective sAPPα fragment 
could be observed for all cell types. This observation is in agreement with Carlson et al. 
(2000). Nonetheless, novel contributions were made since we have shown that the 
accumulation of isAPP was associated with cytoskeletal structures in vesicular-like 
densities. The data also suggests that Aβ was affecting the vesicular secretory pathway, 
and this hypothesis was corroborated in primary cultures. Latter on, studies in both 
primary neuronal cultures and PC12 cells demonstrated that Aβ leads to abnormalities in 
cytoskeleton network-related proteins, which may explain the alterations observed in 
APP trafficking.  
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ABSTRACT 
Aβ contributes to neurodegeneration in Alzheimer’s disease and provides a close 
association between molecular events and pathology, although the underlying molecular 
mechanisms are unclear. In the work here described Aβ did not induce APP expression, 
but APP processing/trafficking was markedly affected. In COS-7 cells Aβ provokes 
retention of intracellular sAPPα (isAPPα). Intracellular holoAPP levels remain unchanged 
and extracellular total sAPP increases, although extracellular sAPPα alone did not alter 
significantly. In primary neuronal cultures and PC12 cells isAPP also increased, but this 
was mirrored by a decrease in extracellular total sAPP. The isAPP retention, was 
particularly associated with the cytoskeletal fraction. The retention “per se” occurred in 
vesicular-like densities, negative for a C-terminal antibody and strongly positive for the 
6E10 antibody, clearly showing abnormal intracellular accumulation of sAPPα in response 
to Aβ. Our data supports a dynamic model for intracellular retention of sAPPα as an 
early response to Aβ exposure. Particularly noteworthy was the observation that removal 
of Aβ reversed the isAPP accumulation. Mechanistically these findings disclose an 
attractive physiological response, revealing the capacity of cells to deal with adverse 
effects induced by Aβ. 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Aβ peptide, amyloid precursor protein (APP), Alzheimer’s Disease, 
cytoskeleton. 
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INTRODUCTION  
One of the principal hallmarks of Alzheimer’s disease (AD) is the presence of senile 
plaques in the neocortex and hippocampus of affected individuals, where a small peptide 
termed Abeta (Aβ) predominates (Glenner and Wong 1984). Aβ is a product of 
proteolytic processing of Alzheimer´s amyloid precursor protein (APP), which can 
undergo proteolytic cleavage by β-secretase (mainly BACE1), yielding an N-terminal 
sAPPβ and a C-terminal fragment (CTFβ) (Vassar et al. 1999; Bennett et al. 2000; Yan et 
al. 2001). The latter is further cleaved by the γ-secretase complex, consisting of 
presenilin-1 or 2, nicastrin, aph1 or aph2, and pen2 (Li et al. 2000a; Li et al. 2000b; Esler 
et al. 2002; Lee et al. 2002; Steiner et al. 2002), giving rise to the Aβ peptide. Under 
pathological conditions this peptide can have neurotoxic effects (Gouras et al. 2005) and 
is able to aggregate into senile plaques. In a non Aβ-generating pathway, APP is cleaved by 
α-secretase [including ADAM 10 and TACE (Buxbaum et al. 1998; Lammich et al. 1999; 
Allinson et al. 2003)] within the Aβ domain, therefore precluding its production and 
generating an N-terminal APP fragment, termed sAPPα and a CTFα. Subsequent cleavage 
of CTFα by γ-secretase gives rise to a small fragment termed p3. 
APP proteolytic processing and trafficking are closely related (reviewed in da Cruz e Silva 
and da Cruz e Silva 2003; Small and Gandy 2006), since APP cleavage may occur in several 
subcellular organelles during its intracellular transport. The major sites of Aβ production 
are the Golgi (Xu et al. 1997; Xia et al. 1998; Greenfield et al. 1999) and the endosomes 
(Perez et al. 1999; Vassar et al. 1999; Huse et al. 2000; Rebelo et al. 2007a). 
The α-secretase cleavage can occur within TGN, post-TGN vesicles, and PM, with the 
ratio between intracellular and cell surface sAPPα production appearing to be cell-type 
specific (Sambamurti et al. 1992; Kuentzel et al. 1993; Parvathy et al. 1999; Jolly-Tornetta 
and Wolf 2000; Khvotchev and Sudhof 2004). The balance between α- and β-secretase 
pathways is of physiological relevance, since several AD patients exhibit abnormally low 
ratios of α-secretase APP processing (Citron et al. 1992; Felsenstein et al. 1994). Further, 
levels of both sAPPα and α-secretase ADAM 10 have been reported to be decreased in 
CSF of AD patients (Colciaghi et al. 2002). Hence, in an AD pathology perspective, not 
only is the presence of additional neurotoxic Aβ relevant, but also the decrease in sAPPα 
levels. The latter have themselves been associated with impaired memory and to 
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hippocampal and cortical neurodegeneration (Turner et al. 2003; Thornton et al. 2006). 
sAPPα is also able to counteract Aβ toxicity (Furukawa et al. 1996; Turner et al. 2003), 
and an increase in ADAM 10 activity is associated with a reduction in the production of 
Aβ peptides and their deposition in plaques (Postina et al. 2004).  
Several studies have reported that exogenously added Aβ affects APP metabolism, either 
by altering APP processing/catabolism (Schmitt et al. 1997; Carlson et al. 2000), and/or by 
inducing APP expression (Le et al. 1995; Moreno-Flores et al. 1998). In fact, it was 
suggested that Aβ1-40 can stimulate its own production in a neuronal hybrid cell line (Le et 
al. 1995), although the underlying mechanisms are controversial. 
Consequently we addressed the effects of Aβ in a non-neuronal cell line, and compared it 
to primary hippocampal neurons and neuronal-like cells lines. We showed that Aβ 
dramatically affected APP processing/trafficking causing a specific increase in intracellular 
sAPP (isAPP). The reversible accumulation of isAPP may represent a cell survival 
mechanism in response to Aβ which deserves further investigation. 
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MATERIALS AND METHODS  
Maintenance of cell cultures 
Non-neuronal COS-7 cells (a monkey kidney cell line) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco) supplemented with 3.7 g/l sodium bicarbonate 
and 10% foetal bovine serum (FBS). Neuronal-like PC12 cells (a rat pheochromocytoma 
cell line) were grown in RPMI 1640 (Gibco) supplemented with 0.85 g/l sodium 
bicarbonate, 10% horse serum and 5% FBS. SH-SY5Y cells (a human neuroblastoma cell 
line) were grown in a 1:1 combination of minimum essential medium (MEM, Gibco) and 
Ham’s F12 medim (Gibco), with 10% FBS, 2 mM L-glutamine, 0.1 mM non-essential amino 
acids, 0.055 g/l sodium pyruvate and 1.5 g/l sodium bicarbonate. All cultures were 
maintained at 37ºC and 5% CO2.  
Primary rat hippocampal neuronal cultures were established from 18 days embryos. 
Briefly, after dissociation with trypsin and deoxyribonuclease I (0.15 mg/ml) in Hank’s 
balanced salt solution (HBSS) (0.75 mg/ml during 5-10 min at 37ºC) cells were plated 
onto poly-D-lysine-coated dishes at a density of 1.0x105 cells/cm2 in B27-supplemented 
Neurobasal medium (Gibco), a serum-free medium combination (Brewer et al. 1993). The 
medium was further supplemented with glutamine (0.5 mM), gentamicin (60 µg/ml), and 
glutamate (25 µM). Cultures were maintained in an atmosphere of 5% CO2 at 37ºC for 9 
days, before being used for experimental purposes. 
 
Exposure to Aβ peptide 
Cultures were incubated with 20 µM Aβ25-35 (Sigma) in complete medium for 24 hr, which 
was replaced in the last 3 hr by serum-free medium with or without Aβ. This was the 
conditioned medium collected to monitor extracellular sAPP production. Additionally, for 
the indicated experimental conditions in COS-7 cells, 50 µg/ml of cycloheximide (CHX) 
were added during the last 5 hr and 30 min prior to cells and media collection. This 
period of exposure to CHX was previously determined (da Cruz  e Silva et al. 2004; 
Henriques et al. 2007) as it minimizes adverse toxic effects and is sufficient to completely 
block APP ‘de novo’ protein synthesis. For the remaining cell lines, the experimental 
conditions were as described above but using the appropriate cell-specific medium. For 
hippocampal cultures, incubations were carried out in neurobasal medium without B27. 
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Northern blot analysis 
Following exposure to Aβ, COS-7 cells (2x106 cells) were lysed using TRI REAGENT 
(Sigma) and total RNA was isolated according to the manufacturer’s instructions. 
Normalized total RNA aliquots (15 µg) were separated by formaldehyde gel 
electrophoresis and transferred to nitrocellulose membranes. To evaluate APP 
expression levels, the blot was then hybridized with a [32P]-labelled APP cDNA probe (25 
ng, 1x106 cpm/ng), as described in the MTN Blot User Manual (Clontech). The APP pan-
isoform probe (756 bp) was obtained by Age I/Bam HI restriction digests of APP751 cDNA, 
labelled with [α-32P]dCTPs (GE Healthcare) using the High Prime DNA Labelling Kit 
(Roche, Alfagene), and purified through NucTrap Probe Purification Columns 
(Stratagene). APP hybridizing RNA was detected using PhosphorImager software (Bio-
Rad). 
 
RT-PCR analysis 
Total RNA was extracted from COS-7 cells and hippocampal cultures (2x106 cells in both 
cases) using the RNAgents® total RNA isolation kit (Promega). One microgram of total 
RNA was reverse transcribed to cDNA using Oligo(dT)18 and Stratascript reverse 
transcriptase (Stratagene). Resulting cDNA was amplified by PCR in 50 µl of reaction 
mixture containing 2.5 U of Pfu Turbo DNA polymerase (Stratagene), 40 mM dNTPs, and 
100 ng/µl primers. The primers used amplified the APP sequence between exon 7 
(forward, AGA ACA ACC AGC ATT GCC ACC AC) and exon 9 (reverse, CCT CTC 
TTT GGC TTT CTG GAA ATG), generating fragments of 390 bp, 330 bp and 162 bp for 
APP770, APP751 and APP695 isoforms, respectively. The cDNA was pre-denaturated for 1 
minute at 95ºC, followed by 40 cycles of denaturation at 95ºC for 30 seconds, annealing 
at 60ºC for 30 seconds, and extension at 68ºC for 3 min, and with a final extension for 10 
min at 68ºC. PCR products were resolved on a 2% agarose gel. The relative pattern of 
APP isoforms was determined as a ratio between the specific isoform level and the total 
amount of all APP isoforms amplified. At least three independent RT-PCR analyses were 
carried out for each condition.  
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Cell fractionation 
SH-SY5Y cells were exposed to Aβ and fractions were prepared using the ProteoExtract 
Subcellular Proteome Extraction Kit (Calbiochem). Sequential extraction steps yielded 
fractions containing cytosolic proteins (“Cytosol”), plasma membrane and organelle 
proteins (“Memb+Org”), nuclear proteins (“Nuclear”) and finally cytoskeleton and 
cytoskeleton-associated proteins (“Cytosk”). Fractions obtained were separated on a 5-
20% gradient SDS-PAGE gel and immunoblotted for specific proteins, as indicated.  
 
Immunocytochemistry 
COS-7 cells were plated onto coverslips at a confluency of approximately 50%. Following 
exposure to Aβ25-35 for 24 hr, cells were fixed in 4% paraformaldehyde, permeabilized 
with methanol and blocked with 3% BSA. Subsequently, cells were immunolabelled with 
specific antibodies. In order to distinguish between KPI-positive sAPP/APP and KPI-
negative sAPP/APP isoforms, or their cleaved fragments, we used an anti-KPI monoclonal 
(Chemicon) and an anti-APP C-terminus (rabbit anti-β-APP, Zymed) antibodies. To 
identify the intracellular sAPPα fragment, the 6E10 antibody (Sigma) was used. Organelle 
markers, namely for the endoplasmic reticulum (ER) (calnexin, Stressgen) and the early 
endosomes (Rab5, Stressgen) were also used. Primary antibody complexes were 
visualized using Texas Red- (Molecular Probes) and Fluorescein-conjugated (Calbiochem) 
secondary antibodies. Coverslips were mounted on microscope glass slides using 
antifading reagents containing or not DAPI for nucleic acids (Vectashield, Vector 
Laboratories). Epifluorescence and Differential Interference Contrast (DIC) images were 
acquired using a LSM 510-Meta confocal microscope (Zeiss), and a 63x/1.4 oil immersion 
objective. Argon laser lines of 405 and 488 nm were used to excite DAPI and Fluorescein, 
respectively, and a 561 nm DPSS laser was used to excite Texas Red. Microphotographs 
were acquired in a sole section in the z-axis (xy-mode), and represent a mean of 16 scans. 
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Sample collection and immunodetection 
Conditioned media and cells were collected into boiling 1% SDS, sonicated and boiled. 
Protein determination of the cellular lysates was carried out using the BCA kit (Pierce). 
Samples normalized for protein content were separated on 7.5% SDS-PAGE and then 
electrophoretically transferred onto a nitrocellulose membrane. Immunoblotting was 
carried out using antibodies which detect holo APP (hAPP) but can also detect sAPP 
(22C11, Boehringer), APP C-terminal fragments (rabbit anti-β-APP, Zymed) and sAPPα 
(6E10, Sigma). In the subcellular fraction analysis, specific organelle markers used were 
pan-cadherin (membrane marker, Abcam), histone 4 (nuclear marker, Santa Cruz 
Biotechnology), HSP70(72) (cytosolic marker, Stressgen), calnexin (ER marker, Stressgen), 
and actin (enriched in cytosolic- and cytoskeleton-associated fractions, Stressgen). 
Primary antibody detection made use of horseradish peroxidase-conjugated secondary 
antibodies (Amersham Pharmacia), for enhanced chemiluminescence (ECL and ECL plus 
Amersham Pharmacia Kits). ECL was used to detect N-terminal and C-terminal 
intracellular APP species, HSP70, pan-cadherin, calnexin and actin. ECL plus was used to 
detect extracellular sAPP, intracellular sAPPα, and C-terminal intracellular hAPP and 
histone 4 in cell fractionation assays.  
 
Quantification and statistical analysis 
Quantity One densitometry software (Bio-Rad) was used to quantify band intensity and 
correlate it to protein levels. Data are expressed as mean±SE determinations, from at 
least three independent experiments. Statistical analysis was carried out using one way 
analysis of variance (ANOVA). When the F values were significant, the Dunnett test was 
applied to compare all groups versus control. The level of significance accepted was 
P<0.05. 
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RESULTS 
Aβ induces intracellular sAPPα accumulation  
COS-7 cells exposed to Aβ25-35 for 24 hr were lysed, prepared for immunoblotting and 
probed with the antibodies 22C11, C-terminal and 6E10 (Fig. 1). The former binds to the 
APP N-terminus, recognizing the full-length protein (hAPP) and the cleaved APP (sAPP) 
fragment. The C-terminal antibody binds the C-terminus of APP and only recognizes full-
length hAPP (at the range of the blot being monitored), while 6E10 recognizes the Aβ 
domain and therefore can be used to monitor full-length APP and α cleaved sAPP 
(sAPPα). Comparison of the blots revealed striking responses to exogenously added Aβ. 
The N-terminal 22C11 antibody (Fig. 1A bands a, b and c) showed an increase in 
intracellular APP immunoreactive bands (3.09±0.21), whereas the C-terminus antibody 
which also revealed the same three bands did not detect any alterations in hAPP levels 
upon addition of Aβ (Fig. 1B). By comparing Fig. 1A with Fig. 1B we can directly deduce 
that the observed increment in APP is solely due to an increase in intracellular sAPP 
(isAPP) for APP751/770 and APP695 (, Fig. 1A) which co-migrate with band a and b 
respectively. Corresponding conditioned medium also showed a significant increase in 
sAPP (P<0.01, 1.93±0.08, Fig. 1C). The reversible nature of this effect is evident given that 
Aβ removal in the last 3 hr of incubation yielded a decrease in isAPP (, Fig. 1A) and a 
further increase in total extracellular sAPP (2.97±0.09, Fig. 1C). Since Aβ withdrawal 
concomitantly decreases intracellular accumulated sAPP and increases medium secreted 
sAPP, the latter appears to result from the removal of an Aβ blocking effect on the 
secretion of intracellularly produced sAPP. 
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Fig. 1. Aβ induces alterations on APP metabolism in COS-7 cells. Cells were exposed to 20 µM Aβ25-35 for a 
period of 24 hr. (A) Intracellular sAPP and (B) holo APP levels were determined using the 22C11 antibody and C-
terminal antibodies respectively. ( a), predominantly immature APP751/770; ( b), predominantly immature APP695; ( 
c), mature APP751/770. (upper arrowhead ), intracellular sAPP751/770, and (lower arrowhead ), intracellular sAPP695. 
(C) Total sAPP (22C11 antibody) and (D) sAPPα (6E10 antibody) secretion in conditioned medium. (E) Accumulation 
of intracellular sAPPα in cellular lysates using 6E10 antibody ( intracellular sAPPα). **P<0.01, significantly different 
from control; Dunnett post hoc test. All values are expressed as mean±SE from at least 3 independent experiments. C, 
Control; Aβ, Aβ exposure during 24 hr; Aβ-Aβ, Aβ removal in the last 3 hr.  
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In order to quantify the Aβ effect on the secretion of sAPPα specifically, being this the 
predominant cleavage product, COS-7 cells conditioned medium was also probed with 
the 6E10 antibody (Fig. 1D). Notably, following Aβ exposure, extracellular sAPPα levels 
did not increase as significantly (1.2 fold increase, Fig. 1D) as did total sAPP (2 fold 
increase, Fig. 1C). Similarly extracellular total sAPP increased comparatively more than 
extracellular sAPPα upon Aβ withdrawal (Fig. 1C, D). Consistently, when cell lysates 
were probed with the 6E10 antibody, a significant intracellular sAPPα retention was 
detected (Fig. 1E), but this decreased started to revert towards basal, following Aβ 
withdrawal in the last 3 hr; and correlated with the extracellular sAPPα increase (Fig. 1E, 
D). The sAPPβ species was not addressed directly as it represents a relatively small 
population, particularly difficult to monitor when endogenous protein levels are 
measured.  
 
Aβ does not increase APP expression levels 
To test if the observed increase in isAPP could be due to APP transcriptional activation, 
experiments were repeated in the presence of cycloheximide (CHX, a drug which inhibits 
“de novo” protein synthesis). Experimental conditions were modified, CHX was added in 
the last 5 hr and 30 min of the 24 hr exposure period to Aβ peptide. This period of CHX 
incubation was chosen given that it was previously shown to be sufficient to deplete APP 
levels in COS-7 cells (da Cruz e Silva et al. 2004). Simultaneous exposure of cells to Aβ 
and CHX still led to an increase in isAPP levels, when compared to CHX addition alone 
(Fig. 2A). Further, when Aβ was removed in the last 3 hr but CHX maintained, isAPP 
levels decreased and extracellular sAPP levels significantly increased (Fig. 2B) suggesting 
that Aβ, in fact, blocks sAPP secretion. 
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Fig. 2. Aβ response is maintained in the absence of “de novo” protein synthesis. (A) APP and sAPP () 
intracellular sAPP levels and (B) sAPP secretion was monitored in the presence of cycloheximide (CHX) during the last 
5 hr and 30 min of the 24 hr Aβ incubation period. **P<0.01, significantly different from control; Dunnett post hoc test. 
All values are expressed as mean±SE from at least 3 independent experiments. C - control; CHX, CHX in the last 5 hr 
and 30 min; CHXAβ, CHX and Aβ; and CHXAβ-Aβ, Aβ removal in the last 3 hr in the presence of CHX.  
 
Further, Northern blot analysis indicated that Aβ exposure did not increase APP mRNA 
levels (Fig. 3A). This is consistent with results in Fig. 1B, where protein levels do not 
increase and with the hypothesis that APP transcriptional activation is not induced by Aβ 
exposure as has been previously observed for other cell types (Schmitt et al. 1997; 
Carlson et al. 2000). Isoform specific responses were also addressed using RT-PCR 
analysis and pan-APP primers. The relative abundance of the three major APP isoforms 
(APP770, APP751 and APP695) was unaltered by Aβ treatment, both in COS-7 cells and in 
primary hippocampal cell cultures (Fig. 3B). Hence it is reasonable to conclude that Aβ 
affects APP processing and does not induce APP transcription. 
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Fig. 3. Aβ effects are independent of APP transcriptional induction. Total RNA was purified from cells treated 
for 24 hr with 20 µM Aβ25-35, and either processed for Northern blotting or RT-PCR analyses. (A) Evaluation of APP 
transcription in COS-7 cells, Northern blotting was performed as described in the methods. (B) After cDNA synthesis, 
RT-PCR was carried out using specific primers for the three major APP isoforms in COS-7 cells (that mainly express 
the APP751/770 isoforms) and in hippocampal cultures (Hippoc, enriched in the APP695 isoform). Results are based on an 
APP isoform to total APP isoforms ratio. All values are expressed as mean±SE of 3 independent experiments. M - 
Molecular weight markers; C, Control; Aβ, Aβ treatment. 
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Aβ effect on sAPP secretion is cell type dependent 
Since AD is a neurodegenerative disorder, the evaluation and comparison of Aβ effects in 
non-neuronal and neuronal cells is of particular interest. Several other cell types were 
incubated with 20 µM Aβ25-35 peptide for 24 hr, and in all cases isAPP accumulation was 
observed (, Fig. 4A). Surprisingly, however, a wide range of responses occurred when 
sAPP secretion into the medium was monitored (Fig. 4A).  
 
 
Fig. 4. Aβ effect on sAPP secretion is cell type dependent. (A) Aβ25-35 effects on APP intracellular levels and 
sAPP secretion in primary hippocampal neurons (Hippoc) and in neuronal–like cell lines (PC12 and SH-SY5Y). 
Intracellular hAPP and sAPP (N-terminal 22C11 antibody) and intracellular hAPP (C-terminal antibody) were detected 
using ECL. (upper arrowhead ), intracellular sAPP751/770; and (lower arrowhead ), intracellular sAPP695. Total 
extracellular sAPP was detected using the ECL plus chemiluminescence reagent. (B) Comparison of migration profile 
for intracellular sAPP and extracellular sAPP (↔) with the antibody 22C11. (C) Intracellular sAPP accumulation in 
response to exposure to different Aβ peptides (20 µM) for primary neuronal cultures. C, Control; Aβ, Aβ25-35 
treatment. 
 
 
Aβ biology and its contribution to AD   Chapter II 
 
136       Centro Biologia Celular 
Universidade de Aveiro 
 
While for hippocampal primary cultures, cortical cultures (data not shown) and PC12 
cells, Aβ led to a dramatic inhibition of sAPP extracellular secretion, a contrasting 
response was observed for COS-7 (Fig. 1) and SH-SY5Y cells, where Aβ caused an 
increase in sAPP released into the medium. Nonetheless, in all cases tested, subsequent 
Aβ removal induced a further increase in extracellular sAPP levels (data not shown), as 
previously observed for COS-7 cells (Fig. 1C). As for COS-7 cells, this was not an APP 
isoform-dependent effect, as all isoforms responded similarly in each cell type. Co-
migration of isAPP and extracellular secreted sAPP was confirmed by running both 
samples (lysates and medium) on the same gel system (Fig. 4B, double headed arrow). 
The physiological relevance of isAPP accumulation was further supported by the 
observation that Aβ1-42 yields the same results (Fig. 4C). In summary, one can deduce that 
Aβ exerts its effect not in an isoform specific manner, but possibly on different secretory 
APP/sAPP trafficking pathways. Hence, subcellular fractionation studies and 
immunofluorescence assays were performed in either SH-SY5Y or COS-7 cells.  
 
sAPP is retained in cytoskeletal-associated structures 
Differential separation of proteins according to their subcellular localization was carried 
out following incubation of SH-SY5Y cells with Aβ. Subcellular organelle markers were 
used to confirm the enrichment of the different fractions (Fig. 5). The cytosolic fraction 
was enriched in HSP70 and cytosolic actin. The membranar fraction contained plasma 
membrane (pan-cadherin enriched) and organelles (ER marker, calnexin), with the nuclear 
fraction being enriched in histone 4, as expected. The cytoskeleton/microtubule fraction 
was actin and pan-cadherin-positive and free of organelle and nuclear markers (Fig. 5).  
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Fig. 5. APP subcellular distribution in response to Aβ treatment. Following incubation with Aβ25-35, SH-SY5Y 
cells were fractionated as described and the resulting fractions analyzed by immunoblotting. Total – total cell lysate; 
Cytosol – cytosolic protein fraction; Memb + Org – membrane and organelle enriched fraction; Nuclear – nuclear 
enriched fraction; and Cytosk – Cytoskeleton protein fraction. (), isAPP forms; ( c), mature hAPP751/770; and ( d), 
potential mature APP695 and also APLP forms. Intracellular sAPP and APP isoforms (N-terminal 22C11 antibody), pan-
cadherin (membrane marker), calnexin (ER marker), HSP70 (cytosolic marker) and actin (cytosolic and cytoskeleton 
marker) were detected using ECL; intracellular hAPP (C-terminal antibody) and histone 4 (nuclear marker) were 
detected using the highly sensitive ECL plus reagent. C, Control; Aβ, Aβ treatment. 
 
Immunoblot analysis of subcellular fractions with 22C11 or C-terminal antibodies allowed 
us to distinguish hAPP () from sAPP (). A substantial accumulation of isAPP in the 
cytoskeletal fraction was evident, and a less marked increase could also be detected in the 
cytosolic fraction. A decrease in membrane-associated mature hAPP following Aβ 
exposure was demonstrated, as determined with both C- and N-terminal antibodies, and 
this was accompanied by an increase in mature hAPP751/770 C-terminal positive isoforms in 
the cytoskeletal fraction ( c, Fig. 5). Other APP species, potentially mature hAPP695 
and/or APLP forms ( d, Fig. 5), which have a higher molecular weight than the N-
terminal isAPP fragments ( isAPP, Fig. 5), also appeared to be retained in cytoskeletal-
associated structures. In essence, Aβ exposure leads to a decrease in mature hAPP 
species in plasma membrane (PM), ER and Golgi-enriched membranar fraction, and to an 
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increase in the cytoskeletal fraction. Simultaneously, isAPP accumulates in the same 
cytoskeletal fraction and in the cytosolic fraction, fractions known to be associated with 
cytoplasmic vesicles. This suggests that mature hAPP is cleaved intracellularly before 
reaching the PM. These results strengthen the previous hypothesis that Aβ is exerting its 
blocking effect at the secretory level, with this being further investigated by 
immunofluorescence analysis. 
 
Aβ induces accumulation of sAPPα-containing vesicular-like densities  
To identify the intracellular site of sAPP retention, a C-terminal antibody that recognizes 
all endogenous hAPP isoforms and CTFs, and an anti-APP KPI antibody (specific for the N 
terminus of hAPP751/770 - the most abundant isoforms in COS-7 cells - and their cleaved 
fragments sAPP751/770) were used (Fig. 6). Under basal conditions, the co-localization of C-
terminal positive and KPI-positive hAPP751/770 was evident in small vesicles distributed 
throughout the cytoplasm (yellow/orange specs). C-terminal-positive and KPI-negative 
staining (APP CTFs and APP695/APPLPs) was detected in the nucleus, vesicles, and in the 
Golgi (typical APP distribution). The latter are known subcellular sites of APP cleavage, 
and subsequent production of CTFs and sAPP.  
Strikingly, Aβ treatment led to a dramatic accumulation of KPI-positive and C-terminal 
negative, green only clusters (white arrow, Fig. 6). Given the immunoreactive profile of 
these clusters, it is reasonable to conclude that they are sAPP751/770–containing vesicular 
structures and therefore consistent with these being the subcellular structures where 
isAPP accumulates. These clusters were found concentrated in the cytoplasm and near 
the PM. 
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Fig. 6. APP and sAPP intracellular distribution in response to Aβ. COS-7 cells were treated with Aβ25-35 and 
endogenous APP and sAPP subcellular localizations were addressed using either a KPI specific or the C-terminal 
antibody. ROI, region of interest (dashed box). Epifluorescence images where acquired using a Zeiss confocal 
microscope. Representative examples are shown for each experimental condition. C, Control; Aβ, Aβ treatment. Bar, 
10 µm. 
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Given that the ER is a possible alternative pathway of sAPP production/secretion (Shin et 
al. 2005; Rebelo et al. 2007b), co-localization studies were carried out with anti-APP KPI 
and anti-calnexin (ER marker) antibodies. Exposure to Aβ did not render any visible effect 
on the ER morphology itself as is evident from the consistency of calnexin staining (red 
cytoplasmic and perinuclear staining). KPI(APP and sAPP)/calnexin(ER) co-localization was 
maintained in cytoplasmic and ER regions even in the presence of Aβ (Fig. 7, intermediate 
focus plane, yellow/orange staining in overlay), supporting the existence of an alternative 
sAPP ER-secretory pathway. Confocal microscopy at the nuclear focus plane, under basal 
conditions (Fig. 7) revealed APP KPI-positive green staining at the perinuclear ER 
(calnexin positive, red staining).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. ER integrity remains unaltered upon Aβ treatment. Following Aβ exposure as previously described, 
perinuclear and cytoplasmic APP (KPI antibody) co-localizations with an endoplasmic reticulum protein marker 
(calnexin) were evaluated at intermediate (above nucleus and below cell surface) and nuclear focus planes. Intense 
green fluorescent isAPP clusters are evident, solid arrow. Epifluorescence images where acquired using a Zeiss confocal 
microscope. C, Control; Aβ, Aβ treatment. Bar, 10 µm. 
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However, upon Aβ addition the green perinuclear staining decreased (dashed arrow), 
consistent with a decrease in hAPP observed for the “Memb+Org” fraction (Fig. 5). As 
described above, accumulation of green clusters were again evident in response to Aβ 
addition (solid arrow). Of note is that the cells are not apoptotic, as revealed by the DAPI 
staining (Fig. 7). Additional studies revealed that the vesicular-like densities, mainly 
negative with the C-terminal antibody but positive with the KPI antibody, are also 6E10 
positive, thus characterizing the APP fragment retained intracellularly as mainly isAPPα 
(Fig. 8A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. sAPPα subcellular localization following Aβ exposure. sAPPα intracellular localization following Aβ 
treatment was determined using either the anti-APP 6E10 antibody and DIC microscopy (white arrows) (A) or the 
6E10 and Rab5 and (an early endossomal marker) antibodies and epifluorescence confocal microscopy (B). Intense 
green fluorescent isAPP clusters are evident upon Aβ treatment. C, Control; Aβ, Aβ treatment. Bar, 10 µm.  
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Moreover, DIC microscopy along with 6E10 immunofluorescence staining showed that 
although the isAPPα accumulation could be detected throughout the cytoplasm it 
occurred mainly near the PM (white solid arrows, Fig. 8A). Immunofluorescent studies 
obtained using the 6E10 and Rab5 (an early endosome marker) antibodies, showed 
virtually no co-localization of the isAPPα containing densities (Fig. 8B), revealing that 
isAPP is not accumulating in endocytic vesicles. In conclusion, the observed isAPPα 
accumulation in cytoplasmic vesicular-like densities near the cell surface is consistent with 
the subcellular fractionation data (Fig. 5) and with Aβ having and inhibitory effect on the 
APP Golgi-to-PM secretion via post-TGN vesicles. 
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DISCUSSION 
Aβ is produced under physiological conditions, but various reports have shown it to be 
potentially neurotoxic. Aβ was added to cells in culture at concentrations where 
induction of apoptosis was minimal. Under conditions tested Aβ altered APP processing 
in a reversible manner. This response was addressed in different cells types using the 
biological active domain Aβ25-35, which shows similar properties to naturally occurring Aβ1-
40 and Aβ1-42 (the principal component of AD senile plaques) (Pike et al. 1995; Xu et al. 
2001a; Xu et al. 2001b; Liao et al. 2007). Hence, Aβ25-35 represents a good experimental 
model to study Aβ-downstream molecular mechanisms that may be involved in AD. 
Several authors have reported that Aβ itself can alter APP metabolism, with the 
underlying mechanisms potentially involving Aβ-dependent induction of APP mRNA (Le et 
al. 1995; Moreno-Flores et al. 1998), or altered APP processing/catabolism (Davis-Salinas 
et al. 1995; Yang et al. 1995; Schmitt et al. 1997; Carlson et al. 2000). In our work, we 
observed that COS-7 cells exposed to Aβ25-35 exhibited an increase in APP intracellular 
levels, as detected with an N-terminal antibody that recognizes both hAPP and sAPP, 
confirming previous reports (Davis-Salinas et al. 1995; Le et al. 1995; Schmitt et al. 1997; 
Moreno-Flores et al. 1998; Carlson et al. 2000). However, by probing with a C-terminal 
antibody no differences could be detected in hAPP levels, allowing us to deduce that the 
observed accumulation resulted from a rise in an intracellular sAPP pool (isAPP). This has 
only been suggested by Carlson et al. (2000). Removal of the Aβ peptide during the last 3 
hr of the 24 hr incubation period (Aβ-Aβ) reverted this effect, resulting in a significant 
isAPP decrease and in increased sAPP secretion. Thus, it seemed reasonable to deduce 
that mechanistically Aβ does not inhibit sAPP production but rather blocks its 
secretion/release to the extracellular milieu. Further, given that upon addition of Aβ the 
expression levels of APP in COS-7 cells are largely unaltered and that both isAPP as well 
as total sAPP in conditioned medium increase, it would appear that Aβ also has the 
capacity to induce sAPP production. 
The use of specific antibodies allowed us to elucidate that Aβ was particularly affecting 
sAPPα secretion/release. Using the 6E10 antibody (Fig. 1E) we observed a high Aβ25-35-
induction of intracellular sAPPα retention in the cellular lysates but only marginal 
increases in sAPPα medium secretion (Fig. 1D). Levels were partially reverted following 
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Aβ withdrawal, again reinforcing a mechanism whereby Aβ blocks sAPPα secretion. This 
is consistent with previous observations of Aβ1-40 on isAPPα (Carlson et al. 2000), and 
may explain the different fold increases in total sAPP (Fig. 1C) and sAPPα secretions (Fig. 
1D). These differences suggest that APP cleavage by β-secretase is also enhanced and that 
sAPPβ is well secreted, leading to higher levels of total sAPP secreted when compared to 
sAPPα only. Noticeably, contrary to previous reports by other authors, increased 
accumulation of APP proteolytic fragments was not due to enhanced APP transcription 
(Figs 2, 3). 
Aβ-induced isAPP retention was also demonstrated for SH-SY5Y and PC12 cells and 
primary neuronal cultures (Fig. 4). Differences however were observed for extracellular 
sAPP secretion. For COS-7 (Fig. 1) and SH-SY5Y there was an increase, whereas for 
PC12 and primary neuronal cultures a decrease was observed. Dissimilar effects on sAPP 
secretion have been reported by several authors upon exposure of different cell lines to 
Aβ peptides (Davis-Salinas et al. 1995; Schmitt et al. 1997; Carlson et al. 2000). We 
propose that these different responses in the levels of secreted sAPP could be due to cell 
type-specific processing pathways. Neuronal and even undifferentiated PC12 cells are well 
known models of highly regulated secretion, presenting not only a constitutive secretory 
vesicular pathway but also stimuli-sensitive regulated vesicular secretion (Greene and 
Tischler 1976; Burgess and Kelly 1987; Martin and Grishanin 2003). In contrast, besides 
the constitutive vesicular pathway, no regulated vesicular secretion has been described 
for COS-7 cells, and in undifferentiated SH-SY5Y cells, only residual regulated vesicular 
machinery appears to exist (Goodall et al. 1997), and not reported to be associated with 
APP/sAPP secretion. Our data suggest that sAPP/APP targeting to secretory pathways 
may be under tight control in neurons and PC12 cells, while it may be less regulated in 
COS-7 and undifferentiated SH-SY5Y cells, where other non-vesicular secretory routes 
may be used. A novel APP α-secretase cleavage pathway was recently described for COS-
7 cells, involving the cytoplasmic-spanning smooth ER (Shin et al. 2005). These authors 
also observed that sAPP deriving from an APP mutant with and ER-retrieval signal did not 
follow the normal post-TGN vesicular secretory pathway. For that mutant, sAPP 
secretion was diminished but not absent, and sAPP appeared to be media secreted via the 
smooth ER, as deduced from strong sAPPα/ER co-localization. Further, in our laboratory, 
an APP phosphomutant with impaired vesicular secretion was observed to produce and 
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secrete normal levels of sAPP, apparently through the cytoplasmic ER (Rebelo et al. 
2007b). Accordingly, in the immunocytochemistry experiments here described, some 
isAPP could be observed to co-localize with the ER marker calnexin (Fig. 7, intermediate 
plane), even upon addition of Aβ. The calnexin positive structures (potentially the smooth 
ER) were themselves largely unaffected by Aβ and did not co-localize with the identified 
sAPP clusters near the PM. Therefore, we postulate that the major APP/sAPP secretory 
pathway (vesicular) is compromised and, since the ER integrity remained unaltered, that in 
the presence of Aβ, sAPP of Golgi/ER origin could be redirected to an alternative, usually 
less used, ER-to-PM secretory pathway. This explains why under Aβ exposure we could 
still observe secretion of a pool of sAPP (Fig. 1). Further, the specificity of the sAPP 
retention effect on sAPPα may derive from the different pools of sAPP production. The 
α-secretase pathway is mainly associated with the TGN, post-TGN vesicles and the PM, 
while the β-secretase pathway mainly occurs at the Golgi and endosomes. Mechanistically 
Aβ appeared to be particularly affecting the vesicular secretory pathway, and in COS-7 
cells, sAPP pools produced at the Golgi and ER (before post-TGN vesicles packaging) 
could still be secreted through the ER.  
Further data supported the hypothesis of an Aβ-dependent inhibition of sAPP vesicle 
secretion. The subcellular fractionation data revealed that isAPP retention was associated 
with the cytoskeleton (, Fig. 5). As the cytoskeleton network has long been associated 
with vesicular motility (Meyer and Burger 1979; Hamm-Alvarez and Sheetz 1998; Buss et 
al. 2004; Lanzetti 2007; Potokar et al. 2007), this is in agreement with an Aβ blocking 
effect at a sAPP/APP secretory vesicular level. Immunofluorescent assays were therefore 
performed in COS-7 cells, and isAPP accumulation was detected in cytoplasmic vesicular-
like structures often aggregated into clusters mainly found just below the PM (Figs 6, 7, 8). 
Further, the pattern of APP/Rab5 co-localizing vesicles was apparently unchanged upon 
Aβ treatment, and isAPPα-positive clusters did not co-localize with this early endosome 
marker (Fig. 8B). Therefore, our results support that isAPP accumulation in response to 
exogenous Aβ is derived from the secretory pathway, where sAPPα generation is known 
to occur. Altered intracellular trafficking in response to Aβ had already been suggested to 
account for increased cellular APP (Carlson et al. 2000). Possible underlying mechanisms 
proposed included Aβ interference with cytoskeleton-mediated transport and associated 
proteins (Salinero et al. 1997; Carlson et al. 2000; Mendoza-Naranjo et al. 2007). Our 
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results validate this hypothesis and are consistent with Aβ impairing vesicle motility along 
the cytoskeleton and/or inhibiting vesicle docking/fusion at the PM, leading to isAPP 
accumulation within vesicular-like structures before reaching the cell membrane. In 
parallel, hAPP at the Golgi and ER is a potential substrate for α- and β-secretases, with 
the resultant sAPP being free to be transported via the ER and subsequently medium 
secreted.  
Our data supports a model where intracellular retention of sAPPα may be an early 
cellular response to Aβ exposure. This is of particular relevance to AD pathology when 
considering that the secretion of this neuroprotective fragment is affected in this disease. 
Indeed, it has been well described that the levels of the memory-related and potential 
regenerating sAPPα fragment are decreased in AD brain and CSF (Colciaghi et al. 2002; 
Olsson et al. 2003). Furthermore, we have shown that Aβ exerts an effect in the APP 
secretory vesicular route, impairing the normal Golgi-to-PM sAPP/APP traffic and blocking 
sAPP secretion. The involvement of cytoskeleton-associated alterations, producing 
vesicular movement abnormalities, is now being further evaluated in our laboratory. 
Removal of Aβ reverses isAPP accumulation thus representing the ability of cells to deal 
with adverse effects. However, continued exposure to Aβ would contribute to 
progressive neurodegeneration. Of note, Aβ had a more dramatic effect in inhibiting sAPP 
secretion in cells known to have highly regulated vesicular secretion, such as neurons. 
These differential Aβ responses in neuronal and non-neuronal cells are of particular 
interest if one considers that AD is a neurodegenerative condition essentially affecting the 
brain and sparing most of the peripheral tissues. 
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ABSTRACT 
In neurons, APP is anterogradelly transported in a kinesin–associated manner to axonal 
vesicular compartments. The major properties attributed to Aβ are its neurotoxic 
properties which may be responsible for AD neurodegeneration. However, Aβ can also 
affect APP processing, and here we show that it can induce the accumulation of 
intracellular sAPP (isAPP), in primary neuronal cultures. Retention of sAPP (positive for 
an APP N-terminal antibody and negative for an APP C-terminal antibody) was localized 
to cytoskeleton associated vesicular-like structures along the neurite processes. These 
structures were also positive for kinesin light chain (KLC). Furthermore Aβ affected both 
actin and microtubule networks, in particular by increasing F-actin polymerization and 
decreasing α-tubulin acetylation. The use of cytoskeleton affecting drugs reversed the Aβ-
induced effects on sAPP secretion. The data here presented supports that Aβ causes 
isAPP retention by inducing alterations in the cytoskeleton network, thus contributing to 
impaired APP vesicular transport. Moreover, the data strengthens the hypothesis of Aβ 
induced neurodegeneration, since impaired vesicular and axonal transport have been 
linked to AD pathology.  
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Aβ peptide, amyloid precursor protein (APP), Alzheimer´s Disease, 
secretory vesicular pathway, neuroprotection, subcellular localization 
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INTRODUCTION 
Alzheimer´s Disease (AD) is a neurodegenerative disorder of the CNS, prevalent in the 
elderly. Neuropathologically AD is characterized by the presence of amyloid plaques 
(Glenner and Wong, 1984), mainly composed of Aβ peptide, and neurofibrillary tangles, 
formed by hyperphosphorylated tau aggregates (Goedert et al., 1992), along with 
widespread synaptic and neuronal loss in distinct brain areas such as the neocortex and 
hippocampus (Hyman et al., 1984; Masliah et al., 1991; Terry et al., 1991). These changes 
have been reported to be accompanied by severe disruption of both axonal and dendritic 
cytoskeleton, suggesting failure in axonal transport in AD. In fact, abnormal axons 
precede amyloid deposition in some mouse models, suggesting that axonal defects may 
play a crucial role in the earliest stages of AD pathogenesis (Stokin et al., 2005). Further, 
AD axonal pathology includes atypical axons that exhibit abnormal accumulations of the 
amyloid precursor protein (APP) (Cras et al., 1991) and its fragments (Sennvik et al., 
2004; Takahashi et al., 2004), consistent with altered or blocked APP axonal transport. In 
AD there is also impaired transport of neurotransmitters and neuropeptides (reviewed in 
Bell and Claudio Cueelo, 2006), processes essential for neuronal viability and function. 
KLC-driven APP axonal transport has been suggested, either by direct APP interaction 
with KLC (Kamal et al., 2000), or indirectly via complex formation with JIP-1 (Inomata et 
al., 2003; Lazarov et al., 2005; Matsuda et al., 2003). Additionally, kinesin-1 reduction 
enhances the development of axonal abnormalities, as well as enhancing aberrant Aβ 
generation and amyloid deposition (Gunawardena and Goldstein, 2001). The latter 
derives from the amyloidogenic processing of APP, as it is sequentially cleaved by β-
secretase (mostly BACE-1) (Vassar et al., 1999; Yan et al., 2001) and the γ- secretase 
complex (comprising presenilin, nicastrin, APH1 and PEN2) (Esler et al., 2002; Lee et al., 
2002; Li et al., 2000; Steiner et al., 2002). Generation of Aβ also leads to the extracellular 
release of sAPPβ and intracellular APP C-terminal domain (AICD). In neurons, APP was 
found in an axonal vesicular compartment which is anterogradelly transported in a 
kinesin-dependent manner (Kamal et al., 2001), a potential subcellular compartment for 
Aβ generation. Alternatively, APP can be processed in a non-amyloidogenic pathway by α-
secretase (Allinson et al., 2003; Buxbaum et al., 1998; Lammich et al., 1999) and the γ-
secretase complex, hence precluding Aβ formation and giving rise to the peptide p3 and 
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sAPPα. Contrary to the Aβ peptide, the latter fragment has been reported to have 
neurotrophic and neuroprotective functions when added to cells in culture (Thornton et 
al., 2006; Turner et al., 2003). 
Alterations in the intracellular transport of APP may affect the extent to which APP is 
available for β- or α-secretase cleavage in specific subcellular compartments, thus 
influencing the balance between the two pathways and subsequent generation of the 
different fragments. Since, APP anterograde transport has been associated either directly 
or indirectly with kinesin-1 complex and microtubules, APP trafficking is susceptible to 
alterations in the cytoskeleton network and its related proteins. Interestingly, Aβ peptide 
was reported to induce cytoskeleton reorganization and morphological alterations in 
astrocytes (Salinero et al., 1997). Additionally, our previous studies in a non-neuronal cell 
line, also demonstrated that Aβ leads to intracellular sAPP (isAPP) retention in vesicular-
like densities associated with the cytoskeleton enriched fraction (Henriques et al., 2009a, 
in press). We demonstrated that the neuroprotective sAPPα fragment was particularly 
affected, being found in high density clusters in the cytoplasm. sAPP intracellular retention 
was observed in non-neuronal and neuronal-like cell lines and primary cultures, as 
confirmed in the study here described. From the evidence available one can deduce that 
Aβ interferes with APP processing and sequential release of proteolytic sAPP fragments. 
As explained above, in neurons APP is axonally transported and this is tightly associated 
with the secretory vesicular pathway. Further, APP axonal trafficking has been associated 
with kinesin-driven transport along the microtubule network. Thus, we went on to 
characterize Aβ-induced effects on neuronal APP processing and vesicular trafficking and 
to relate these to altered neuronal cytoskeleton network dynamics. 
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MATERIALS AND METHODS 
Cell culture  
Primary rat cortical and hippocampal neuronal cultures were established from 18 days rat 
embryos as previously described (Henriques et al., 2007). Following dissociation with 
trypsin and deoxyribonuclease I (0.15 mg/ml) in Hank’s balanced salt solution (HBSS) 
(0.45 mg/ml for cortical cultures or 0.75 mg/ml for hippocampal cultures during 5-10 
minutes at 37ºC), cells were plated onto poly-D-lysine coated dishes at a density of 
1.0x105 cells/cm2 in B27-supplemented Neurobasal medium (Gibco), a serum-free 
medium combination (Brewer et al., 1993). The medium was further supplemented with 
glutamine (0.5 mM), gentamicin (60 µg/ml), and glutamate (25 µM, for hippocampal 
cultures only). Cultures were maintained in an atmosphere of 5% CO2 at 37ºC for 9 days, 
before being used for experimental purposes. 
Neuronal-like PC12 cells (a rat pheochromocytoma cell line) were grown in RPMI 1640 
medium (Gibco) supplemented with 0.85 g/l sodium bicarbonate, 10% horse serum and 
5% FBS, and maintained at 37ºC and 5% CO2. For experimental procedures, cells were 
plated at a density of 5.0x105 cells/cm2 in poly-L-ornithine coated dishes. 
 
Exposure to Aβ  
Both primary neuronal cultures and PC12 cells were incubated with 20 µM Aβ25-35 (Sigma) 
during 24 h in the appropriate medium, which was replaced in the last 3 h by serum free 
medium with or without Aβ peptide. This was the conditioned medium collected to 
monitor extracellular sAPP production. For primary neuronal cultures experiments were 
carried out in Neurobasal medium-free of B27. 
 
Sample collection and immunodetection 
Following Aβ treatment, conditioned media and cells were collected as previously 
described (Amador et al., 2004). Cells were harvested into boiling 1% SDS, sonicated and 
boiled for 10 minutes. Protein determination of the cellular lysates was carried out using 
the BCA kit (Pierce). Samples normalized for protein content were separated on 7.5% 
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SDS-PAGE and then electrophoretically transferred onto a nitrocellulose membrane. 
Immunoblotting detection of APP and sAPP was carried out using antibodies that permit 
distinguishing between holo APP (hAPP)/APP CTFs (C-terminal fragments) and sAPP. The 
antibodies used were an APP N-terminal antibody (22C11, Boehringer) and an APP C-
terminal antibody (rabbit anti-β-APP, Zymed). 
Conditioned media were also processed to detect secreted proteins. Briefly, samples 
separated by SDS-PAGE, processed as described above, were fixed in a solution 
containing 50% methanol and 5% acetic acid for 30 minutes. The fixing solution was 
replaced with 50% methanol for 15 minutes, after which sensitizing solution [0.02% (w/v) 
sodium thiosulphate] was added for 1 minute. Subsequently, a staining solution of 0.2% 
(w/v) of silver nitrate chilled to 4ºC was added to the gel and allowed to incubate for 25 
minutes. Finally, the gel was incubated with developing solution of 3% sodium carbonate 
and 0.025% (v/v) of 37% formaldehyde and developed for a maximum of 10 minutes, using 
a 1.4% (w/v) sodium EDTA solution to stop color development.  
 
Quantification and statistical analysis 
Quantity One densitometry software (Bio-Rad) was used to quantify band intensity and 
correlate it to protein levels. Data are expressed as mean±s.e.m. determinations, from at 
least three independent experiments. Statistical analysis was carried out using one way 
analysis of variance (ANOVA). When the F values were significant, the Dunnett test was 
applied to compare all groups versus control. The level of significance accepted was 
P<0.05. 
 
Subcellular fractionation  
Primary neuronal cultures and PC12 were exposed to Aβ as previously described and 
subcellular fractions were prepared using the ProteoExtract Subcellular Proteome 
Extraction Kit (Calbiochem). The differential solubility of the subcellular compartments in 
specific reagent mixtures enables the differential extraction of proteins according to their 
subcellular localization. Sequential extraction steps yielded fractions containing cytosolic 
proteins (“Cytosol”), plasma membrane and organelle proteins (“Memb+Org”), and 
cytoskeleton and cytoskeleton-associated proteins (“Cytosk”). Fractions obtained were 
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separated on a 5-20 % gradient SDS-PAGE gel and immunoblotted for specific proteins, as 
indicated.  
For the subcellular fractionation studies, specific organelle markers used included 
HSP70(72) (cytosolic marker, Stressgen) and syntaxin 6 (Golgi marker, BD Biosciences). 
Actin (Stressgen) and β-tubulin (Zymed) confirmed subcellular enrichment in cytosolic- 
and cytoskeleton-associated fractions. Primary antibody detection made use of 
horseradish peroxidase-conjugated secondary antibodies (Amersham Pharmacia) for 
enhanced chemiluminescence detection (ECL, Amersham Pharmacia). ECL Plus was used 
to detect extracellular sAPP, syntaxin, carboxipeptidase E (CPE) and intracellular hAPP.  
 
APP and sAPP localization  
For immunofluorescence analysis, cells were plated onto coverslips at a confluency of 
approximately 50%. Following exposure to Aβ25-35 for 24 h, cells were fixed in 4% 
paraformaldehyde, permeabilized with methanol and blocked with 3% BSA. Subsequently, 
cells were immunolabelled with specific antibodies. To distinguish between APP and sAPP, 
or other APP cleaved fragments, primary cultures were incubated with an antibody 
against APP N-terminal (22C11, Boheringer) and an anti-APP C-terminus antibody (rabbit 
anti-β-APP, Zymed). The kinesin light chain (KLC) antibody (Santa Cruz Biotechnology) 
was used as a marker for the APP vesicular anterograde transport.  
Primary antibody complexes were visualized using Texas Red- (Molecular Probes) and 
Fluorescein-conjugated (Calbiochem) secondary antibodies. Coverslips were mounted on 
microscope glass slides using antifading reagents (Vectashield, Vector Laboratories) 
containing in some cases DAPI for nucleic acid staining. Epifluorescence images were 
acquired using a Zeiss LSM 510-Meta confocal microscope and a 63x/1.4 oil immersion 
lens. Argon laser lines of 405 and 488 nm were used to excite DAPI and Fluorescein, 
respectively, and a 561 nm DPSS laser was used to excite Texas Red. Microphotographs 
were acquired in a sole section in the z-axis (xy-mode) and represent a mean of 16 scans. 
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Labbeling F-actin and acetylated α-tubulin  
Cells fixed with paraformaldehyde were permeabilized with a solution of acetone at -20 
ºC for 3 min. Subsequently, cells were washed with PBS and then incubated with PBS 
containing 1% BSA for 1 hour. This blocking solution was removed and phallotoxin 
staining solution (labels F-actin) was added to cells (1.5 U/100 µl in PBS containing 1% 
BSA) for 30 min at RT. After PBS washing, cells were incubated with an anti-acetylated α-
tubulin antibody (Zymed) for 2 h and primary complexes visualized using Fluorescein 
conjugated secondary antibody (Calbiochem). Coverslips were mounted and visualized as 
previously described. 
 
Biochemical assays on cytoskeleton polymerization 
Cells were incubated with Aβ25-35 for 21 hour, followed by a 3 h incubation period with 
fresh medium with or without Aβ in the presence or absence of 10-40 µM cytochalasin D 
(a compound that drives actin depolymerization) or 20-40 µM taxol (that drives 
microtubule stabilization).  
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RESULTS  
Aβ-induced intracellular sAPP accumulation in primary neuronal cultures is 
associated with the cytoskeleton  
Primary neuronal cultures and PC12 cells were incubated with Aβ25-35 peptide for 24 h, 
and in the last 3 h of the incubation, the medium was replaced by fresh medium 
containing Aβ (Aβ) or without Aβ (Aβ-Aβ). To distinguish between cleaved APP (sAPP) 
and the full-length holoAPP (hAPP) protein, two antibodies were used, an anti-APP N-
terminus 22C11 antibody, which recognizes both holo APP and sAPP, and an anti-APP C-
terminal antibody, that recognizes hAPP, were used. We observed that in both primary 
cortical and hippocampal neuronal cultures, Aβ induced an increase in APP intracellular 
levels (Fig. 1A) of 2.0±0.18 and 1.6±0.13 fold, respectively. Conversely, Aβ decreased 
hAPP levels (C-terminal antibody) to 0.6±0.01 for cortical cultures and 0.7±0.05 for 
hippocampal cultures, of control levels. In agreement with these observations, a decrease 
in APP mRNA was observed for neuronal cultures (Henriques et al. 2009b, in press). 
Under the same conditions, extracellular sAPP secretion was markedly decreased in both 
neuronal cultures, to 0.2±0.04 (cortical) and 0.1±0.04 (hippocampal). Further, if Aβ was 
removed during the last 3 h of incubation, the secretory block was released (Fig. 1A), 
leading to an increase in extracellular sAPP, reaching control levels in both hippocampal 
(1.1±0.09) and cortical neurons (1.3±0.14). This confirms that isAPP retention/sAPP 
secretory block in primary neuronal cultures are indeed Aβ-specific inhibitory effects. 
Additionally, analysis of the conditioned media demonstrated that the Aβ inhibitory effect 
on secretion was not generalized since many secreted proteins were unchanged after Aβ 
treatment, as revealed by silver staining proteins present in the conditioned medium (Fig. 
1B). In parallel, similar data were obtained for PC12 cells, both in terms of intracellular 
APP accumulation and sAPP secretion (Fig. 1C). 
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Fig. 1. Aβ induces intracellular sAPP retention in primary neuronal cultures and PC12 cells. Immunoblot 
analysis of cellular lysates and conditioned medium was performed with the specified antibodies (A and C). (), isAPP. 
B. The total protein content of primary neuronal cultures conditioned medium was analyzed by silver staining. Full 
arrows: bands with increased intensity upon Aβ treatment. Dashed arrows: bands with decreased intensity upon Aβ 
treatment. Unfilled arrowheads: roughly unchanged bands. (C), control cells; (Aβ), cells exposed to Aβ for 24 h; (Aβ-
Aβ), cells exposed to Aβ for 21 h, and further incubated in Aβ-free medium for 3 h. 
 
In order to characterize the nature of this isAPP retention we performed both subcellular 
fractionation analysis and immunofluoresecence analysis. We observed the association of 
isAPP with cytoskeleton structures, for both PC12 cells and for primary cortical neurons 
(Figs 2A, B). The cytoskeleton/microtubule containing fraction was actin and β-tubulin-
positive and largely free of organelle markers (Fig. 2), while the cytosolic fractions were 
enriched in HSP70. Immunoblot analysis of the subcellular fractions with 22C11 or C-
terminal antibodies allowed us to distinguish hAPP (unfilled arrowheads, ) from sAPP 
(solid arrowheads, ).  
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Fig. 2. Intracellular cytoskeletal sAPP retention. Following incubation with Aβ25-35, PC12 cells (A) and primary 
cortical cultures (B) were fractionated as described, and the resulting fractions analyzed by immunoblotting. Total – 
total cell lysate; Cytosol – cytosolic protein fraction; “Memb+Org” – membrane and organelles enriched fraction; and 
Cytosk – cytoskeleton protein fraction. (), isAPP forms; (), mature hAPP. Intracellular sAPP and APP levels (N-
terminal 22C11 antibody), HSP70 (cytosolic marker) and actin and β-tubulin (cytosolic and cytoskeleton marker) were 
detected using ECL; intracellular hAPP (C-terminal antibody), CPE (carboxypeptidase E, marker of regulated vesicular 
secretion), and syntaxin-6 (Golgi marker) were detected using the highly sensitive ECL plus reagent. (C), Control; (Aβ), 
Aβ exposure. 
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For PC12 cells, Aβ exposure led to some isAPP (solid arrowheads, ) accumulation in 
the cytosolic fraction, but much more markedly in the cytoskeleton enriched fraction. 
This was accompanied by an increase in mature hAPP751/770 C-terminal positive isoforms in 
the cytoskeleton fraction (arrowhead , Fig. 2A). For primary neuronal cortical cultures 
similar data were obtained: isAPP accumulated mainly in the cytoskeleton fraction (Fig. 
2B, solid arrowheads, ). Further, carboxypeptidase E (CPE), a protein involved in 
regulated vesicular secretion, was also found to increase in the cytoskeletal fraction in 
response Aβ to treatment, although its total intracellular levels were decreased. The 
observed isAPP accumulation in cytoskeleton and cytosolic fractions, known to be 
associated with cytoplasmic vesicles, suggested that hAPP was being cleaved intracellularly 
before reaching the plasma membrane. These results strengthen the hypothesis that Aβ 
exerts an inhibitory effect at the vesicular secretory level, leading to intravesicular isAPP 
retention. 
 
 
isAPP retention occurs in secretory vesicles  
To characterize the location of intracellular sAPP retention in primary hippocampal 
neurons we performed immunofluorescence microscopy analyses. The vesicular axonal 
transport of APP has been linked, directly or indirectly, with the microtubule-associated 
motor protein kinesin 1. The latter is known to be responsible for a wide range of 
protein vesicular secretion and is composed of two subunits of KHC and two subunits of 
KLC. Co-localization of KLC with APP/sAPP was therefore addressed under basal and Aβ 
exposure conditions. These studies were carried out with the 22C11 (N-terminal APP) 
and C-terminal antibodies to distinguish between hAPP and sAPP. 
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Fig. 3. Aβ induces intracellular sAPP retention in secretory vesicles. Following Aβ treatment, primary 
hippocampal cultures were prepared for immunofluorescence analysis. Both 22C11 (Fluoresceine-labelled, green) and 
C-terminal (labelled with Alexa 350, blue) antibodies allowed to discriminate between hAPP and the sAPP. KLC 
antibody was used as a marker of secretory vesicles (Texas Red-labelled, red). A. Represents hAPP localization under 
basal conditions. B. Represents sAPP localization under Aβ treated conditions. Solid arrows indicate 
KLC+ve/22C11+ve structures, and dashed arrows indicate KLC+ve/C-terminal–ve structures. Images were acquired 
using a Zeiss confocal microscope. (C), control cells; (Aβ), cells exposed to Aβ for 24 h. ROI (region of interest).  Bar, 
10 µm. 
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Under basal conditions 64%±3 of the 22C11 positive population co-localizes with the C-
terminal immunoreactive population (hAPP), while with Aβ treatement only 44%±5 of the 
22C11 positive population co-localizes with the C-terminal antibody, indicating that the 
remaining 22C11 positive population is sAPP (36% under basal and 56% with Aβ). This is 
in agreement with increased isAPP retention upon Aβ addition. We also observed that 
under basal conditions both 22C11 and C-terminal antibodies co-localize with KLC in the 
majority of the neurites observed (Fig 3A). Thus we can deduce that hAPP and KLC co-
localize intracellularly (Fig. 3A, triple co-localization). However, Aβ exposure led to 
decreased C-terminal immunoreactivity and diminished KLC co-localization at the 
neurites (Fig. 3B, dashed arrows). In contrast, the 22C11 and KLC co-localization signal 
was maintained or increased in most neurites (Fig. 3B, solid arrows). This is consistent 
with isAPP accumulating in neuritic KLC-positive vesicles (Fig. 3B, mainly double co-
localization).  
 
 
Aβ interferes with the cytoskeleton network 
The results described above indicate that Aβ affects KLC-driven APP vesicular transport 
which is known to be associated with the cytoskeleton network and dependent on 
microtubule tracks. Therefore, alterations in vesicular secretion may be associated with 
altered cytoskeletal dynamics. Thus, we addressed Aβ effects on the major protein 
constitutents of the cytoskeleton network, actin and tubulin. As the 
polymerization/depolymerization dynamics of these proteins are key processes in 
transport, we evaluated F-actin polymerization (filamentous actin deriving from globular 
actin polymerization) and α-tubulin acetylation (a measurement of microtubule stability) 
in both primary neuronal cultures and PC12 cells (Fig. 4).  
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Fig. 4. Aβ leads to alterations in the cytoskeletal networks of neuronal cultures and PC12 cells. Upon Aβ 
treatment, cells (A., primary hippocampal cultures and B., PC12 cells) were stained with Texas red conjugated 
phallotoxin solution (labelled filamentous F-actin) and with acetylated α-tubulin antibody (labeled with Fluoresceine, 
green staining). Confocal images were acquired using a Zeiss confocal microscope. (C), control cells; (Aβ), Aβ for 24 h. 
Arrows indicate F-Actin polymerization. Bar, 10 µm.  
 
For primary neuronal cultures, exposure to Aβ25-35 leads to a dramatic decrease on α-
tubulin acetylation (measure of microtubule stability). For PC12 cells a redistribution of 
α-tubulin acetylation to the periphery could be observed. With respect to F-actin 
polymerization, Aβ exposure lead to a significant increase, as is evident for PC12 cells 
(Fig. 4B). In fact increased polymerization is clearly visible around the PM and in cytoplasm 
(solid arrows). This effect is less obvious for primary neuronal cultures (Fig. 4A). 
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The Aβ blocking effect on APP/sAPP trafficking can be reversed by altering 
cytoskeleton dynamics 
The Aβ induced isAPP retention and its relation with altered cytoskeleton dynamics was 
further established using an actin depolymerization agent (cytochalasin D, cytD) and a 
microtubule stabilization drug (taxol). In PC12 cells, although co-incubation of Aβ and 
cytD in the last 3 h had no noticeable effect on isAPP retention (data not shown), it 
reversed considerably the Aβ block on sAPP secretion (Fig. 5A), similarly to the effect 
obtained with Aβ removal in the last 3 h (Fig. 1A). Higher concentrations of the F-actin 
depolymerizing agent did not further increased sAPP secretion.  Likewise, co-incubation 
with Aβ and taxol, could also partial reverse Aβ-induced effect on sAPP secretion (Fig. 
5B). The results indicate that the Aβ inhibitory effect on sAPP secretion could be partially 
reversed by drugs which affect both the actin and microtubule networks.  
 
 
 
Fig. 5. Aβ effects can be reversed by drugs actin on cytoskeleton dynamics. Extracellular sAPP secretion 
levels were evaluated upon co-incubation of Aβ with drugs able to modulate cytoskeleton dynamics. PC12 cells were 
treated with Aβ and cytochalasin D (A) or taxol (B) during the last 3 h of the 24 h incubation period. (C), Control; 
(Aβ, Aβ treatment during 24 h; (CytD), Cytochalasin D. 
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DISCUSSION 
Due to its ability to trigger a set of biochemical and cellular alterations, Aβ has been 
described as a key player in the amyloid cascade hypothesis leading to progressive 
neurotoxicity and neuronal death observed in AD (Hardy and Selkoe, 2002; Hardy and 
Higgins, 1992). Besides the well described neurotoxic/apoptotic effects, Aβ also provokes 
alterations in APP metabolism (Carlson et al., 2000; Davis-Salinas et al., 1995; Schmitt et 
al., 1997). Previous work from our laboratory demonstrated that Aβ also exerts an effect 
on APP trafficking/processing leading to isAPPα accumulation in cytoskeleton-associated 
vesicular-like structures in a non-neuronal cell line. This isAPP retention was observed in 
non-neuronal cell lines as well as in primary hippocampal and PC12 cells (Henriques et al. 
2009a, in press). Nonetheless, differences could be observed at the level of sAPP 
secretion between these cell lines. Hence, we went on to evaluate the specificity and the 
origin of this potential pathological intracellular sAPP retention and to characterize the 
cellular structures mediating this Aβ response in neurons and in PC12 cells. Aβ-induced 
inhibition of sAPP secretion was considerable in both primary cortical and hippocampal 
cultures (Fig. 1A). This effect on sAPP secretion was relatively specific, since other 
medium secreted proteins were unaffected by Aβ treatment (Fig. 1B).   
Intracellular sAPP retention was associated with cytoskeleton structures, as determined 
by subcellular fractioning studies in both PC12 and primary neuronal cultures (Fig. 2). It is 
well stablished that vesicular motility is intimately associated with cytoskeleton network 
(Hamm-Alvarez and Sheetz, 1998; Lanzetti, 2007; Meyer and Burger, 1979; Potokar et al., 
2007), which in the light of our data, may explain the observed isAPP retention in this 
subcellular fraction. Of note, mature hAPP was also observed to accumulate in the 
cytoskeleton fraction (Fig. 2, more visible for PC12 cells). It appears then, that as a 
response to Aβ exposure, sAPP is intracellularly produced and retained in cytoskeleton-
associated secretory vesicles. Indeed, co-immunocytochemistry studies located isAPP 
retention to KLC-positive secretory vesicles in Aβ treated cells (Fig. 3). Our data clearly 
shows that isAPP and KLC localize to the same subcellular structure, of course this is also 
in accordance with a direct or indirect interaction between KLC and APP in the late 
anterograde transport. However, from the results presented in Fig. 3B it is tempting to 
conclude that APP/KLC interaction, is not direct. Previous reports have suggested that 
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this interaction is mediated via the cytoplasmic tail of APP (Kamal et al., 2000). Our data 
does not exclude this possibility, but retention of isAPP which correlates with KLC 
immunoreactivity, does not support this hypothesis. 
Since vesicular transport is related to the cytoskeleton network, hindered APP/sAPP 
vesicular transport induced by Aβ could be mediated by altered cytoskeleton dynamics. In 
fact, immunocytochemistry and immunoblot studies revealed that Aβ25-35 affected the 
dynamics of polymerization/depolymerization of both actin and tubulin. Aβ25-35 was 
previously shown to affect axonal transport by inducing neuronal actin polymerization and 
aggregation (Hiruma et al., 2003). Induction of F-actin polymerization by fibrillar Aβ1-42 
was also reported by Mendoza-Naranjo (2007) in hippocampal neurons. We have 
detected not only an increase in F-actin polymerization but also a decrease in α-tubulin 
acetylation in response to Aβ25-35, for both primary neurons and PC12 cells (Fig. 4). α-
tubulin acetylation is an indirect measure of the amount of the tubulin polymer and of 
microtubule stability (Black et al., 1989; Bloom, 2004). Taken together the data suggests 
that Aβ altered vesicular trafficking by affecting cytoskeleton dynamics. Indeed, as 
observed with Aβ withdrawal (Fig. 1), the effects induced by Aβ on sAPP secretion could 
be partial reversed both by inducing actin depolymerization or microtubule stabilization, 
clearly correlating Aβ effects on sAPP retention/secretion with altered cytoskeleton 
dynamics.  
In synthesis, this work reveals that in neurons Aβ  impairs APP/sAPP vesicular anterograde 
transport and exocytosis, in a mechanism mediated by alterations in the cytoskeleton 
dynamics of both microtubule and actin networks. The results described allow the 
disclosure of Aβ-mediated mechanisms that may contribute to neurodegeneration. 
Microtubule destabilization has been reported to be associated with neurotoxicity, and 
Aβ-induced neurodegeneration could be prevented by microtubule stabilization drugs 
(Michaelis et al., 2005; Michaelis et al., 1998; Seyb et al., 2006). An important consequence 
of the Aβ effects here reported resides in altered APP/sAPP neuritic transport and in 
decreased sAPP secretion. As extracellular sAPPα has potential neurotrophic and 
neuroprotective properties, this depletion is of extreme importance in a background of 
neuronal damage and loss as in AD. We hope that our results will improve the 
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understanding of the molecular basis of the disease, and might provide fundamental 
insights necessary for the development of effective therapeutic strategies. 
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Chapter Outline 
One of the functions most recently attributed to APP is a role as a signal transduction 
molecule involved in transcriptional activation. This function was reported to be mediated 
by the APP intracellular domain (AICD), a product of APP CTFs intramembranous γ-
secretase cleavage which is released into the cytoplasm and can to relocalize to the 
nucleus (Cupers et al. 2001; Kimberly et al. 2001; Kinoshita et al. 2002). At this 
subcellular location, AICD can function as a transcriptional regulator. Indeed, AICD was 
shown to form a transcriptionally active nuclear complex together with Fe65 and Tip60 
(Cao and Sudhof 2001), which is able to activate several downstream target genes, 
including APP itself (von Rotz et al. 2004). The studies performed in primary neuronal 
cultures presented in the previous chapter, revealed a decrease in holoAPP intracellular 
levels upon exposure to Aβ peptide. This led us to speculate that besides having an effect 
on APP processing, Aβ could also have consequences on APP transcriptional activation. 
Therefore, a set of experiments were designed to investigate the effects of Aβ on APP 
nuclear signaling. Interestingly, under our experimental conditions, Aβ induced a decrease 
in APP expression that together with the observations of increased APP CTFs and 
decreased APP-C-terminus nuclear staining (immunofluorescence analysis), suggest a 
decrease in both AICD production and subsequent transcriptional activation. This Aβ 
effect on APP nuclear targeting is of particular importance since this peptide may induce a 
cascade of events which consequently decrease its own production.  
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ABSTRACT 
The intracellular domain of the Alzheimer´s amyloid precursor protein (AICD) has been 
described as an important player in the transactivation of specific genes. It results from 
proteolytic processing of the Alzheimer´s amyloid precursor protein (APP), as does the 
neurotoxic Aβ peptide. Although normally produced in cells, Aβ is typically considered to 
be a neurotoxic peptide, causing devastating effects. By exposing primary neuronal 
cultures to relatively low Aβ concentrations, this peptide was shown to affect APP 
processing. Our findings indicate that APP C-terminal fragments (CTFs) are increased 
with concomitant reduction in the expression levels of APP itself. AICD nuclear 
immunoreactivity detected under control conditions was dramatically reduced in 
response to Aβ exposure. Additionally, intracellular protein levels of Fe65 and GSK3 
were also decreased in response to Aβ. APP nuclear signaling is altered by Aβ, affecting 
not only AICD production but also its nuclear translocation and complex formation with 
Fe65. In effect, Aβ can trigger a physiological negative feedback mechanism that modulates 
its own production.  
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Aβ peptide, APP RIP signaling, Alzheimer´s Disease, Fe65, CTFs, AICD  
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INTRODUCTION  
Aβ was originally defined as a pathogenic peptide associated with Alzheimer’s Disease 
(AD), but it is now known to be produced during normal intracellular processing of the 
Alzheimer’s amyloid precursor protein (APP) (Haass et al., 1992; Haass et al., 1993; 
Selkoe, 1993; da Cruz e Silva et al., 2004). Consecutive APP cleavage by α-secretase 
(Sisodia, 1992; Buxbaum et al., 1998; Allinson et al., 2003) and the γ-secretase complex (Li 
et al., 2000; Sastre et al., 2001; Esler et al., 2002; Lee et al., 2002; Capell et al., 2005) 
precludes Aβ production and produces a smaller fragment termed P3, whereas cleavage 
by β-secretase and γ-secretase results in the production of Aβ peptides, mainly in Golgi 
and endosomes (Vassar et al., 1999; Yan et al., 2001; Rebelo et al., 2007). The former 
non-amyloidogenic cleavage pathway also leads to the production of sAPPα, while the 
latter results in sAPPβ production. Proteolytic sAPP products are typically secreted, 
although intracellular sAPP (isAPP) production has been detected (Carlson et al., 2000; 
Henriques et al. 2009, in press). Resulting APP C-terminal fragments (CTFs), the products 
of α− and β− secretase activities, may be cleaved intracellularly by γ-secretase at γ- and ε-
sites, giving rise to the APP intracellular domain (AICD) (Sastre et al., 2001). Cao and 
Sudhof (2001) have shown that AICD exhibits transcriptional activity, enhanced by the 
formation of a transcriptional active complex comprising AICD, Fe65 and the histone 
acetylase Tip60. This trimeric complex was reported to localize to multiple spherical 
nuclear compartments (von Rotz et al., 2004). AICD and Fe65 localize together at the 
nucleus (Kimberly et al., 2001; Minopoli et al., 2001; Walsh et al., 2003), and nuclear 
AICD-containing complexes were reported to activate the transcription of several genes, 
including APP itself, BACE, Tip60 (von Rotz et al., 2004), GSK3β (Kim et al., 2003; Ryan and 
Pimplikar, 2005), KAI1 (Baek et al., 2002) and Neprilysin (Pardossi-Piquard et al., 2005). 
However, it is still unclear how the translocation of Fe65 and AICD from the cytoplasm 
and/or membrane into the nucleus is accomplished.  
APP/Fe65 interaction is also known to modulate APP metabolism, including sAPP 
secretion and Aβ production (Sabo et al., 1999; Ando et al., 2001). Sabo et al. (1999) 
reported that in MDCK cells stably expressing APP695, Fe65 increased APP translocation 
to the plasma membrane (PM), which was accompanied by an increase in Aβ and 
sAPPα secretion. Recently Xie et al. (2007) showed that Fe65 RNAi silencing leads to an 
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increase in CTF levels and a decrease in Aβ levels, thus suggesting a role for Fe65 as a 
positive regulator of γ-secretase activity. 
The present work focuses on the effect of exogenously added Aβ on APP metabolism in 
primary neuronal cultures, and its effects on AICD/Fe65 nuclear signaling. The data 
obtained supports the hypothesis that Aβ plays a role in APP processing and RIP signaling, 
by altering APP intracellular proteolytic cleavage and by decreasing both APP and Fe65 
intracellular and nuclear levels. The intracellular Aβ effects appear to include decreased 
AICD production, given the increase in CTFs production, and decreased targeting and 
nuclear co-localization of AICD/Fe65.  
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MATERIALS AND METHODS  
Preparation and maintenance of primary neuronal cultures 
Rat cortical and hippocampal cultures were established from embryonic day 18 embryos 
as previously described (Henriques et al., 2007). After dissociation with trypsin (0.45 or 
0.75 mg/ml for cortical or hippocampal cultures, respectively, for 5-10 min at 37ºC) and 
deoxyribonuclease I (0.15 mg/ml) in Hank’s balanced salt solution, cells were plated on 
poly-D-lysine-coated dishes at a density of 1.0x105 cells/cm2 in B27-supplemented 
Neurobasal medium (GIBCO), a serum-free medium combination (Brewer et al., 1993). 
The medium was supplemented with glutamine (0.5 mM), gentamicin (60 µg/ml), and with 
or without glutamate (25 µM) for hippocampal or cortical cultures, respectively. Cultures 
were maintained in an atmosphere of 5% CO2 at 37ºC for 9 days before being used for 
experimental procedures.  
 
Incubation with Aβ peptide 
Aβ25-35 peptide (Sigma Aldrich) was dissolved in distilled water to prepare a 1 mM stock. 
Rat primary neuronal cultures were incubated for 24 h in Neurobasal medium free of B27 
containing 20 µM Aβ25-35, with the medium being replaced during the last 3 h of incubation 
by fresh medium with or without Aβ25-35. 
 
Sample collection and immunoblotting 
Following exposure to Aβ, conditioned media and cells were collected in boiling 1% SDS 
and the lysates were homogenized as previously described (Amador et al., 2004). Protein 
determination was carried out using the BCA kit (Pierce). Samples normalized for protein 
content were separated on 7.5% or 5-20% gradient SDS-PAGE gels and then 
electrophoretically transferred onto nitrocellulose membranes for immunoblotting. 
Intracellular APP/isAPP and extracellular sAPP detection was carried out using the 22C11 
mouse monoclonal antibody directed against the APP N-terminus (Boehringer), while for 
holoAPP and endogenous C-terminal fragments an APP C-terminal antibody was used 
(rabbit polyclonal anti-β-APP C-terminus, Zymed). Detection of total GSK3 was achieved 
using a rabbit polyclonal anti-glycogen synthase kinase 3 antibody (Chemicon). For Fe65 
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detection the antibody clone 3H6 (Upstate) was used, and tubulin detection was carried 
out using the monoclonal anti-β-tubulin antibody (Zymed). Following incubation with the 
primary antibodies, immunodetection made use of horseradish peroxidase-conjugated 
anti-mouse or anti-rabbit IgGs secondary antibodies (Amersham Pharmacia) and for 
visualization enhanced chemiluminescence detection (ECL) was employed (Amersham 
Pharmacia). The ECL Plus reagent was used for extracellular sAPP, CTFs and Fe65 
detection. 
 
Quantification 
Quantity One Densitometry software (Bio-Rad) was used to quantify band intensity and 
correlate it to protein levels. Data are expressed as mean±SEM of at least three 
independent experiments. Statistical analysis was carried out using one way analysis of 
variance (ANOVA). When significantly different, the Dunnett test was applied to compare 
all groups to the control. The level of statistical significance accepted was P<0.05. 
 
Northern blot analysis 
Total RNA was isolated from control primary cortical cultures (3.0x106 cells) following 
Aβ treatment (TRI REAGENT, Sigma). Normalized total RNA aliquots (10 µg) were 
separated by formaldehyde gel electrophoresis and transferred to nitrocellulose 
membranes using standard laboratory protocols (da Cruz e Silva et al., 2008). The blot 
was then hybridized with a [32P]-labelled APP cDNA probe (25 ng, 1x106 cpm/ng) to 
evaluate APP expression levels. The APP probe used (756 bp) was obtained by 
AgeI/BamHI restriction enzyme digestion of the APP751 cDNA, and labelled with [α-
32P]dCTP (GE Healthcare) using the High Prime DNA Labelling Kit (Roche, Alfagene). 
Purification of the probe through NucTrap Probe Purification Columns (Stratagene, 
Alfagene) was performed prior to hybridization APP hybridizing RNA was detected using 
Kodak Biomax XAR film (Sigma). 
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Monitoring nuclear targeting of APP C-terminal proteolytic products  
For evaluating nuclear targeting of APP C-terminal proteolytic products and Fe65, cells 
were fixed with 4% paraformaldehyde, permeabilized with methanol for 2 min and 
blocked with 3% bovine serum albumin in PBS for 1 h, and further incubated with primary 
antibody (C-terminal APP antibody and Fe65 antibody) for 3 h. The antibody 4G8 (anti-
Abeta 17-24 aa antibody, Chemicon) was used in co-localization studies with the APP C-
terminal antibody, to rule out nuclear CTFs and confirm the identity of AICD at the 
nucleus. After washing with PBS, Texas Red-conjugated goat anti-rabbit (Molecular 
Probes) or Fluoresceine-conjugated goat anti-mouse (Calbiochem) secondary antibodies 
were added for 2 h at room temperature. Coverslips were mounted on microscope glass 
slides using FluoroGuard (BioRad) as an antifading reagent or Vectashield (Vector 
Laboratories), an antifading reagent containing DAPI for nucleic acid labelling. Nuclear 
targeting and co-localization studies of APP C-terminal fragments and Fe65 was carried 
out by immunofluorescence analysis. Acquisition of epifluorescence images made use of a 
LSM 510-Meta confocal microscope (Zeiss) and a 63x/1.4 oil immersion objective. The 
argon laser lines of 405 nm (DAPI), 488 nm (Fluorescein) and a 561 nm DPSS laser (Texas 
Red) were used. Microphotographs were acquired in a sole section in the z-axis (xy-
mode), and represent a mean of 16 scans. 
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RESULTS AND DISCUSSION 
Aβ  affects APP expression levels  
Aβ effects on APP metabolism are unclear, with some reports suggesting that Aβ may be 
affecting APP transcription, while others suggest it to have an effect at the APP 
processing/catabolic levels (Davis-Salinas et al., 1995; Schmitt et al., 1997; Carlson et al., 
2000). In our work, primary neuronal cultures were incubated with and without Aβ25-35 
during 24 h and total RNA extracted for Northern blot analysis (Fig. 1A).  
 
 
Fig. 1. Aβ decreases APP expression in primary neuronal cultures. Primary cortical neuronal cultures were 
treated with 20 µM Aβ25-35 for 24 h as described in the methods. A. Total mRNA was isolated and APP mRNA 
expression in primary cultures was monitored in response to Aβ exposure. B. Intracellular holoAPP (hAPP) protein 
detection was carried out using an antibody to the APP C-terminus. C. Tubulin was used as a control. (C), Control; 
(Aβ), Aβ treatment for 24 h.  **P<0.01, significantly different from control using Dunnett post hoc test. 
 
 
 
Aβ biology and its contribution to AD   Chapter III 
 
188       Centro Biologia Celular 
Universidade de Aveiro 
 
Although Aβ induction of APP transcription was previously reported in a neuronal hybrid 
cell line and in cultured astrocytes (Le et al., 1995; Moreno-Flores et al., 1998), under our 
experimental conditions Aβ treatment lead to a clear decrease in APP expression in 
primary cortical cultures. Accordingly, APP intracellular protein levels also dropped a 
concordant 0.4 fold below control levels upon Aβ exposure (Fig. 1B). Similar results were 
obtained for hippocampal cultures, with Aβ leading to a decrease in APP intracellular 
levels, as detected by using an APP C-terminal antibody (Fig. 2A), again supporting a role 
for Aβ in modulating APP transcriptional levels in primary hippocampal cultures.  
 
Aβ  induces accumulation of APP C-terminal fragments  
Our data shows that Aβ25-35 provokes a decrease in intracellular holoAPP (hAPP, Fig. 2A), 
detected using the APP C-terminal antibody in primary neuronal cultures. Concomitantly, 
using the APP N-terminal antibody 22C11 we could observe a decrease in extracellular 
sAPP secretion (esAPP, Fig. 2A) and an increase in APP intracellular levels. The latter 
represents intracellularly accumulated sAPP (isAPP, Fig. 2A) since hAPP levels decreased. 
This isAPP retention was previously reported by us (Henriques et al. 2009, in press) in 
various cell types, and Aβ1-42 elicits a similar response. Retention of isAPP was also 
observed with the physiological Aβ1-40 peptide (Carlson et al., 2000). In this case, 
increases in medium secreted proteins, such as IL-8, concomitant with decreases in sAPP 
secretion, by 10-30%, were reported. 
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Fig. 2. Effect of Aβ on CTF production. Following incubation of hippocampal neurons with Aβ peptide, cell lysates 
and conditioned medium were collected and analyzed. A. Endogenous intracellular holoAPP (hAPP), extracellular 
secreted sAPP (esAPP) and intracellular sAPP (isAPP). APP and sAPP were distinguished using the APP C-terminal 
antibody and the APP N-terminal antibody. B. APP C-terminal fragments (APP CTFs) were detected with an anti-β-APP 
C-terminal antibody. C. Total GSK3 expression levels. *P<0.05 and **P<0.01, significantly different from control using 
Dunnett post hoc test. Values are expressed as mean±SEM from 3 independent experiments. (C), Control; (Aβ), Aβ 
treatment for 24 h. 
 
Given that Aβ was clearly altering APP processing (Fig. 2), we monitored the levels of 
other APP proteolytic fragments and observed that these too were affected. The levels of 
endogenous CTFs produced by APP proteolytic processing increased with Aβ treatment 
(Fig. 2B). This suggests that γ-secretase activity was inhibited by Aβ and/or that CTFs 
were not accessible for γ-secretase cleavage. However, direct measurement of γ-
secretase activity did not yield any significant alteration (data not shown), suggesting that 
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CTF cleavage by γ-secretase activity per se was not hindered. An accumulation of 
amyloidogenic APP CTFs in response to Aβ1-42 exposure was previously observed by Yang 
et al. (1995) in APP transfected HEK293 cells. In neuronally derived cells, γ-secretase 
cleavage was described to occur at the plasma membrane and/or early endosomes 
(Kaether et al. 2006). Thus, the neuronal CTF increase observed (Fig. 2B) probably 
reflects a block in the transport to plasma membrane and a subsequent decrease in 
proteolytic cleavage of CTFs. This correlates well with our findings of isAPP retention 
within cytoskeleton-associated vesicular-like structures (Henriques et al. 2009, in press). 
Hence increased accumulation of CTFs also correlates with decreased AICD production. 
AICD has been described as an APP nuclear signal peptide that can form a transcriptional 
active complex with Fe65 (Cao and Sudhof, 2001). AICD-containing complexes were 
reported to induce transcriptional activation of several genes, including APP itself and 
GSK3β (Kim et al., 2003; von Rotz et al., 2004; Ryan and Pimplikar, 2005). Thus, increased 
CTFs and concomitant decreased AICD levels would predict decreases in the AICD 
nuclear pool and signaling. This is consistent with the observed decrease in APP 
expression levels (Fig. 1A) and a significant decrease in total GSK3 levels (Fig. 2C). Direct 
measurements of AICD were not possible given that the endogenous levels in primary 
cultures are difficult to detect.  
 
Aβ decreases nuclear targeting of APP C-terminal proteolytic products and Fe65 
Our observation that Aβ increased APP CTF levels, decreased APP transcriptional 
activation and GSK3 expression levels (Fig. 1 and 2), is consistent with a decrease in 
AICD production and subsequent decreased transactivation of AICD-downstream genes. 
Hence, we focussed on AICD/Fe65 nuclear targeting and complex formation. The nuclear 
targeting of APP C-terminal proteolytic products was clearly hindered in the presence of 
Aβ (Fig. 3A, Texas Red staining). The APP C-terminal peptides detected in the nucleus 
and positive for the APP C-terminal antibody were negative for the 4G8 antibody, 
reinforcing the identity of the nuclear targeted APP C-terminal peptides as AICD 
proteolytic fragments (Fig. 3C). Under our experimental conditions Aβ exposure 
decreased not only the intensity of nuclear APP C-terminal punctuate immunoreactivity 
(Fig. 3A, Texas Red staining), but also Fe65 nuclear intensity and targeting (Fig. 3A, green 
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Fluoresceine staining). As a consequence, the co-localization of nuclear AICD-Fe65 was 
also compromised. 
 
 
 
Fig. 3. Aβ induces alterations in AICD and Fe65 nuclear targeting. Hippocampal neuronal cultures were 
incubated with Aβ25-35 for 24 h and subsequently fixed with paraformaldehyde. Immunofluorescence analyses were 
carried out using anti-β-APP C-terminal and anti-Fe65 antibodies, labelled with a Texas Red-conjugated (red staining) or 
with a Fluoresceine-conjugated (green staining) antibody, respectively. Cells were mounted with an antifading reagent 
containg DAPI for nuclei acids staining. A. AICD and Fe65 immunoreactivity was analyzed by confocal microscopy. B. 
Representative staining profiles. Fluorescence intensity profiles represent the voxels through the white lines indicated in 
the merged image shown in A. C. The identity of AICD fragments at the nucleus was shown by the positive 
immunoreactivity for the APP C-terminal antibody (Texas Red-conjugated, red staining) and the negative 
immunoreactivity for the 4G8 antibody (Fluoresceine-conjugated, green staining). (C), Control, (Aβ), Aβ treatment for 
24 h. 
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Confocal profiling demonstrated that both proteins dramatically decreased in the nucleus 
(DAPI-positive organelle) following Aβ treatment (Fig. 3B). Hence the blue trace (denotes 
the nucleus) is sustained with Aβ exposure, whereas the red and green traces for AICD 
and Fe65, respectively, drop similarly. Of note, this analysis was carried out in non-
apoptotic cells, as denoted by nucleus morphology (DAPI staining).  
Detailed co-localization studies of AICD and Fe65 immunoreactivity in the nucleus using 
Zeiss confocal co-localization software (Table 1) also confirmed Aβ induced alterations in 
the nuclear targeting of both proteins. The percentage of both AICD and Fe65 positive 
pixels present in the nucleus, relative to the total neuronal soma population, showed a 
decrease of 42% and 56%, respectively.  
 
Table 1. AICD and Fe65 nuclear targeting and co-localization in response to Aβ. 
 
 
Nuclear targeting as a %  
of total population 
% of each protein co-localizing to 
the complex in the nucleus 
C Aβ % Dec 
+ Aβ C Aβ 
% Dec 
+ Aβ 
AICD 46 ± 3.0 27 ± 1.7  42  33 ± 2.0 21 ± 1.9  36  
Fe65 36 ± 2.0 16 ± 1.4  56  22 ± 1.1 20 ± 1.6  10  
 
 
Analysis was carried out using Zeiss confocal microscospe co-localization software. The % of 
nuclear AICD and Fe65 immuno-positive pixels were determined relative to the total neuronal 
cell populations, excluding dendrites and axons (“nuclear targeting as a % of total population”). 
The “% of each protein co-localizing to the complex in the nucleus” represents the % of each 
protein (AICD or Fe65) co-localizing to the other, and relative to its total nuclear population.  
“% Dec + Aβ”, percentage decrease upon Aβ addition. Data is presented as mean±SEM of 40 
analysed cells. 
 
Focusing on the nuclear population alone, we were able to determine that the AICD 
nuclear population co-localizing with Fe65 dropped from 33% to 21% upon addition of 
Aβ, which represents a 36% decrease. There was no significant difference in the 
percentage of the Fe65 nuclear population that co-localized with AICD (22% and 20%). 
Additionally we determined that the AICD population, as a percentage of the total APP 
C-terminal immunoreactivity, co-localizing to Fe65 in the nucleus decreased from ~15% 
(33% of the 46% of the nuclear targeted population, see Table 1) to ~5% (21% of 27%) 
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upon exposure to Aβ. Likewise we determined the values for Fe65, and the decrease was 
from ~7% (22% of 36%) to ~4% (20% of 16%). 
Given that the nuclear abundance of both AICD and Fe65 were affected, we also tested 
the latter directly by immunoblotting and imunofluorescence. Our data showed a clear 
decrease in Fe65 intracellular levels in response to Aβ (Fig. 4A). This was also evident by 
confocal microscopy at a focus plane above the nucleus and just below the plasma 
membrane, where Fe65 immunoreactivity decreased overall, being particularly visible 
along neurites (Fig. 4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Aβ effect on Fe65. Fe65 intracellular levels were evaluated using both immunoblotting (A.) and 
immunofluorescence (B.). Fe65 immunoreactivity was analysed by confocal microscopy at a focus plane above the 
nucleus and just below the plasma membrane. **P<0.01, significantly different from control using Dunnett post hoc test. 
(C), Control; (Aβ), Aβ treatment for 24 h. 
 
Taken together, our results suggest that Aβ is affecting AICD production, its nuclear 
translocation, and nuclear complex formation with Fe65, whose nuclear targeting is itself 
decreased. A decrease in AICD production and in the formation of AICD/Fe65 
transactivation complexes, potentially leads to altered APP nuclear signaling in the 
presence of Aβ, leading to impaired gene transcriptional activation. 
In summary, we propose that Aβ leads to reduced APP expression and consequential 
diminished Aβ production, which is important for cells exposed to an Aβ saturated 
environment. It is attractive to postulate that the above mentioned mechanisms 
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congregate to reduce intracellular accumulation of Aβ, and that exogenous Aβ appears to 
induce a set of concerted cellular responses to prevent its own production, including 
reduced AICD/Fe65 nuclear targeting. We hypothesize that a physiologically relevant 
negative feedback mechanism may be operating, tightly coordinating the levels of APP 
expression, and AICD and Aβ production. Further, as APP CTF levels progressively 
decrease in AD (Sergeant et al., 2002), this feedback mechanism may be lost with the 
progression of the disease. This would be a physiologically relevant process given that 
neurons exhibit higher levels of Aβ production. Nonetheless we cannot exclude that non-
physiological Aβ concentrations may trigger neuronal stress mechanisms which may in 
turn affect APP metabolism and Aβ production, future research will address this question. 
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Chapter Outline 
 
Histopathologically AD is characterized by the presence of both extracellular senile 
plaques and intracellular neurofibrillary tangles (NFTs). Several studies in transgenic mice 
suggest that Aβ deposition develops prior to Tau pathology (Lewis et al. 2001; Oddo et 
al. 2003). Hence, amyloid deposition would precede and may lead to formation of NFTs. 
More, in Down´s syndrome patients the Aβ deposits exist in the absence of NFTs, in 
brains areas most affected by AD (Leverenz and Raskind 1998; Gouras et al. 2000). NFTs 
are mainly composed of hyperphosphorylated Tau protein and this has been attributed to 
an imbalance of cellular kinase/phosphatase activities, which may be triggered by Aβ.  
The aggregation state of the Aβ peptide also appears to be a factor associated with the 
set of AD pathogenesis. Although Aβ aggregated forms were shown to induce damage to 
cultures neuronal cells (Pike et al. 1993; Lorenzo and Yankner 1994), subsequent studies 
suggested that rather than highly aggregated species, oligomeric Aβ may represent the 
principal neurotoxic entity that causes synaptic dysfunction (Lambert et al. 1998; Hartley 
et al. 1999).  
Clearly, it appears that Aβ is able to trigger, directly or indirectly, mechanisms that 
ultimately lead to neuronal degeneration, and several novel therapeutic strategies are 
based on lowering Aβ levels or by preventing the formation of the neurotoxic oligomeric 
or more aggregated Aβ species. Other therapeutic approaches under development have 
focused on the prevention of Tau-induced neurodegeneration.  
Therefore, due to the importance of the Aβ aggregation state to its neurotoxic 
properties, we address whether Aβ binding proteins (involved either in Aβ disaggregation 
or clearance) could affect the latter in terms of its neurotoxicity and effect on APP 
metabolism. The observation that these proteins could partially reverse the neurotoxicity 
and the isAPP accumulation induced by Aβ, suggested their therapeutic potential as 
modulators of APP processing and neuroprotectors. 
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Further, and according to the “amyloid cascade hypothesis”, Aβ may trigger a set of 
signaling cascades which ultimately lead to neurodegeneration. Key players in signal 
transduction mechanisms are the protein kinases and phosphatases. One possible 
explanation for abnormal Tau phosphorylation involves abnormal kinase and/or 
phosphatase activities. Previous studies have shown that Aβ activates various PKC 
isoforms in different cell lines (Nakai et al. 2001, Tanimukai et al. 2002). Here we focus 
on Aβ effects on protein phosphatase 1 (PP1) activity. Our studies reveal for the first 
time the existence of an inhibitory effect on the different PP isoforms, suggesting that Aβ 
can interfere with neuronal signal transduction events.  
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ABSTRACT 
Aβ induces several cellular responses associated with neurotoxicity. Of note, it was also 
shown that the fibrillar/aggregated species of Aβ are far more toxic. Thus, therapeutic 
strategies aimed at Aβ depolymerization represent attractive avenues of intervention. 
Laminin and gelsolin provide such a model, given that both prevent Aβ fibril formation, 
giving rise to Aβ-laminin and Aβ-gelsolin complexes. By forming these complexes the 
neurotoxic effects of Aβ are attenuated. Additionally, we have recently shown that Aβ 
can lead to intracellular accumulation of sAPP; pre-incubation of Aβ with laminin and 
gelsolin also renders it less potent in this respect. In conclusion, our data lead us to 
conclude that Aβ-laminin and Aβ-gelsolin complexes are less neurotoxic and less potent 
at inducing intracellular sAPP retention than fibrillar Aβ. These findings validate the 
potential of both proteins as therapeutic targets, preventing Aβ-induced effects, both at 
the neurotoxic and at the APP metabolic levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Aβ, fibril inhibition, aggregation, APP processing. 
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INTRODUCTION  
The deposition and accumulation of aggregates of fibrillar Abeta (Aβ) peptides into 
amyloid plaques is considered one of the key processes underlying neuronal loss in 
Alzheimer´s Disease pathology. The amyloid plaques are mainly composed of Abeta (Aβ) 
(Glenner and Wong 1984), but also include a number of other compounds such as 
inflammatory molecules, proteoglycans, metal ions, antioxidant proteins and protease and 
clearance related compounds (for review see Atwood et al. 2002). 
Several investigators have reported that Aβ neurotoxicity is related to the degree of 
fibrillization, the β-sheet structure and the size of the peptides (Pike et al. 1993; Lorenzo 
and Yankner 1994; Dahlgren et al. 2002). The molecular mechanisms responsible for the 
passage of normal soluble Aβ forms to fibrils are not well understood, nonetheless, it is 
known that Aβ binds several proteins that can modulate its aggregation or its fibrillar 
state. Among these are laminin (Bronfman et al. 1996; Drouet et al. 1999; Monji et al. 
1999; Morgan et al. 2002) and gelsolin (Chauhan et al. 1999; Ray et al. 2000; Qiao et al. 
2005; Chauhan et al. 2008). Both have been shown to bind and form complexes with Aβ. 
Laminin is a major basement membrane protein shown to inhibit Aβ fibril formation and 
to disaggregate preformed Aβ fibrils (Monji et al. 1999; Morgan and Inestrosa 2001; 
Morgan et al. 2002). Gelsolin is found both as an intracellular protein (Tanaka and Sobue 
1994; Ji et al. 2008) - that is able to modulate actin assembly and disassembly (Janmey et 
al. 1985; Howard et al. 1990) - and as a secreted plasma and CSF protein (Kwiatkowski et 
al. 1988; Paunio 1994; Kulakowska et al. 2008). Like laminin, it was reported to prevent 
Aβ fibrillogenesis, being also able to defibrillize preformed fibrils (Ray et al. 2000; 
Chauhan et al. 2008). 
Aβ is an intracellular product of the proteolytic processing of Alzheimer´s amyloid 
precursor protein (APP). It is generated by sequential cleavage of β-secretase (mainly 
BACE1) (Vassar et al. 1999; Yan et al. 2001) and the γ-secretase complex (Li et al. 2000; 
Esler et al. 2002; Lee et al. 2002; Steiner et al. 2002). The physiological function of Aβ is 
unknown although it triggers many cellular responses. Among the most devastating is its 
ability to trigger several apoptotic mechanism and hence cellular death (Kienlen-Campard 
et al. 2002; Pereira et al. 2004). Other reports have associated Aβ to altered APP 
metabolism (Davis-Salinas et al. 1995; Schmitt et al. 1997; Moreno-Flores et al. 1998; 
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Carlson et al. 2000; Henriques et al. 2009a, in press). The latter is likely to be of 
physiological significance, given that Aβ may modulates APP processing and trafficking 
(Henriques et al. 2009a, in press), and decrease AICD production with consequences in 
decreased APP expression levels (Henriques et al. 2009b, in press), thus keeping “in 
check” its own production. 
In the work here described we addressed the effects of Aβ aggregation on APP 
processing. Further, and since fibrillization is such an important event in AD pathogenesis, 
we also evaluated the effect of proteins involved in Aβ depolymerization and its 
complexes on APP processing. Our data demonstrated that inhibition of Aβ fibril 
formation by either laminin or gelsolin, was able to partially revert Aβ effects on APP 
metabolism, thus suggesting a therapeutic potential for these proteins in AD treatment. 
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MATERIALS AND METHODS 
Materials 
Laminin (from basement membrane of Engelbreth-Holm-Swarm mouse carcinoma) and 
gelsolin (from bovine plasma) were purchased from Sigma. Gelsolin was prepared as an 10 
µM stock dissolved in 25 mM Tris-HCl, pH 7,5. Aβ peptide, corresponding to residues 
25-35 (Sigma), Aβ1-40 and Aβ1-42 peptides (American Peptide Company) and Aβ25-35 with a 
scrambled sequence (Aβscrb, from NeoMPS) were dissolved in sterile distilled water to 
obtain a 1mM stock solution. Thioflavine-T (Sigma) was prepared as a 30 mM stock in 
distilled water. 
The monoclonal antibody 22C11 directed against the APP N-terminus (Boehringer) was 
used in this study to detect APP and total sAPP. Holo APP was achieved using the APP C-
terminal antibody (rabbit polyclonal anti-β-APP C-terminus, Zymed). The monoclonal 
anti-β-tubulin antibody (Amersham Pharmacia) was used as a control protein. Anti-mouse 
IgG horseradish peroxidase-linked whole secondary antibody (Amersham Pharmacia) was 
used for enhanced chemiluminescence (ECL or ECL plus). 
 
Aβ aggregation 
Aβ aggregation was achieved by incubating the different peptides for 48 hr at 37ºC. These 
preparations were shown to contain Aβ fibril forms (Drouet et al. 1999; Ray et al. 2000 
and data not shown). 
For co-incubation assays 100 µM Aβ25-35 was incubated in the presence of either laminin 
at 0,5 µM (laminin/Aβ molar ration of 1:200) or gelsolin at 2,2 µM (gelsolin/ Aβ molar 
ratio of 1:45) in PBS (phosphate buffer saline, pH 7,4) for 48 hr at 37ºC. 
Fibrillar peptide and peptide complexes were then diluted before addition to the cells in 
culture (see Aβ treatment section). 
 
 
 
 
Aβ biology and its contribution to AD   Chapter IV 
 
Centro Biologia Celular  209 
Universidade de Aveiro 
 
Thioflavine T fluorimetric (TH-T) assay 
Aβ25-35 fibril formation in the presence or absence of the proteins mentioned above was 
monitored by a TH-T fluorometric assay as described by H. LeVine (1993), with a few 
modifications. TH-T fluorescence was measured at 0 hr and 48 hr of incubation at 37ºC, 
using a Jasco FP-777 spectrofluorimeter. TH-T measurements used 20 µl of incubated 
sample mixed with 980 µl 15 µM TH-T in PBS. Samples were monitored at: λEx = 450 nm, 
5 nM bandpass and λEm = 482 nm, 10 nM bandpass. The background fluorescence of TH-T 
and buffer alone were subtracted from the fluorescence obtained value for each sample. 
 
Cell culture  
Rat cortical neuronal cell cultures were prepared from embryonic day 18 Wistar rat 
foetuses as previously described (Henriques et al. 2007). Briefly, after dissociation with 
trypsin (1.0 mg/ml; 10 min; 37ºC) the cells were plated on poly-D-lysine-coated dishes at 
a density 1,0x105 cells/cm2 in B27-supplemented Neurobasal medium (GIBCO), a serum-
free medium combination (Brewer et al. 1993), supplemented with glutamine (0.5 mM), 
gentamicin (60 µg/ml). Cultures were maintained in an atmosphere of 5% CO2 at 37ºC 
during 9 days before being subject to various experimental conditions. 
 
Aβ treatment 
Exposure of cells to Aβ was preceded by an aggregation step. For Fig. 1 the effect of 
different Aβ peptides and concentrations were evaluated. Subsequent experiments were 
carried out by pre-incubating Aβ25-35 peptide alone or in the presence of the different 
proteins (laminin and gelsolin) during 48 hr at 37ºC; 100 µl of each preparation were then 
diluted in 900 µl of the complete corresponding medium and added to the cells for a 24 
hr period. Under these conditions Aβ was used in a final concentration of 10 µM, laminin 
of 50 nM and gelsolin of 220 nM. 
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Monotoring of apoptosis 
In order to morphologically access apoptosis, cells were plated at a density of 0,8x105 
cells/cm2 on poly-D-lysine-coated coverslips. After the appropriate treatments cells were 
fixed with 4% paraformaldehyde diluted in media (1:1) for 2 minutes, and then incubated 
for 15 minutes in undiluted paraformaldehyde. After 3 washes with PBS, cells were 
incubated with Hoescht dye 33258 (5 mg/ml stock, Sigma) at 5 µg/ml in PBS for 3 minutes 
to allow nuclear staining. For quantitative analysis of apoptosis, cell nuclei were visualized 
using a DAPI filter in an Olympus IX-81 inverted epifluorescence microscope. To evaluate 
the percentage of apoptotic cells, 10 independent fields were analyzed (approximately 400 
cells) per experimental condition. Under control conditions primary neuronal cultures 
exhibited approximately 10% of apoptotic cells. 
 
Sample collection and protein analysis 
Following appropriate treatments, conditioned media and cells were collected into boiling 
1% SDS and the samples were homogenized as previously described (Amador et al. 2004). 
Protein determination of the lysates was carried out with the BCA kit (Pierce). Samples 
normalized for protein content, were run on 7.5% SDS-PAGE and then 
electrophoretically transferred onto a nitrocellulose membrane. Immunoblotting was 
carried out by incubating overnight with 22C11 primary antibody for the detection of 
APP and total sAPP, or anti-β-tubulin antibody for tubulin detection. Detection was 
achieved using ECL  or ECL plus detection systems. 
 
Quantification and statistical analysis 
Quantity One Densitometry software (Bio-Rad) was used to scan and quantify 
immunoblot intensity. Data are expressed as means ± SEM of triplicate determinations, 
from at least three independent experiments. Statistical analysis was carried out using one 
way analysis of variance (ANOVA). When the F values were significant, the Tukey test 
was applied to compare all pairs of groups. Statistical differences have been determined at 
P<0,05. 
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RESULTS 
Effect of different aggregated Aβ peptides on intracellular sAPP accumulation 
Previous data from our laboratory showed that “fresh” Aβ25-35 peptide preparations led to 
intracellular sAPP accumulation (isAPP) in non-neuronal, neuronal-like and neuronal cells 
(Henriques et al. 2009a, in press). This was confirmed using both APP N-terminal (22C11) 
and APP C-terminal antibodies which permit distinction between APP and sAPP. For cells, 
particularly those neuronal in origin, alterations in APP expression levels could also be 
detected (Henriques et al. 2009b, in press). In this study we addressed the effect of 
Aβ25-35, Aβ1-40 and Aβ1-42 aggregated peptides on APP metabolism in neuronal cortical cells. 
Similar to “fresh” Aβ25-35, aggregated Aβ25-35 and Aβ1-42 led to a significant increase in APP 
intracellular levels, as detected using the 22C11 antibody (Fig. 1A). Of note, the more 
aggregated Aβ25-35 state (as denoted by TH-T assay, Fig. 2) resulted in a higher fold 
increase in intracellular APP levels (approximately 4.5 fold, Fig. 1A), than the “fresh” Aβ 
(2 fold, Henriques et al. 2009b, in press). At 20 µM concentration Aβ1-40 peptide was 
much less effective in inducing an increase in APP intracellular levels that Aβ25-35 and Aβ1-42 
peptides.  
As previously observed, medium secreted sAPP decreased upon exposure to Aβ for both 
non aggregated “fresh” (Henriques et al. 2009b, in press) and aggregated Aβ25-35 forms 
(Fig. 1). The other peptides Aβ1-40 (20 µM), Aβ1-42 (5 µM), Aβ1-42 (20 µM) increased 
systematically in toxicity. This peptide species and concentration dependent effect was 
mirrored in isAPP retention (Fig. 1A). The scramble Aβ25-35 peptide was used as a control, 
and confirmed the specificity of the Aβ response. 
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Fig. 1. Effect of different aggregated peptides on APP processing. Aβ25-35, Aβ1-40 and Aβ1-42 were aggregated 
for 48 hr at 37ºC. Following aggregation peptides were added to primary neuronal cultures at different concentrations 
for 24 hr. Scramble 25-35 peptide was used as a control (Scrb). (A) Intracellular holo APP protein was detected using a 
C-terminal antibody. The levels of intracellular APP and extracellular sAPP were detected using the N-terminal antibody 
22C11. (B) Quantitative results are expressed as mean±SEM of 3 independent experiments. isAPP, intracellular sAPP 
and APP levels; esAPP, extracellular secreted sAPP; ◄, intracellular sAPP retention. **P<0,01 and ***P<0,001 
significantly different from control; Tukey post hoc test.  
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Inhibition of Aβ25−35 aggregation by laminin and gelsolin 
Previous observations showed that both laminin (Drouet et al. 1999; Morgan et al. 2002) 
and gelsolin (Ray et al. 2000; Qiao et al. 2005) are able to inhibit fibril formation or to 
depolymerize the preformed fibrils of both Aβ1-40 and Aβ1-42 peptides. Here we addressed 
the effect of both proteins on Aβ25-35 aggregation and subsequent effects on APP 
metabolism. We quantified the extent of Aβ25-35 aggregation using the TH-T fluorescence 
assay. Although it has been reported that Aβ25-35 spontaneously aggregates in solution, 48 
hr after incubation of the latter at 37ºC, revealed an increase in the relative fluorescence 
of the TH-T emission intensity (Fig. 2), indicating the existence of a more Aβ aggregated 
form.  
 
 
 
Fig. 2. Measurement of Aβ aggregation. Aβ25-35 was incubated at 37ºC for 48 hr either alone or in the presence of 
0,5 µM laminin (Lam) or 2,2 µM gelsolin (Gel). The fluorescence intensity of TH-T was measured at λex = 450 nm, λem 
= 482 nm. Results are expressed as mean±SEM of three independent experiments. **P<0,01, significantly different from 
48 h control; # #P<0,05 and # # #P<0,001 difference between 0 h and 48 h treatment, for each condition, Tukey post hoc 
test. 
 
Under these conditions laminin was used in a molar ratio of 1:200 (Aβ:laminin) and 
gelsolin of 1:45 (Aβ:gelsolin). By comparing to incubation of Aβ alone, we obtained a 
significant decrease in the fluorescence of TH-T when Aβ was co-incubation with laminin 
or gelsolin for 48 hr (from 22 fluorescence units to 4 and 3, respectively). These data 
indicate that in the presence of these two proteins Aβ25-35 fibril formation was inhibited. 
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Neurotoxicity of Aβ25-35 when complexed with laminin and with gelsolin 
The neurotoxicity of Aβ and Aβ-complexes was evaluated, by analysis of cell nuclei 
following Hoescht staining. Representatative images of each condition are shown in Fig. 
3A. The percentage of apoptosis was estimated, for primary cortical cultures when 
subjected to 10 µM of Aβ25-35, both in the absence and presence of laminin (50 nM) or 
gelsolin (220 nM) for 24 hr (Fig. 3B). The apoptosis induced by Aβ peptide alone was low 
(~15% above control levels). However, the levels could be decreased to ~5% above 
control if Aβ was pre-incubated with both laminin and gelsolin. Thus, indicating that 
laminin and gelsolin can attenuate the toxic effects of Aβ as deduced from the decrease in 
apoptotic levels in the presence of both proteins.  
 
A.  
 
 
 
B.  
 
 
 
 
 
 
Fig. 3. Aβ25-35 apoptotic effects in primary cortical cultures. (A) Hoescht stain was used to visualize cell nuclei 
in order to address the effects of 10 µM Aβ25-35 incubation during 24 hr, either alone or in the presence of laminin 
(Lam) and gelsolin (Gel) on the viability of neuronal cortical cultures. (B) Quantitative results of the percentage of 
apoptotic cells for each condition. Ten independent fields of microscope were analyzed (approximately 400 cells) per 
experimental condition. ***P<0,001, significantly different from control;  # #P<0,01, significantly different from Aβ; Tukey 
post hoc test. 
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Effect of Aβ-laminin and Aβ-gelsolin complexes on APP metabolism 
As discussed above the Aβ binding proteins (laminin and gelsolin) prevent fibrillogenesis 
rendering Aβ less neurotoxicity. Consequently we took advantage of this phenomenon to 
evaluate whether APP anomalous processing was also affected by Aβ aggregation state. 
Hence these Aβ-protein complexes were added to cultured cells. When primary cortical 
cultures were treated with 10 µM of aggregated Aβ for 24 hr we detected an 
approximate 4,0 fold increase in isAPP levels (Fig. 4).  
 
 
 
Fig. 4. Effect of Aβ-laminin and Aβ-gelsolin complexes on APP processing in primary cortical cultures. 
Primary cortical cultures were incubated during 24 hr with 10 µM of Aβ in the presence or absence of various proteins: 
laminin (Lam) and gelsolin (Gel). (A) Intracellular APP and total extracellular sAPP were detected using the 22C11 
primary antibody. β-tubulin was used as a control protein. (B) Quantitative results are expressed as mean±SEM of 3 
independent experiments. isAPP, intracellular sAPP and APP levels; esAPP, extracellular secreted sAPP; ◄, intracellular 
sAPP retention. *P<0,05; **P<0,01; ***P<0,001, significantly different from control; #P<0,01 and # # #P<0,01, significantly 
different from Aβ;  Tukey post hoc test. 
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In the presence of Aβ-laminin and Aβ-gelsolin complexes, the levels of isAPP decreased 
to 2,0 fold and 2,5 fold, respectively, when compared to Aβ treatment alone. These data 
suggest that these proteins which decrease Aβ fibrillogenesis, favour a less toxic Aβ 
species resulting in a decrease in Aβ-induced intracellular sAPP accumulation. Laminin and 
gelsolin alone showed no effect on APP intracellular levels. With respect to medium 
secreted sAPP we observed that aggregated Aβ25-35 resulted in decreased total 
extracellular sAPP levels, as previously reported. For the proteins tested it would be 
expected that inhibition of isAPP retention resulted in increased sAPP secretion. 
Nonetheless, only co-incubation of Aβ and laminin induced a slight increase on secreted 
sAPP (from 0,3 to around 0,5) showing a tendency of this protein to revert the inhibition 
of sAPP secretion induced by fibrillar Aβ alone. Aβ-gelsolin complexes had no significant 
effect on sAPP extracellular levels. Of note, both laminin and gelsolin alone slightly 
decreased sAPP extracellular secretion. 
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DISCUSSION  
We previously reported that “fresh” Aβ25-35 peptide leads to increased isAPP 
accumulation in non-neuronal cells (mainly isAPPα retention) and neuronal cultures 
(Henriques et al. 2009a, in press). Since the sAPPα proteolytic fragment has been shown 
to hold neurotrophic and neuroprotective properties when added to cells in culture, we 
proposed that retention of sAPP may be a physiologically relevant mechanism. The 
neurotoxic effects of the Aβ peptide per se appear to be associated with its 
polymerization state (Pike et al. 1993; Lorenzo and Yankner 1994; Dahlgren et al. 2002). 
From the data here presented it is reasonable to deduce that the aggregated Aβ25-35 
peptide showed a higher potential to induce isAPP retention when compared to “fresh” 
Aβ (4,5 fold versus 2,0 fold). This indicates that increasing Aβ aggregation leads to an 
enhanced toxic effect.  
Given that Aβ toxicity is closely associated with its fibril state, proteins which can 
modulate the latter may therefore prevent some of the Aβ amyloidogenic effects. Both 
laminin and gelsolin have been shown to inhibit fibril formation and also to promote 
defibrillization of Aβ1-40 and Aβ1-42 peptides, and this was associated with a decrease in Aβ-
induced neurotoxicity (Morgan et al. 2002; Qiao et al. 2005). We evaluated the effect of 
laminin and gelsolin on Aβ25-35 aggregation. In agreement with previous observations for 
the longer peptides, these proteins were able to inhibit the aggregation of Aβ25-35 as 
showed by TH-T assay (Fig. 2) and to prevent Aβ25-35 neurotoxic effects (Fig. 3). Thus the 
Aβ25-35 region must comprise at least one binding site for laminin and gelsolin. The 
resulting Aβ-laminin and Aβ-gelsolin complexes were effective in decreasing anomalous 
isAPP retention induced by the Aβ peptide alone. For medium secreted sAPP, only 
laminin was able to marginally provoke an increase, thus reverting the effect of fibrillar 
Aβ. Laminin was previously shown to decrease APP secretion and to affect intracellular 
APP biogenesis and catabolism (Monning et al. 1995; Bronfman et al. 1996). 
Presently it is difficult to interpret the significance of the decrease in isAPP levels induced 
by these Aβ-protein complexes, because the metabolism and clearance of the compounds 
tested are not completely understood. Nonetheless, we postulate that the laminin- or 
gelsolin- Aβ complexes might be inhibiting Aβ signaling and/or be intracellularly targeted 
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for degradation, therefore preventing Aβ-induced responses. Peripheral administration of 
plasma gelsolin resulted in a reduction of Aβ1-40/Aβ1-42 and Aβ load in the brains of APP/PS 
transgenic mice that exhibited elevated intraneuronal Aβ1-42 levels (Matsuoka et al. 2003). 
Moreover, in similar transgenic mouse models of AD, peripheral delivery of plasmid DNA 
of plasma gelsolin, also lead to a reduction in Aβ levels in the brain (Hirko et al. 2007). 
The reduction in Aβ pathology appeared to be related with an increase in activated and 
reactive microglia and with soluble oligomeric forms. Our study suggest that by 
interacting with Aβ peptide, laminin and gelsolin may be protective with respect to Aβ 
induced neurotoxicity and may play a role as modulators of APP metabolism. Further, due 
to their depolymerization properties and their capacity to bind Aβ these proteins could 
alter the Aβ periphery/brain load leading to its reduction in brain. This may be of 
therapeutic value to the development of future drugs designed to act at the level of Aβ 
fibrillogenesis. 
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ABSTRACT 
Abnormal protein phosphorylation has been associated with several neurodegenerative 
disorders, including Alzheimer’s Disease (AD).  Aβ is the toxic peptide that results from 
proteolytic cleavage of the Alzheimer’s amyloid precursor protein, a process where 
protein phosphatases are known to impact. The data presented here demonstrates that 
protein phosphatase 1 (PP1), an abundant neuronal serine/threonine-specific phosphatase 
highly enriched in dendritic spines, is specifically inhibited by Aβ peptides both ‘in vitro’ 
and ‘ex vivo’.  Indeed, the pathologically relevant Aβ1-40 and Aβ1-42 peptides, as well as 
Aβ25-35, specifically inhibit PP1 with low micromolar potency, as compared to inactive 
controls and other disease related peptides (e.g. the prion related Pr118-135 and Pr106-126).  
Interestingly, PP1 inhibition is increased by Aβ aggregation, indicating a possible direct 
neurotoxic effect of the aggregated peptide.  PP1 involvement in processes like long-term 
depression, memory and learning, and synaptic plasticity, prompt us to suggest that PP1 
may constitute an important physiological target for Aβ and, therefore, increased Aβ 
production and/or aggregation may lead to abnormal PP1 activity and likely contribute to 
the progressive neuropsychiatric AD condition. Thus, PP1 activity and levels constitute 
potential biomolecular candidates for diagnostics and therapeutics. 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Phosphatase, PP1, Amyloid peptide, Alzheimer’s disease, phosphorylation, 
Abeta aggregation 
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1. INTRODUCTION 
Protein phosphorylation is a key post-translational modification that regulates numerous 
physiological processes.  Thus, protein kinases and protein phosphatases are key pivotal 
players in signal transduction cascades, modulating many biological functions.  Altered 
signal transduction leads to a variety of disorders, including neurodegenerative conditions.  
Protein phosphatase 1 (PP1) is the most widely expressed and highly regulated member 
of the serine/threonine-specific phosphatase family.  The three known mammalian PP1 
catalytic subunit genes (PP1α, PP1β and PP1γ) are abundantly expressed in the mammalian 
brain [6], sustaining the importance of PP1 in the control of brain functions.  Both PP1α 
and PP1γ1 were shown to be highly and specifically concentrated in dendritic spines [29], 
placing them at the centre of neuronal signaling.  Indeed, PP1, via regulation by the 
dopamine- and cAMP-regulated phosphoprotein, DARPP-32 [18], in the neostriatum [30], 
mediates the action of several neurotransmitters, like dopamine, serotonin and glutamate 
[26].  Perturbations of these neurotransmitter systems are known to contribute to the 
etiology of several neuropsychiatric disorders and play an important role in the actions of 
drugs of abuse. 
Alzheimer's disease (AD) is characterized clinically as a dementia of insidious onset and 
inexorable progression, and pathologically by the presence of large numbers of neuritic 
plaques and neurofibrillary tangles.  The neuritic plaques are largely extracellular lesions 
consisting of deposits of 40–42/43 amino acids long peptides, termed Aβ, derived from 
the proteolytic processing of the Alzheimer’s amyloid precursor protein (APP) [15,17].  
Direct APP phosphorylation and phosphorylation-dependent APP processing have been 
shown to regulate Aβ formation [7,31], and thus altered cellular phosphorylation may 
lead to increased neuronal amyloid production and accumulation.  Indeed, protein kinase 
C (PKC) and protein phosphatase 2B (PP2B) were reported to bidirectionally regulate Aβ 
formation in cell-free preparations [12].  Additionally, PP1 is also known to stimulate the 
secretion of APP, suggesting that it plays a central role in this process [5].  As mentioned 
above, AD patients also present characteristic neurofibrillary tangles in their brains, 
composed largely of hyperphosphorylated tau protein.  Altered PP1 and protein 
phosphatase 2A (PP2A) activities are both thought to contribute to tau 
hyperphosphorylation [2].  Further, the cognitive decline observed in AD is largely 
thought to be related to the marked decrease observed in synaptic contacts [11,34], 
Aβ biology and its contribution to AD   Chapter IV 
 
Centro Biologia Celular  227 
Universidade de Aveiro 
 
where PP1 plays a central role since it is highly enriched in post-synaptic dendritic spines.  
Not only is PP1 involved in the control of long-term depression and synaptic plasticity 
[24], but also in aging-related memory defects [14].  The abnormal phosphorylation of key 
proteins linked to neurodegeneration and the demonstrated neurotoxicity of Aβ led us to 
investigate the effect of this peptide on PP1.  Our previous work showed that PP1 was 
involved in secreted APP production [5] and that its intracellular levels were altered after 
incubation of cells in culture with Aβ peptides [1].  Herein we demonstrate that the 
activity of different isoforms of PP1 is highly and specifically inhibited by Aβ and that this 
effect is potentiated by Aβ aggregation.  Our results provide novel insights into the 
molecular mechanisms associated with Alzheimer’s disease that lead to 
neurodegeneration and dementia. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Phosphorylase b and phosphorylase kinase were purchase from Sigma, [γ-32P]ATP 
(3000Ci/mmol) from Amersham Pharmacia Biotech (Portugal), and PP1α and inhibitor I2 
from New England Biolabs (USA).  PP1γ1 and PP1γ2 were expressed and purified, 
essentially as previously described [35]. 
Aβ peptide fragments 25-35, 1-40 and 1-42 (American Peptide Company, USA) were 
reconstituted in distilled water to concentrations of 1 and 5mM.  The peptides used as 
controls were Aβ40-1 (Bachem, Belgium) and Aβ25-35 with a scrambled sequence, AβSCR 
(NeoMPS, France).  The control peptides were reconstituted in distilled water to 5 and 
10mM.  Aβ1-42 pre-treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) was purchased 
from rPeptide (USA) and reconstituted in DMSO to 1mM.  The prion peptide Pr106-126 and 
its scrambled control, Pr106-126SCR (NeoMPS, France), were reconstituted in water to 5mM.  
Pr118-135 (American Peptide Company, USA) was first dissolved in DMSO and then brought 
to 5mM with water.  All reconstituted peptides were immediately frozen and stored at –
20ºC. 
 
2.2. Methods 
2.2.1. Determination of peptide IC50 against PP1. The effect of all peptides on the 
activity of purified PP1 isoforms was assessed using 32P-phosphorylase a and myelin basic 
protein (MBP) as substrates.  The preparation of substrate and the assays using 32P-MBP 
were carried out as described by the manufacturer (New England Biolabs, USA).  32P-
phosphorylase a was prepared from phosphorylase b using [γ-32P]ATP and phosphorylase 
kinase as previously described [35].  Peptide stock solutions were diluted in inhibitor 
buffer [50mM Tris-HCl (pH7.5), 0.1mM EGTA, 0.03% (v/v) Brij-35], just before use.  PP1 
catalytic subunits diluted in phosphatase buffer [50mM Tris-HCl (pH7.5), 1mM MnCl2, 
0.1mM EGTA, 0.1% (v/v) 2-mercaptoethanol, 1mg/ml BSA] were incubated with the 
prepared peptides for 5min at 30ºC.  The reaction was started with the addition of 32P-
phosphorylase a (3mg/ml) substrate.  After 10min, 100µl of ice-cold 20% (w/v) 
trichloroacetic acid (TCA) were added and the mixture was centrifuged at 12000g for 
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2min at room temperature.  The 32P-phosphate released into the supernatant was 
measured using a scintillation counter (kept below 20% of total substrate radioactivity for 
the control in order to ensure linearity).  For each peptide, an appropriate range of 
concentrations was used and the IC50 calculated using the BioDataFit 1.02 software.  The 
standard deviation was calculated from at least three independent experiments. 
 
2.2.2. Effect of peptide aggregation on PP1γ1.  For Aβ oligomer preparation [32], 
0.1mM Aβ1-42 (HFIP) or 1mM Aβ1-40 were incubated for 24h at 4ºC.  For fibrillar Aβ 
preparation [32], the same concentrations of Aβ1-42 (HFIP) and Aβ1-40 in 10mM HCl were 
incubated for 24h at 37ºC.  The acid was then neutralised and both preparations used in 
the phosphatase assay.  The prion peptide Pr118-135 remains soluble if kept at –20ºC [3].  
Fibrillar Pr118-135 was prepared by incubation of 1mM of peptide for 72h at room 
temperature [3]. 
 
2.2.3. Incubation of PC12 cells with Aβ25-35.  PC12 cells were cultured in RPMI1640 
medium (Alfagene, Portugal) supplemented with 5% fetal bovine serum and 10% horse 
serum.  Cells were plated onto poly-L-ornithine coated dishes at a density of 5x105 
cells/cm2 and washed with serum-free medium prior to Aβ25-35 treatment.  Cells were then 
exposed to 20 or 50µM Aβ for 2 or 24h in serum-free medium and after incubation were 
washed in cold Tris-HCl/EDTA buffer [50mM Tris-HCl (pH7.5), 0.1mM EDTA] and 
resuspended in homogenizing buffer [50mM Tris-HCl (pH7.5), 0.1mM DTT, 0.1mM 
EDTA, 0.1mM EGTA, 0.1mM PMSF, 1mM benzamidine, 150mM NaCl and 5µg/ml 
leupeptin].  Cell homogenates were normalized for total protein content, as determined 
by the BCA method (Pierce, USA), before being used in the phosphatase assay. 
 
2.2.4. Phosphatase activity assay of cell extracts.  The total phosphatase activity of 
control and Aβ-treated cell extracts was determined by assaying appropriate dilutions in 
phosphatase buffer with 32P-phosphorylase a.  PP2A specific activity was determined by 
pre-incubating the cell extracts with 200nM of I2 for 15min at 30ºC before substrate 
addition.  The PP1 specific activity was calculated as the difference between the total 
phosphatase activity and the PP2A specific activity. 
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3. RESULTS 
3.1. Aβ peptides inhibit PP1 at low micromolar concentration 
The effect of the different Aβ peptides and their controls (Aβ25-35, Aβ1-40, Aβ1-42, AβSCR and 
Aβ40-1) on the activities of the two main neuronal PP1 isoforms (PP1α and PP1γ1) was 
assessed by determining the respective IC50 values (Table 1).   
 
Table 1. Comparison of PP1 isoform inhibition by various Aβ and prion peptides 
  IC50 (µM)a) 
Peptides PP1α PP1γ1 
Aβ25-35 8.2 ± 0.5 4.1 ± 0.3 
Aβ1-40 2.8 ± 0.4 1.3 ± 0.7 
Aβ1-42 2.3 ± 0.7 1.9 ± 0.5 
Aβ25−35 SCR Nd >1000
b) 
Aβ40-1 Nd 137
  
Pr106-126 Nd 122 ± 8 
Pr118-135 Nd ~500
c) 
 
a) Values are expressed as mean±S.E.M. of at least three independent experiments using phosphorylase a as 
substrate. 
b) Concentration yielding 20-30% inhibition. 
c) Concentration yielding ~50 % inhibition for three independent experiments. 
Nd - not determined.  
 
PP1γ1 inhibition by Aβ1-40 and Aβ1-42 was very similarly (IC50 of 1.3±0.7µM and 1.9± 0.5µM, 
respectively), while inhibition by Aβ25-35 was about two fold less potent (IC50 of 
4.1±0.3µM).  In contrast, the control peptide Aβ40-1 was around 100-fold less potent than 
its Aβ1-40 counterpart, and AβSCR yielded only a maximum of about 20% inhibition at 1mM 
(the highest concentration tested).  Comparing the effect of the Aβ peptides on the two 
PP1 isoforms, the data obtained indicates that PP1γ1 is approximately twice as sensitive to 
inhibition by all three Aβ peptides, compared to PP1α. 
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3.2. PP1 is relatively insensitive to inhibition by prion peptides 
The accumulation in the brain of a pathological form of the normal cellular prion protein 
(PrP) is associated with the neurodegeneration of the transmissible spongiform 
encephalopathies.  Fragments of PrP, like Pr106-126 and Pr118-135, can polymerise into 
amyloid-like fibrils [3,10].  In order to test the specificity of PP1 inhibition by Aβ, we 
determined the IC50 values for Pr106-126 and Pr118-135 against PP1γ1 (Table 1).  The IC50 values 
obtained for the prion peptides were approximately 100 times higher than that of the Aβ 
peptides, confirming the specificity of Aβ inhibition of PP1 activity. 
 
3.3. Aβ inhibition of PP1 is not dependent on the substrate used 
The PP1 catalytic subunit can dephosphorylate multiple substrates both in vivo and in vitro.  
In order to assess if the observed inhibitory effect was a substrate dependent 
phenomenon, we further compared the IC50 values of the Aβ peptides using MBP and 
phosphorylase a.  Table 2 shows that PP1 inhibition by Aβ does not differ substantially 
when using different substrates.  However, the use of a different lot (from the same 
supplier) of the Aβ25-35 peptide yielded a slightly different IC50 value.  Discrepancies 
between different lots of Aβ peptides have been widely reported [23], possibly related to 
their state of aggregation in solution.   
 
Table 2. Comparison of PP1γ1 inhibition by Aβ peptides using different substrates 
 IC50 (µM)a) 
Peptides Phosphorylase a MBP 
Aβ25-35 1.1 ± 0.1
b) 0.24 ± 0.18 
Aβ1-42 1.9 ± 0.5  6.5 ± 0.4 
 
a) Values are expressed as mean±S.E.M. of at least three independent experiments. 
b) This value was obtained using a different lot of Aβ peptide 
 
Given that Aβ aggregation is thought to play a major role in AD development, this led us 
to investigate how this might affect Aβ inhibition of PP1 activity. 
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3.4. Aβ aggregation increases its potency against PP1 
The IC50 values of the fibrillar forms of the peptides were compared to those obtained 
with their oligomeric forms, and the fold effect was calculated (Table 3).  
 
Table 3. Aβ fibril formation increases its inhibitory potency against PP1 
Peptide Fold effect 
(Oligomer/Fibril) 
Aβ40-1 1 
Aβ1-40 7 
Aβ1-42 9 
 
Each peptide was processed as described to form oligomers or fibrils and assayed 
against PP1γ1.  The fold effect of fibril formation on the corresponding IC50 values 
was determined graphically from at least three independent experiments. 
 
 Aggregation of Aβ1-40 and Aβ1-42 significantly augmented their potency against PP1γ1, 
whereas at the tested peptide concentrations the aggregating conditions applied to Aβ40-1 
did not affect its PP1 inhibition curve significantly.  Fibril formation of Aβ1-40 and Aβ1-42 
decreased their IC50 against PP1γ1 by approximately 7-fold and 9-fold, respectively (Table 
3).  Aggregating conditions were also tested for Pr118-135 but, like for Aβ40-1, no significant 
effect was observed on PP1γ1 inhibition (data not shown), thus confirming the specificity 
of the effect for the Aβ peptide. 
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3.5. Effect of Aβ on phosphatase activity in PC12 cells 
PC12 cells were exposed to Aβ25-35 (20 and 50µM) for 2 and 24h, and PP1 and PP2A 
activities were determined (Fig. 1).   
 
 
 
Fig. 1. Effect of Aβ25-35 on PP1 and PP2A activities in PC12 cells.  PC12 cells were incubated with 20 and 50µM 
Aβ25-35 for 2 and 24h and the respective homogenates were assayed as described using 32P-phosphorylase a.  The values 
obtained from control cells incubated without Aβ were taken as 100%.  Values statistically different from control 
[P<0.05 (*) and P<0.01 (**)] and between themselves [P<0.02 (#) and P<0.01 (††)] are indicated. 
 
Overall, in this cell line, PP1 activity was significantly more affected by Aβ exposure than 
PP2A activity.  Statistically significant decreases in activity were observed at 24h exposure.  
Moreover, a time and concentration dependent decrease of PP1 activity was observed.  In 
particular, a decrease in activity was seen with time of exposure with 50µM Aβ (P<0.05) 
and also with increasing Aβ concentrations at 24h (P<0.01).  Therefore, this “ex vivo” data 
support the “in vitro” data, showing that Aβ is capable of exercising an inhibitory effect on 
PP1 activity. 
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4. DISCUSSION 
Altered signal transduction is thought to contribute significantly to the development of 
neurodegenerative conditions like AD. Indeed, several studies have reported abnormal 
protein kinase [19] and protein phosphatase [16] activities in AD brains, compared to 
normal aged controls. Moreover, APP processing is a phosphorylation-dependent event 
[13], in which protein kinase C (PKC) and PP1 appear to be central players by affecting 
intracellular trafficking events [4].  Furthermore, a potential PKC phosphorylation site 
within the cytoplasmic domain of APP was shown to be phosphorylated in vivo [28].  
Besides its neurotoxic actions, Aβ might also have a feedback regulatory role on APP 
processing.  Previous studies have shown that Aβ activates various PKC isoforms in 
different cell lines [27,33].  Here we focussed on PP1, demonstrating that Aβ also directly 
affects phosphatase activity. Indeed, Aβ peptides inhibit different PP1 isoforms at low 
micromolar concentrations. As aggregation of Aβ appears to be important for its 
neurotoxic effects, we investigated how Aβ aggregation affects PP1 activity. Fibril 
formation of Aβ1-40 and Aβ1-42 significantly increased their inhibitory potency against PP1.  
PP1γ1 was inhibited at concentrations up to 9-fold lower compared to their oligomeric 
state, thus making the fibrillar forms even more potent phosphatase inhibitors.  
Interestingly, aggregation of prion peptides did not increase their inhibitory effect on PP1, 
demonstrating specificity for the Aβ peptide aggregation effect on PP1 activity.  In PC12 
cells, 24h incubation with Aβ also affected both PP1 and PP2A activities in a dose-
dependent manner.  These results, taken together with the fact that Aβ causes alterations 
in PP1 intracellular levels in mammalian cells [1], lead us to conclude that Aβ can interfere 
with normal neuronal signal transduction events. Thus, concomitant activation of PKC 
and inhibition of PP1 may explain the observed hyperphosphorylation of key proteins 
associated with Alzheimer’s disease (i.e. APP and tau). However, since a direct link 
between altered phosphorylation processes and Aβ neurotoxicity remains to be 
conclusively established, our results provide interesting support for further investigation. 
Nevertheless, given the critical role played by PP1 in LTD, age-related memory and 
learning and synaptic plasticity, it is not surprising that some of the neurotoxic effects of 
Aβ might be related to its direct effect on PP1. Indeed, a two-week continuous infusion of 
Aβ into the cerebral ventricles of adult rats leads to an impairment of learning and 
memory compared to control animals [25]. However, LTP impairment induced by Aβ 
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oligomers can be reversed by PP1 inhibition in vitro [20].  It is unclear how those 
observations might be related to our demonstration of PP1 inhibition by Aβ.  Also, since 
APP phosphorylation affects its own processing [8] and PP1 modulates APP secretion [5], 
Aβ might also be affecting its own production through modulation of PP1 activity.  
Further, as PP1 is known to dephosphorylate tau [22], the reported Aβ oligomer 
induction of tau hyperphosphorylation [9] might occur via inhibition of PP1 activity.  PP1 
inhibition by Aβ may explain not only tau hyperphosphorylation in AD brains, but also the 
reported hyperphosphorylation of APP itself in those patients [21]. 
The contribution of Aβ to the development of AD may be related to physiological 
inhibition of PP1 activity and thus underlie age-related and/or AD-related biochemical 
abnormalities, given the ubiquitous expression and wide variety of physiological roles of 
PP1. Although it is unclear what concentration of Aβ peptides occur in the brain, the 
production of Aβ in intracellular sites where PP1 is abundant may be sufficient to upset 
the exquisite balance that controls cellular health and vitality, especially if Aβ production 
is increased due to age-related or disease-related factors. The potential usefulness of PP1 
for diagnostic purposes needs to be investigated in AD patients, although it may prove 
more interesting as a therapeutic target. Since PP1 occurs in complexes with other 
proteins that confer upon it physiological specificity, the development of drugs targeting 
specific PP1 binding proteins involved in APP processing may constitute potential 
therapeutic agents for AD. Work is currently underway to identify such proteins. 
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5.1 Aβ-MEDIATED EFFECTS ON APP PROCESSING AND TRAFFICKING 
Aβ peptide is the major component of senile plaques (Glenner and Wong 1984), one of 
the principal hallmarks of AD. Although it exists physiologically (Haass et al. 1992; Haass 
et al. 1993), in AD it aggregates and deposits in specific brain regions (Arnold et al. 1991; 
Braak and Braak 1991), thus interfering with crucial neuronal processes. Several in vitro 
and in vivo studies have shown that Aβ fibril formation can trigger several 
neurodegenerative mechanisms, including cytoskeletal associated morphological 
alterations of neurites (Pike et al. 1992; Busciglio et al. 1995; Grace et al. 2002; Mendoza-
Naranjo et al. 2007). 
Aβ derives from the amyloidogenic processing of APP, hence factors contributing to 
altered APP processing may potentially lead to increased Aβ production. Aβ itself has 
been described to alter APP metabolism although controversy exists. While some 
authors suggest that Aβ affects APP processing/catabolism (Davis-Salinas et al. 1995; Yang 
et al. 1995; Schmitt et al. 1997; Carlson et al. 2000) others reported that it can also 
induce APP expression (Le et al. 1995; Moreno-Flores et al. 1998). Therefore, the first 
chapters of this work were aimed at characterizing these Aβ effects on APP 
processing/trafficking and expression in different cell types. 
 
Inhibition of sAPP secretion due to altered cytoskeletal dynamics 
Aβ-induced cellular responses were addressed using the biological active peptide Aβ25−35, 
which shows similar properties to naturally occurring Aβ1-40 and Aβ1-42 (Pike et al. 1995; 
Xu et al. 2001a; Xu et al. 2001b; Liao et al. 2007) and thus represents a good 
experimental model to study Aβ-downstream molecular mechanisms that may be 
involved in AD. We addressed the effects of exogenously added Aβ on APP trafficking 
and metabolism in non-neuronal, neuronal-like and neuronal cells (Chapter II). Aβ was 
reported to be efficiently internalized (Saavedra et al. 2007; Nielsen et al. 2008; Yamada 
et al. 2008) thus making possible the induction of a set of intracellular responses. In non-
neuronal COS-7 cells we showed that this peptide leads to intracellular sAPPα (isAPPα) 
retention, in agreement with a previous report by Carlson et al. (2000). Interestingly, and 
despite isAPP retention, an increase in extracellular sAPP secretion could also be 
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observed. We postulated that sAPP secretion could partially occur via an alternative 
endoplasmic reticulum (ER) secretory pathway. This was based on the observation that 
isAPP co-localized to the ER and that the latter maintained its integrity upon Aβ 
treatment. Concordant with this hypothesis, Shin et al. (2005) observed that sAPP 
deriving from an APP mutant with an ER-retrieval signal, did not follow the normal post-
TGN vesicular secretory pathway in COS-7 cells. For this mutant, sAPP secretion was 
diminished but not absent, and sAPP appeared to be media secreted via the smooth ER, 
as deduced from strong sAPPα/ER co-localization. Further, data from our laboratory 
showed that an APP phosphomutant expressed in COS-7 cells, exhibited impaired 
vesicular secretion, but still produced and secreted normal levels of sAPPα (Rebelo et al. 
2007).  
Aβ-induced isAPP retention was also demonstrated for SH-SY5Y and PC12 cells and 
primary neuronal cultures. Nonetheless, differences were observed in the degree of 
extracellular sAPP secretion, with both PC12 and neuronal cells being particularly 
affected. Neuronal and even undifferentiated PC12 cells are well known models of highly 
regulated secretion, presenting not only a constitutive secretory vesicular pathway but 
also stimuli-sensitive vesicular secretion (Greene and Tischler 1976; Burgess and Kelly 
1987; Martin and Grishanin 2003). In contrast, besides the constitutive vesicular pathway, 
no regulated vesicular secretion has been described for COS-7 cells, and in 
undifferentiated SH-SY5Y cells only residual regulated vesicular machinery appears to 
exist (Goodall et al. 1997). Thus it seems reasonable to deduce that, Aβ compromises the 
major APP/sAPP TGN-to-PM vesicular secretory pathway and that, at least for non-
neuronal cells (i.e. COS-7), sAPP of Golgi/ER origin can be redirected to an alternative, 
usually less used ER-to-PM pathway. Hence, sAPP is still secreted. This shift does not 
occur in PC12 cells and primary cultures, for the reasons described above, and the net 
effect is a decrease in extracellular sAPP. These differential Aβ responses in neuronal and 
non-neuronal cells are of particular importance given that AD is a neurodegenerative 
disorder essentially affecting the brain and sparing most of the peripheral tissues. It is 
worth mentioning that sAPPα levels are decreased in cerebrospinal fluid (CSF) in AD 
patients (Colciaghi et al. 2002; Olsson et al. 2003), which is consistent with our data on 
primary cultures, that is isAPP retention and decreased sAPP secretion, in response to 
excess Aβ. Due to the sAPPα neurotrophic/neuroprotective putative functions (Turner 
Aβ biology and its contribution to AD   Chapter V 
 
Centro Biologia Celular  245 
Universidade de Aveiro 
 
et al. 2003; Thornton et al. 2006), extracellular depletion of this fragment may represent a 
pathogenic mechanism by which Aβ leads to neurotoxicity, thus contributing to the 
neuronal degeneration and death observed in AD. Of note, Aβ and sAPPα have been 
described to have opposite effects in several cellular mechanisms. For instance, while 
Aβ was reported to inhibit glucose receptors exocytosis and glucose uptake as well as 
glutamate transport, these effects were attenuated by sAPPα (Mattson et al. 1999; 
Uemura and Greenlee 2001). Therefore, an imbalance in Aβ/sAPPα 
intracellular/extracellular levels may underlie alterations in fundamental survival processes, 
contributing to progressive neurodegeneration. 
Interestingly, we associated isAPP retention in response to Aβ exposure, to vesicular-like 
densities in COS-7 cells.  Further, for all cells, subcellular fractionation assays revealed 
that isAPP accumulation was predominantly associated with cytoskeleton fraction. Since 
vesicular trafficking has long been associated with the cytoskeleton network (Hamm-
Alvarez and Sheetz 1998; Gross 2004; Lanzetti 2007; Nakata and Hirokawa 2007; Potokar 
et al. 2007), the data here presented corroborates the hypothesis that Aβ impairs vesicle 
motility along the cytoskeleton, and/or inhibits vesicle docking/fusion at the PM. Thus we 
observe isAPP production/retention within cytoskeletal-associated vesicular-like 
structures and subsequent inhibition of sAPP secretion.  
In neurons, KLC-driven APP vesicular axonal transport has been reported, either by 
direct APP interaction with KLC (Kamal et al. 2000), or indirectly via complex formation 
with JIP-1 (Matsuda et al. 2003; Lazarov et al. 2005). Despite the controversy around the 
mode of interaction between APP and KLCs, the presence of isAPP in kinesin-associated 
vesicles in neuronal cultures (represented in Figure 1, page 256 and 257), supports KLC 
mediated axonal transport of APP. Interestingly, this data clearly shows that APP can be 
intracellularly cleaved giving rise to isAPP production, which due to hindered APP axonal 
transport accumulates in the cytoskeletal fraction. 
Clearly, Aβ affects APP/sAPP balance. Since alterations in cytoskeleton dynamics may 
account for altered protein axonal transport and vesicular secretion, and even 
neurodegeneration, we analysed Aβ effects on both microtubule and actin networks.  
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Aβ led to an increase in F-actin polymerization for both PC12 cells and in primary 
neuronal hippocampal cultures. This is consistent with previous  observations showing 
that Aβ can interfere with the actin network (Song et al. 2002; Hiruma et al. 2003; 
Mendoza-Naranjo et al. 2007) thus contributing to neurodegeneration (Maloney and 
Bamburg 2007). Possible underlying mechanisms may include increased F-actin 
polymerization in a Rac1/Cdc42 dependent way (Mendoza-Naranjo et al. 2007) or 
through p38 mitogen-activated protein kinase pathway (Song et al. 2002).   
Interestingly, our results also showed that Aβ was interfering with the microtubule 
network as demonstrated by changes in α-tubulin acetylation, which is an indirect 
measure of microtubule stability (Black et al. 1989; Bloom 2004). In particular, neuronal 
hippocampal cells exhibited a marked decrease in α-tubulin acetylation along neurites, as 
shown by immunofluorescence analyses. For PC12 cells, we also observed a decrease and 
an apparent redistribution of α-tubulin acetylation in response to Aβ peptide exposure. 
Of note, a recent study showed that tubulin acetylation could play a key role in 
microtubule-based transport, by demonstrating that α-tubulin acetylation can influence 
the binding and the motility of the microtubule motor kinesin-1 (Reed et al. 2006). 
Additionally, Gardiner et al. (2007) hypothesized that increased α-tubulin acetylation was 
associated with increased transport along microtubules. It follows that, by decreasing α-
tubulin acetylation and increasing F-actin polymerization Aβ is potentially decreasing sAPP 
vesicular transport/secretion. 
To confirm that Aβ disrupts cytoskeleton dynamics/stability and consequently sAPP 
secretion, experiments were repeated in the presence of an actin depolymerizing drug 
(cytochalasin D, CytD) or by interfering with microtubule stability (taxol). In PC12 cells, 
the use of CytD led to a robust reversion on sAPP secretion when compared to Aβ 
treatment alone. Likewise CytD, the microtubule stabilization drug, could also partially 
reverse the Aβ-induced inhibition of sAPP secretion. These results suggested that, for 
PC12 cells, sAPP secretion is more dependent on actin than on the microtubule network. 
These differences, in terms of reversion of sAPP secretion, may be associated with cell 
specific cytoskeleton organization of the actin and tubulin networks. For PC12 cells the 
actin cytoskeleton is very important for both vesicular motility and exocytosis (Martin 
and Grishanin 2003; Lanzetti 2007).  
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In summary, these novel findings clear show that Aβ is affecting both networks (illustrated 
in Figure 1, page 256 and 257), since both drugs could partially reverse the impaired sAPP 
secretion. Therefore, the Aβ-mediated effects on cytoskeleton dynamics/networks can 
account for the alterations in APP vesicular transport and decreased sAPP secretion 
associated with the disease. Highly relevant is the report that Aβ-induced 
neurodegeneration could be prevented by microtubule stabilizing drugs (Michaelis et al. 
1998; Michaelis et al. 2005; Seyb et al. 2006). These results together with our data 
support the potential use of drugs targeting cytoskeletal integrity/dynamics as therapeutic 
strategies to prevent/ameliorate failures in axonal transport and neurodegeneration 
characteristic of AD.  
 
5.2  Aβ-MEDIATED EFFECTS ON APP EXPRESSION 
As explained above, previous reports documented that Aβ can induce APP expression 
levels. However, as described in Chapter II, and for the cell lines we tested, the increased 
immunoreactive associated with antibodies such as 22C11 is related with increased isAPP. 
In particular for primary neuronal cultures, holoAPP levels decreased in response to Aβ, 
rather suggesting reduced APP transcription. Further, APP has been described to be 
processed by “regulated intramembrane proteolysis” (RIP), giving rise to an active 
fragment, the APP intracellular domain (AICD), which plays a role in the regulation of 
nuclear signaling events. Hence, it became critical to address how Aβ affected APP 
expression levels, AICD production and nuclear targeting in primary neuronal cultures 
(Chapter III). 
 
Regulation of AICD and Fe65 nuclear targeting  
The AICD provides a mechanism by which APP can regulate its own expression. This APP 
proteolytic fragment is nuclear targeted and exhibits transcriptional activity, being a 
component of transcriptional active complexes such as the one comprising AICD, Fe65 
and the histone acetylase Tip60 (Cao and Sudhof 2001). Several lines of evidence 
indicated that the adaptor protein Fe65 modulates the stability of AICD, thereby 
potentiating its subsequent nuclear translocation (Kimberly et al. 2001; Kinoshita et al. 
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2002; Walsh et al. 2003). Nuclear AICD/Fe65-containing complexes were reported to 
activate the transcription of several genes, including APP itself, BACE, Tip60 (von Rotz et al. 
2004), GSK3β (Kim et al. 2003; Ryan and Pimplikar 2005), KAI1 (Baek et al. 2002) and 
Neprilysin (Pardossi-Piquard et al. 2005).  
Neuronal data obtained in Chapter II, led us to hypothesize that besides having an effect 
on APP trafficking/processing, Aβ could also have consequences on APP transcriptional 
activity. Indeed, a decrease in hAPP intracellular levels in Aβ-treated neuronal cells was 
observed, suggesting decreased APP mRNA expression. Subsequent experiments revealed 
that Aβ was in fact inducing a decrease in neuronal APP expression. Additionally, at the 
processing level we observed an increase in APP CTFs implying decreased AICD 
production. Interestingly, CTF accumulation is consistent with APP retention in 
intracellular vesicles that do not reach the PM. γ-secretase cleavage has been shown to 
occur mainly in endosomes and also at the PM (Fukumori et al. 2006; Kaether et al. 
2006). If APP/CTFs are not reaching the PM, then subsequent Aβ and AICD production is 
expected to decrease. Diminished AICD production correlates well with decreased AICD 
nuclear targeting and reduced APP transcriptional activation. Consistently, we detected a 
decrease in the nuclear targeting of both AICD and Fe65, along with a decrease in the 
AICD/Fe65 nuclear complexes. Down-regulation of Fe65 was clearly evident, which is in 
agreement with previous observations that Fe65 affects APP processing. A report by Xie 
et al. (2007) showing that RNAi of Fe65 leads to increased CTFs accumulation is also 
consistent with our data. Further, Fe65 overexpression was associated with increased 
APP translocation to the cell surface, as well as increased sAPPα and Aβ secretion (Sabo 
et al., 1999). Hence, reduced Fe65 levels may account at least in part for the intracellular 
retention of APP/sAPP. At the transcriptional activation level, the results suggest that Aβ 
is affecting AICD production, its nuclear translocation and its nuclear complex formation 
with Fe65, whose nuclear targeting is also decreased. A potential decrease in AICD 
production and in the formation of AICD/Fe65 transactivator complexes lead us to 
conclude that APP nuclear signaling is altered in the presence of Aβ, leading to impaired 
specific gene transcription (illustrated in the following Figure). This effect on APP/Fe65 
nuclear targeting is of particular importance, placing Aβ as a pivotal regulator of its own 
production. 
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Given the data discussed above for APP metabolism and trafficking in reponse to Aβ, a 
putative model for neuronal cultures was schemed in Figure 1A, representing basal 
conditions, and in Figure 1B integrating Aβ-induced alterations. 
 
 
 
             Symbol identity 
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Figure 1. Putative model for Aβ−induced responses in primary neuronal cultures. A. Under basal conditions 
APP follows the normal and well described TGN-to-PM secretory pathway. At the cell surface APP can be proteolytic 
cleaved, mainly by α-secretase pathway giving rise to sAPPα production and secretion The latter is described to be 
neurotrophic and neuroprotective, and to be able to counteract Aβ toxicity. At the PM or upon internalization via the 
endocytic pathway, APP/CTFs can be cleaved by γ-secretase, giving rise to AICD and Aβ production. B. Upon Aβ 
exposure, abnormal Aβ-induced alterations of cytoskeleton networks occurs, i.e. increased F-actin polymerization and 
decreased α-tubulin acetylation (resulting in microtubule destability - represented by fragmented microtubule). These 
alterations on cytoskeleton dynamics lead to impaired APP vesicular trafficking and targeting. Consequently, sAPP and 
CTFs are intracellularly produced and accumulated in secretory vesicles, that do not reach PM. Decreased AICD 
production will hinder nuclear targeting, and potential inhibition of extracellular sAPPα secretion will contribute to 
progressive neurodegeneration. sAPPα was not directly measured in neurons, but this pathway is the most abundant 
under physiological conditions. Further, sAPPα was shown in the work herein presented to be highly retained in non-
neuronal cells. PM, Plasma membrane; SV, secretory vesicles; End, endocytic vesicles; ER, endoplasmic reticulum; MT, 
microtubule network. 
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5.3 THERAPEUTIC APPROACHES TARGETING Aβ-MEDIATED EFFECTS 
 
In the last decades, the treatment of AD patients focused mainly on symptomatical 
strategies. Nonetheless, improved knowledge of the mechanisms underlying AD 
pathology, in particularly the molecular causes and consequences of the disease, 
contribute to the development of novel therapeutic approaches. Considering that AD is a 
multifactorial disorder it is likely that combined therapeutic approaches will be most 
effective in future strategies for AD treatment. 
Early evidence indicated that fibrillar aggregates of Aβ are neurotoxic (Lorenzo and 
Yankner 1994; Grace et al. 2002). Nonetheless, other reports demonstrated that Aβ 
soluble oligomers and protofibrils are also neurotoxic and potentially a major cause of 
neurodegeneration in AD (Hartley et al. 1999; Chimon et al. 2007; Cerpa et al. 2008). 
Eventhough the neurotoxicity, with respect to the different forms of Aβ is controversial, 
effective therapeutics are being directed towards both oligomeric and fibrillar species of 
Aβ. Several novel therapeutic strategies are based in decreasing or inhibiting Aβ 
production, stimulating the clearance of aggregated Aβ or preventing the aggregation of 
Aβ into amyloid plaques. All these interventions congregate to find drugs that are 
effective in lowering Aβ levels in the brain, thus preventing Aβ-induced 
neurodegeneration. 
 
Prevention of isAPP retention by inhibiting Aβ fibril formation 
Due to the importance of Aβ aggregation on its neurotoxicity, in Chapter IV we 
evaluated the effect of Aβ aggregation on isAPP retention. Our data demonstrated that 
10 µM of Aβ aggregated, results in higher isAPP retention than 20 µM of freshly added 
Aβ (4.5 and 2 fold, respectively). These data are consistent with previous observations 
where Aβ neurotoxicity is related to its degree of fibrillization, the β-sheet structure and 
the size of the peptides (Lorenzo and Yankner 1994; Grace et al. 2002). 
The molecular mechanisms responsible for the passage of normal soluble Aβ forms to 
fibrils are not well understood, but it is known that Aβ binds several proteins that can 
modulate its aggregation or fibril state (Table 2, Chapter I).  
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Since Aβ aggregation and/or clearance may be dependent on its interacting proteins we 
evaluated if Aβ effects could be quenched by Aβ binding proteins - involved either in Aβ 
disaggregation or clearance. Among these are laminin and gelsolin, two proteins known to 
be involved either in preventing Aβ fibrillogenesis or in promoting disaggregation and 
clearance (Ray et al. 2000; Morgan et al. 2002). Consistent with previous observations, 
preceding Aβ co-incubation with these proteins led to a decrease in the aggregation state 
of the peptide, as revealed by the TH-T assay. Subsequent addition of Aβ-complexes to 
primary neuronal cultures lead to a reduced accumulation of isAPP when compared to 
aggregated Aβ alone. This is in agreement with the capacity of these proteins to bind Aβ 
and promote disaggregation or decrease Aβ levels. Further, the preformed laminin- or 
gelsolin-Aβ complexes might be inhibiting Aβ signaling and/or be intracellularly targeted 
for degradation, therefore preventing Aβ-induced isAPP retention. In agreement with the 
last hypothesis, peripheral expression of plasma gelsolin in an AD transgenic mouse 
model lead to reduced Aβ load in the brain (Hirko et al. 2007). Of note, the decreased 
intracellular sAPP accumulation in the presence of these proteins was accompanied by a 
slight decrease in neuronal apoptotic levels, indicative of the anti-apoptotic capacity of 
these Aβ binding proteins. 
At the secretory level, laminin was able to marginally increase sAPP extracellular 
secretion, thus partially reversing the Aβ inhibitory effect. Nonetheless, this reversion did 
not reach control levels. Laminin was previously shown to decrease APP secretion and to 
affect intracellular APP biogenesis and catabolism (Monning et al. 1995; Bronfman et al. 
1996). Likewise, gelsolin treatment also leads to a decrease in medium secreted sAPP. 
Another possible explanation for the diminished sAPP secretion even in the presence of 
these proteins, may be due to non-complexed Aβ, which is still available to block sAPP 
trafficking/secretion, particularly if laminin and gelsolin concentration are limiting factors. 
It is worth mentioning that the metabolism and clearance of both Aβ binding proteins is 
unclear, making it difficult to interpret the differences in extracellular and intracellular 
sAPP levels. Nonetheless the data here discussed points to a therapeutic potential for 
these proteins in terms of modulating Aβ induced effects on APP metabolism and 
subsequent neurotoxicity. 
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PP1 as a potential therapeutic target for Aβ-induced responses 
Of particular interest is the observation that altered signal transduction has been linked 
to the development of many neurodegenerative disorders, such as AD. Alterations in 
signal transduction cascades may be related to abnormal balance of protein kinases and 
phosphatases, which are key players in the reversible phosphorylation mechanism, 
involved in many cellular regulatory processes. Accordingly, abnormal activities of these 
proteins have been reported in AD brains (Gong et al. 1993; Jin and Saitoh 1995) when 
compared to normal aged controls.  Of note, is PP1, a Ser/Thr-phosphatase widely 
expressed in adult mammalian brain both in neurons and glia (da Cruz e Silva et al. 
1995b). Although ubiquitously expressed through the periphery, the three known 
catalytic subunits (PP1α, PP1β and PP1γ) are particularly abundant in mammalian brain, 
sustaining the importance of PP1 in brain function. Moreover, the cognitive decline 
observed in AD is thought to be related to the decrease in synaptic contacts (DeKosky 
and Scheff 1990; Terry et al. 1991), where PP1 plays a role since it is highly enriched in 
post-synaptic dendritic spines (Ouimet et al. 1995). PP1 was also shown to be involved in 
the control of LTD and synaptic plasticity (Morishita et al. 2001), as well as in aging-
related memory defects (Genoux et al. 2002), thereby influencing learning and memory. 
This places PP1 at the center of neuronal signaling cascades. Furthermore, many AD 
pathogenic alterations may be associated with abnormal phosphorylation events. For 
instance, abnormal Tau phosphorylation involves decreases in protein phosphatase 1 
(PP1) and phosphatase 2A (PP2A) activities (Bennecib et al. 2000; Liu et al. 2005). 
Moreover, APP processing can also be modulated by specific protein phosphatase 
inhibitors, resulting in increased sAPP secretion (da Cruz e Silva et al. 1995a). Thus 
protein phosphatases can modulate APP processing and consequent Aβ production. 
Adding complexity to the signaling cascades, Aβ was previously shown to induce 
alterations in PP1 intracellular levels (Amador et al. 2004), suggesting that Aβ can 
interfere with normal neuronal signaling events. Recently, Aβ oligomers were also shown 
to induce Tau hyperphosphorylation in hippocampal neurons (De Felice et al. 2008).  
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The abnormal phosphorylation of key proteins linked to AD and the possibility that Aβ 
mediated effects on APP metabolism may be associated with abnormal phosphorylation 
lead us to investigate the direct effect of this peptide on PP1. Our studies confirm the 
existence of an inhibitory effect on different PP isoforms directly provoked by Aβ both in 
vitro and in vivo. Additionally, and since aggregation of Aβ appears to be important for its 
neurotoxic properties, we investigated how Aβ aggregation affects PP1 activity. Fibril 
forms of Aβ peptides increased their inhibitory effect on PP1 activity. Hence, the 
abnormal production of Aβ in intracellular sites where PP1 is abundant may be sufficient 
to alter the equilibrium of phosphatase activities and lead to a set of abnormal signal 
transduction pathways. It therefore appears reasonable to conclude that PP1 may 
constitute an important physiological target for Aβ, and that physiological inhibition of 
PP1 activity by Aβ is likely to contribute to progressive neurodegeneration characteristic 
of AD. Nonetheless, since PP1 occurs in complexes with other proteins that confer it 
physiological specificity, the development of drugs targeting specific PP1 binding proteins, 
might constitute potential therapeutic agents for AD. 
 
 
 
 
 
 
 
 
 
 
 
Aβ biology and its contribution to AD   Chapter V 
 
Centro Biologia Celular  255 
Universidade de Aveiro 
 
CONCLUDING REMARKS 
The study of Aβ, often viewed as a neurotoxic peptide and the central culprit in AD, may 
in fact hold some important leads in terms of AD diagnostic and therapeutic advances. 
The work here described identified putative approaches for intervention. Defining, for the 
first time, isAPP retention at cytoskeletal-associated vesicles as a response to Aβ 
exposure brings the former proteolytic fragment to the centre stage of biomarkers in 
AD. The same experimental data set substantiates future efforts directed at finding 
putative therapeutic strategies in AD. These include identification of cytoskeletal–
associated and Aβ-clearance drugs, which may modulate Aβ downstream effects. 
The work carried out in this project also offers a molecular basis which may link the two 
neuropathological hallmarks in AD. Aβ can alter APP processing but can also affect signal 
transduction cascades; namely by interfering with protein phosphorylation processes. In 
the previous sections the consequences on APP metabolism was discussed, but Tau is 
phosphorylated in AD. Aβ via its effects on protein phosphatases may be a contributing 
factor to this hyperphosphorylation state, this deserves further investigation. 
Nonetheless, Aβ has the potential to be a common factor of pathological relevance which 
can contribute to the formation of amyloid plaques and NFTs. 
In closing, it has been rewarding to acknowledge that molecular and cellular studies are of 
direct relevance to Alzheimer´s disease, and provide the basis for future strategies in the 
fight against this debilititating disease. 
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Appendix I 
 
METHODS AND KITS 
 
(The medium and solutions composition used for the different techniques are listed on 
Appendix II). 
 
1. CELL CULTURE AND RAT PRIMARY CULTURES 
Cell culture maintenance 
Non-neuronal COS-7 cells (a monkey kidney cell line) were grown in complete DMEM 
medium supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin 
(Gibco).  
Neuronal-like PC12 cells (a rat pheochromocytoma cell line) were grown in RPMI 1640 
(Gibco) supplemented with 10% horse serum and 5% FBS, 100 U/ml penicillin and 100 
mg/ml streptomycin (Gibco).  
SH-SY5Y cells (a human neuroblastoma cell line) were grown in a 1:1 combination of 
minimum essential medium (MEM, Gibco) and Ham’s F12 medim (Gibco), supplemented 
with 10% FBS. 
All cultures were plated in 100 mm diameter plates or 6-well plates (35 mm diameter), 
and grown in a humidified incubator at 37 ºC and 5% CO2. Cells were subcultured 
whenever ∼95% confluence was reached.  
 
Rat cortical/hippocampal primary cultures 
Rat cortical neurons were isolated from cortex or hipoccampus of Wistar Hannover 18 
days rat embryos whose mother was killed by rapid cervical dislocation. After brain 
dissection, tissues were dissociated with trypsin (0.45 mg/ml for cortical cultures or 0.75 
mg/ml for hippocampal cultures) and deoxyribonuclease I (0.15 mg/ml) in Hank’s balanced 
salt solution (HBSS), supplemented with BSA (Merck), during 5-10 min at 37ºC. Cells 
were washed with HBSS supplemented with 10% FBS to stop trypsinization, centrifuged at 
1,000 rpm for 3 min, and further washed and centrifuged with HBSS for serum withdraw. 
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Cells pellet was ressuspended in complete Neurobasal medium, which is supplemented 
with 2% B27. Viability and cellular concentration were assessed by using the Trypan Blue 
excluding dye [0.4% Trypan Blue solution (Sigma)], and cells with (dead) or without 
(living) intracellular blue staining were counted in a hemocytometer chamber. Cellular 
viability was calculated and normally higher than 95%. These neuronal cells were plated 
onto 100 µg/ml poly-D-lysine pre-coated glass coverslips at a density of 1.0 x 105 
cells/cm2. Cells were maintained in 2 ml of complete Neurobasal medium and three and 
seven days after plating, 500 µl of cultured medium was replaced with 500 µl of fresh 
medium. Cultures were maintained in an atmosphere of 5% CO2 at 37ºC for 9 days, 
before being used for experimental purposes. 
 
 
Culture cells fixation and immunocytochemistry 
Fixation 
COS-7 and neuronal primary cells were grown in 1M HCl pre-treated glass coverslips 
pre-coated with 100 µg/ml poly-L-ornithine or poly-D-lysine, respectively. After the 
experimental procedures, cells were washed three times with 1 ml of the serum-free 
DMEM, after which 1 ml of a 1:1 DMEM/4% paraformaldehyde fixative solution was gently 
added and allowed to stand for 1-2 min. Subsequently, 1 ml of fixative solution was gently 
added for 25 minutes. Finally, cells were washed 3 times with PBS for 10 min, being ready 
for immunocytochemistry procedures or to be directly mounted on glass microscope 
slides for confocal microscopy analysis.  
 
Immunocytochemistry 
For immunocytochemistry procedures, a permeabilization step with methanol was taken 
(2 min at RT) and cells were immediately washed four times with PBS. Afterward, cells 
were incubated with primary antibody diluted in 3% BSA in PBS for 2-4 h at RT. The 
primary antibody was removed by washing the coverslips 3 times with PBS and a 
secondary antibody (also diluted in 3% BSA in PBS) was added for 2 h at RT. After 
washing 3 times with PBS the coverslips were mounted with one drop of the antifading 
reagent on a glass slide.  
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Labbeling of F-actin 
Following paraformaldehyde fixation cells were permeabilized with a solution of acetone 
at ≤-20 ºC for 3 min. After that, cells were washed 2 times with PBS and then incubated 
with PBS containing 1% BSA for 20 min. This blocking solution is removed and pallotoxin 
staining solution is then added to cells (1.5 U/100 µl in PBS containing 1% BSA) for 30 min 
at RT. After washing 3 times with PBS were mounted with one drop of the antifading 
reagent on a glass slide.  
 
2. PROTEINS MANIPULATION 
Protein assay kit (BCA, Pierce) 
Samples total protein measurements were performed with Pierce’s BCA protein assay kit, 
following the manufacturer’s instructions. The method combines the reduction of Cu2+ to 
Cu+ by protein in an alkaline medium (the biuret reaction) with a sensitive colorimetric 
detection of the Cu+ cation using a reagent containing bicinchoninic acid (BCA). The 
purple-coloured reaction product of this assay is formed by the chelation of two 
molecules of BCA with one Cu+ ion. This water-soluble complex exhibits a strong 
absorbance at 562 nm that is linear with increasing protein concentration over a working 
range of 20 µg/ml to 2000 µg/ml.  
 
Working Reagent (W.R.) 
The W.R. was prepared by mixing X ml of BCA reagent A with Y ml of BCA reagent B in 
the proportion of 50:1.  
 
Samples preparation 
A microtube per sample was prepared to be assayed with 25 µl of each sample plus 25 µl 
of the solution in which the sample was collected (1% SDS).  
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Standard curve 
Microtubes with standard protein concentrations were prepared as described below 
(Table 1).  
 
Table 1 – Standards used in the BCA protein assay method. BSA, Bovine serum albumin solution (2 mg/ml). 
Standard BSA (µl) 10% SDS (µl) H2O (µl) Protein mass (µg) W.R. (ml) 
P0 - 5 45 0 1 
P1 1 5 44 2 1 
P2 2 5 43 4 1 
P3 5 5 40 10 1 
P4 10 5 35 20 1 
P5 20 5 25 40 1 
P6 40 5 5 80 1 
 
Incubation and absorbance measurement 
1 ml of W.R. was rapidly added to each microtube (standards and samples) and the 
microtubes were incubated at 37 ºC exactly for 30 min. Tubes cool to RT and 
immediately measure their absorbance at 562 nm.  
 
Samples concentration 
A standard curve is prepared by plotting BSA standard absorbance vs. BSA concentration, 
and used to determine the total protein concentration of each sample. 
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SDS-PAGE (for Western blotting) 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) separations were carried out using 
well established methods (Laemmli, 1970), where proteins are separated by their 
molecular weight and negative net charge due to SDS-amino acid binding. The gels 
percentage and size chosen depend on the molecular weight of the proteins to be 
separated in the gel. Gels were prepared by mixing several components (Appendix I). The 
resolving gel solution was immediately and carefully pipetted down the spacer into the gel 
sandwich, leaving free space for the stacking gel. Water was carefully added to cover the 
top of the gel and the gel was allowed to polymerize for 1 h. Stacking gel solution was 
prepared according to Appendix I. The water was poured out and the stacking gel was 
added to the gel sandwich; a comb was inserted and the gel allowed to polymerize for 1 
h. In parallel, samples were prepared by adding to the protein sample solution ¼ volume 
of 4X LB (Loading Buffer). Samples microtubes were boiled and spinned down, the combs 
removed and the gels wells filled with Tris-Glycine running buffer. The samples were 
carefully loaded into the wells, and electrophoretically separated using a 90 mA electric 
current. Molecular weight markers (Kaleidoscope Prestained Standards or Prestained 
SDS-PAGE Standards – Broad Range, Bio Rad) were also loaded and resolved side-by-side 
with the samples. 
 
Proteins electrotransfer 
Through the Western Blotting technique, proteins that were electrophoretically 
separated by SDS-PAGE can be transferred to membranes (nitrocellulose membranes, for 
instance), while keeping their positions. 3MM blotter papers and a nitrocellulose 
membrane were used to build up the transfer sandwich. The gel was removed from the 
electrophoresis device and the stacking gel discarded. A transfer sandwich was assembled 
under transfer buffer, in the following order: sponge, 3MM blotter paper, gel, 
nitrocellulose membrane, 3MM paper, sponge. The cassette was placed in the transfer 
device, previously filled with transfer buffer, oriented so that the negatively charged 
proteins migrate towards the anode. Electrotransfer was allowed to proceed for 18 h at 
200 mA, after what the membrane was allowed to dry on a clean paper. 
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Immunoblot analysis 
After proteins electrotransfer, the nitrocellulose membranes could be used immediately, 
and membranes were initially soaped in 1X TBS for 10 min. Blocking of possible non-
specific binding sites of the primary antibody was performed by immersing the membrane 
in 5% (w/v) non-fat dry milk in 1X TBST solution for 1-4 h. Further incubation with 
primary antibody was carried out for the specified times, ranging from 2 h to overnight 
incubation at 4 ºC with agitation. After three washes with 1X TBS-T, of 10 min each, the 
membrane was further incubated with the appropriate secondary antibody for 2 h with 
agitation. All primary and secondary antibodies used were diluted in 1X TBS-T/non-fat 
dry milk (3% w/v). Membranes were additional washed three times with 1X TBST, before 
being submitted to one of the following detection methods: 
 
Enhanced chemiluminescence detection (ECL and ECL plus Kits, Amersham 
Pharmacia) 
ECLTM Western blotting from Amersham Pharmacia Biotech is a light emitting non-
radioactive method for detection of immobilised specific antigens, conjugated directly or 
indirectly with horseradish peroxidase-labelled antibodies (Fig. 1). 
 
Fig. 1. The ECL analysis system detects the presence of an antibody labelled with horseradish peroxidase by catalysing 
the oxidation of luminol, leading to the emission of light, which can be detected by an autoradiography film (From the 
manufacturer datasheet). 
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The membrane was incubated for 1 min at RT with the ECL detection solution or for 5 
min with the ECL+ detection solution. These solutions were prepared fresh following the 
manufacturer’s instructions. ECL/ECL+ detection solution in excess was drained by 
touching the edge of the membrane against tissue paper and the membrane was gently 
wrapped in cling-film, eliminating all the air bubbles. In a dark room, an autoradiography 
film (XAR-5 film, Kodak, Sigma Aldrich) was placed on the top of the membrane, inside a 
film cassette. The cassette was closed and the blot exposed for an appropriate period of 
time. The film was then removed and developed in a developing solution (Kodak, Sigma 
Aldrich), washed in water, and fixed in a fixing solution (Kodak, Sigma Aldrich).  
 
 Table 1. List of the antibodies used and specific dilutions for each assay. 
Target Protein Primary Antibody Assay/Dilution 
APP/sAPP 22C11 (Boehringer) 
WB/1:250 
IF/ 1:50 
APP/CTFs Anti-β-APP (Zymed) WB/1µg/ml 
IF/ 2.5µg/ml 
APP/sAPPα/Aβ 6E10 (Sigma) WB/1:1000 
IF/ 1:200 
APP751/770/sAPP751/770 KPI (Chemicon) 
WB/1:1000 
IF/ 1:200 
APP/CTFα/Aβ 4G8 (Chemicon) WB/1:1000 
IF/ 1:200 
Actin Actin (Stressgen) WB/1:1000 
ER Calnexin (Stressgen) 
WB/1:500 
IF/1:200 
Fe65 Fe65, clone 3H6 (Upstate) 
WB/1:5000 
IF/1:500 
GSk3 total Glycogen synthase kinase 3 (Chemicon) WB/1:1000 
Histone 4 Histone H4 (Santa Cruz Biotechnology) WB/1:200 
HSP70 HSP70 (Stressgen) WB/1:10000 
KLC KLC (Santa Cruz Biotechnology) 
WB/1:1000 
IF/ 1:200 
Pan- cadherin Pan-cadherin (Abcam) WB/1:200 
Rab5 Rab5 (Stressgen) IF/1:400 
Syntaxin 6 Syntaxin 6 (BD Biosciences) WB/1:350 
Acetylated α-Tubulin Acetyated α-tubulin (Zymed) 
WB/1µg/ml 
IF/1µg/ml 
β-tubulin β-tubulin (Zymed) WB/1:5000 
   WB - Western blotting 
 
 IF - Immunofluorescence 
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Subcellular fractionation 
For subcellular fractionation the Calbiochem ProteoExtract Subcellular Proteome 
Extraction Kit was used. It allows subcellular extraction of proteins according to their 
subcellular localization, i.e. from the cytosolic, organelle and membrane, nuclear and 
cytoskeletal fractions. It takes advantage of the differential solubility of proteins in 
different subcellular compartments and utilizes highly specialized extraction buffers to 
target specific subcellular compartments and simultaneously preserve the structural 
integrity of the proteins before and during each sequential extraction. 
As the extraction buffers contain components that might interfere with protein 
quantification, each fraction was overnight precipitated with acetone, centrifuged 15 min 
at 15 000 g, ressuspended in SDS1% and normalized for protein content using BCA assay. 
 
Protein silver stain 
Silver staining is one of the procedures available for detecting proteins separated by gel 
electrophoresis. Switzer et al., introduced silver staining in 1979, a technique that today 
provides a very sensitive tool for protein visualization with a detection level down to the 
0.3-10 ng level (Switzer et al. 1979). The basic mechanisms underlying silver staining of 
proteins in gels are relatively well understood. Basically, protein detection depends on the 
binding of silver ions to the amino acid side chains, primary the sulfhydril and carboxiyl 
groups of proteins (Switzer et al. 1979; Oakley et al. 1980; Merril et al. 1981; Merril et al. 
1986), followed by reduction to free metallic silver (Rabilloud, 1990; Rabilloud, 1999). The 
proteins are visualized as bands where the reduction occurs and, as a result, the image of 
protein distribution within the gel is based on the difference in oxidation-reduction 
potential between the gel’s area occupied by proteins and the free adjacent sites.  
Protein silver was performed according to the protocol adapted from Blum et al. (1987). 
This protocol stain is useful for protein concentrations ranging from <1ug to >1ng. 
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Gel staining protocol: Everything Fresh!  
 
 
 
 
 
 
 
 
 
 
 
 
3. MEASUREMENT OF PROTEIN PHOSPHATASE ACTIVITY 
Sample and Substrate preparation 
Peptide stock solutions were diluted in inhibitor buffer, just before use. PP1 catalytic 
subunits were diluted in phosphatase buffer. 
 
“In vitro” assay 
Effects of all peptides on purified PP1 isoforms activity were assessed using 32P-
phosphorylase a and (myelin basic protein) MyBP as substrates. The preparation of 
substrate and the assays using 32P-MyBP were done as described by the phosphatase kit 
supplier (Neb). 32P-phosphorylase a was prepared from phosphorylase b using [γ-32P]ATP 
and phosphorylase kinase as previously described in MacKintosh reference.  
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PP1 catalytic subunits were incubated with previously prepared peptides for 5 min at 30 
ºC. The reaction started with the addition of 32P-phosphorylase a (3 mg/ml) to a final 
volume of 30 µl. After 10 min, 100 µl of ice-cold 20% (w/v) TCA were added and the 
mixture centrifuged at 12000 g for 2 min at room temperature. The 32P-phosphate 
released into the supernatant was measured in a scintillation counter. The control 
phosphatase activity was 10-20% of total substrate radioactivity to ensure linearity. For 
each peptide, an appropriate range of concentrations was used, and the IC50 calculated 
using the BioDataFit 1.02 software.  
 
“In vivo” assay 
PC12 cells were plated in poly-L-ornithine coated dishes at a density of 5x105cells/cm2 
and washed twice with serum free medium prior Aβ25-35 treatments.  Cells were exposed 
to 20 or 50 µM Aβ during 2 or 24 h in serum-free medium. After incubation cells were 
washed twice in cold Tris-HCl/EDTA buffer and ressuspended in homogenizing buffer. 
The total phosphatase activity of the control and Aβ-pre-incubated cell extracts was 
determined by reacting the appropriate dilution in phosphatase buffer with 32P-
phosphorylase a. The PP2A activity was determined by pre-incubating the same dilution of 
cell extracts with 200 nM of I2 for 15 min at 30 ºC before adding the substrate. The PP1 
activity in the cell extracts was calculated as the total phosphatase activity minus the 
PP2A activity towards 32P-phosphorylase a. 
 
4. RNA EXTRACTION  
Solutions/plastic material used for this RNA extraction was done/treated with Nuclease-
Free Water (DEPC- treated H20). 
 
Isolation of total RNA from monolayer cells  
Total RNA extraction was performed according to TRI ReagentTM (Sigma) protocol. COS-
7 cells were plated in the day before RNA extraction at a density of (2.0x106 cells). For 
primary neuronal cultures cells were plated at a density of (3.0x106 cells). Following 
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extraction samples were used either for analysis of APP expression levels (Northern blot) 
or for analysis of the APP isoform pattern (RT-PCR). 
 
Sample preparation 
Cells were directly lysated on the culture dish, using 1 ml of the TRI REAGENT per 10 
cm2 of glass culture plate surface area. After addition of the reagent, the cell lysate was 
passed several times through a pipette to form a homogenous lysate. After 
homogenization, homogenate is centrifuged at 12.000 g for 10 min at 4ºC to remove 
insoluble material (extracellular membranes, polysaccharides, and high molecular weight 
DNA). The supernatant contains RNA and protein. The clear supernatant was transferred 
to a fresh tube. To ensure complete dissociation of nucleoprotein complexes, samples 
stand for 5 minutes at room temperature, and then 0.2 ml of chloroform per ml of TRI 
REAGENT was added. After, shake vigorously for 15 seconds and allow to stand for 2-15 
min at room temperature, samples were centriguged at 12.000 g for 15 min at 4 ºC. 
Centrigugation separates the mixture into 3 phases: a red organic phase (containing 
protein), an interphase (containing DNA), and a colorless upper aqueous phase 
(containing RNA). 
 
RNA Isolation 
The aqueous phase was then transferred to a fresh tube and added 0.5 ml of isopropanol 
per ml of TRI REAGENT (used in Sample Preparation). After mixing, samples stand for 5-
10 minutes at room temperature, and were then centrifuged at 12.000 g for 10 minutes at 
4 ºC. The RNA precipitate forms a pellet on the side and bottom of the tube. Then, 
supernatant was removed and the RNA pellet washed by adding 1 ml (minimum) of 75% 
ethanol per 1 ml of TRI REAGENT (used in Sample Preparation). Samples were vortexed 
and then centrifuge at 7,500 x g for 5 minutes at 4 ºC. After briefly dry of the pellets for 
5-10 min under vacuum, the RNA pellets were dissolved in RNAse free water and if not 
used immediately stored at -70 ºC. 
The final preparation of RNA is free of DNA and proteins if 260/280 ratio is ≥1.7. 
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Electrophoretic analysis of RNA 
An agarose gel was prepared by melting the appropriate amount of agarose in water, 
cooling it to 60ºC, and adding 5X formaldehyde gel-running buffer and formaldehyde to 
produce a final concentration of 1X and 2.2M, respectively. The gel was then cast in a 
chemical hood and allowed to set for 30 min at room temperature. 
The RNA samples were prepared by mixing the following components in a sterile 
microtube: 
 - RNA (≈10µg)    4.5 µl 
 - 5X formaldehyde gel-running buffer 2.0 µl 
 - 17.5% formaldehyde   3.5 µl 
 - 50% formamide    10.0 µl 
 
The samples were incubated for 15 min at 65ºC, chilled on ice and centrifuged to deposit 
all of the fluid in the bottom of the tubes. Before applying the samples the gel was pre-run 
for 5 min at 5V/cm submerged in 1X formaldehyde gel-running buffer. After loading the 
samples the gel was run at 3V/cm for 4h.  
 
Northern blot analysis 
Probe isolation - The DNA to be labelled was cut with the appropriate restriction 
enzymes in order to release the appropriate fragment, which will allow the detection of 
APP mRNA. Then the fragments were separated by electrophoresis on 1.5% low melting 
agarose. After staining the gel in ethidium bromide (0.2 µg/ml) for 30 min, the desired 
band was cut out of the gel and placed in a pre-weighted microtube. After, 3 ml of dH2O 
were added per gram of gel slice and placed in a boiling water bath for 7 min. The sample 
was stored at –20ºC. Prior to using the DNA in a labelling reaction the DNA was 
denatured by boiling for 10 min and kept at 37ºC. 
 
Labelling reaction - 25 ng of template DNA was dissolved in a final volume of 8 µl dH2O 
and denatured in a boiling water bath for 3 min. Then, the following components were 
added to the DNA: 4 µl of High Prime reaction mixture (Roche) containing random 
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primer mixture, Klenow polymerase and reaction buffer followed by 1 µl of dATP, 1 µl of 
dGTP and 1µl of dTTP and 5µl (50µCi) [α32P]dCTP (3000Ci/mmol). This mixture was 
incubated for 2 h at 37ºC. The reaction was stopped by adding 2 µl 0.2 M EDTA (pH 8.0) 
and gelsolining at 65ºC for 10 min. 
 
Probe purification - Stratagene’s NucTrap probe purification columns were used to 
rapidly separate unincorporated nucleotides from the radiolabeled DNA, according to the 
manufacturer’s instructions.  
 
Membrane hybridization - ExpressHyb Solution Clontech was warmed at 65ºC to 
completely dissolve any precipitate. The membrane was rehydrated in DEPC-H20 and 
then prehybridized in 10 ml of ExpressHyb Solution with continuous shaking at 68ºC for 
5 h. Meanwhile, the radioactively labelled DNA probe was denatured at 100ºC for 5 min 
and chilled on ice. After, the ExpressHyb Solution was replaced with the fresh solution 
containing the radiolabeled probe and the membrane was incubated overnight. 
The blot was then rinsed at 65ºC in solution I (2X SSC/ 0.05% SDS), 2 times for 10 min 
plus 1 time for 20 min.  Then, 2 washes with Solution I at 50ºC for 30min were 
performed. Finally, the blot was covered with plastic wrap and exposed for 3 days in using 
an autoradiography film (XAR-5 film, Kodak, Sigma Aldrich). The film was then developed 
and fixed with the appropriate solutions.  
 
RT-PCR (reverse transcriptase polymerase chain reaction) analysis 
RT-PCR analyses were performed using the ProSTARTM Ultra HF RT-PCR system 
(Stratagene), which is a two-step system designed for high-fidelity, high-efficiency cDNA 
synthesis and PCR. First, cDNA is synthesized from total RNA in a reaction primed with 
oligo(dT) primer. Second, a portion of the cDNA synthesis reaction is transferred to a 
new tube and then amplified by PCR using APP isoform specific primers. PCR 
amplification was achieved by employing PfuTurbo® DNA polymerase. This system can 
amplify cDNA of 0.1-8 Kb in length synthesized from 10-500 ng of total RNA.  
 
Aβ biology and its contribution to AD   Appendix 
 
278          Centro Biologia Celular 
                                                                                                                    Universidade de Aveiro 
 
cDNA synthesis and RT-PCR 
cDNA synthesis - The control and experimental reactions were prepared by adding the 
following components to separate microtubes in order: 
5.9 µl RNase-free water (not DEPC-treated water) 
1.0 µl 10X StrataScript RT buffer (Strategene) 
 0.6 µl oligo(dT) primer (100 ng/µl) 
1.0 µl dNTP mix (40 mM) 
 1.0 µl RNA (100 ng) or 1.0 µl control mRNA 
 
Reactions were incubated at 65ºC for 5min and then cooled at RT for 5min to allow the 
primers to anneal to the RNA. After, 0.5 µl of StrataScript Reverse Transcriptase 
(20U/µl) were added to each reaction. The tubes were incubated for 30 min at 42ºC. At 
the end the completed first-strand cDNA synthesis reactions were placed on ice for 
subsequent use in the PCR amplification.  
 
PCR amplification – controls and experimental condition were preparing by adding the 
following components to separate microtubes in order: 
41.0 µl RNase-free water (not DEPC-treated water) 
5.0 µl 10X Ultra HF PCR buffer 
 1.0 µl dNTP mix (40mM) 
 1.0 µl of upstream primer (100 ng/µl) or 0 µl for negative control 
 1.0 ml of downstream primer (100 ng/µl) or 0 µl for negative control 
 1.0 µl of experimental first-strand cDNA reaction 
 1.0 µl of PfuTurbo DNA polymerase (2.5 U/µl) 
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The PCR conditions were as follows:  
95ºC, 5 min 
95ºC, 30 sec 
60ºC, 30 sec        40 cycles 
68ºC, 1 min 
 68ºC, 10 min 
 
PCR products were run in a 2% agarose gel containing 2 µg/ml of ethidium bromide, and 
further analyzed using Quantity One quantitation software (Bio-Rad). 
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Appendix II 
 
REAGENTS AND SOLUTIONS 
 
1. CELL CULTURE AND RAT PRIMARY NEURONAL CULTURES 
Cells seeding and maintenance  
 
 DMEM medium (COS-7 cells) 
For a final volume of 1 L, dissolve one pack of DMEM powder (with L-glutamine and 4500 
mg glucose/L, Gibco) in deionised H2O and add: 
- NaHCO3 (Sigma)     3.7 g 
adjust to pH 7.4  and before sterilizing add: 
- Fetal Bovine Serum (FBS) (Gibco)   100 ml (10% v/v) 
 
 RPMI 1640 medium (PC12 cells) 
For a final volume of 1 L, dissolve one pack of RPMI 1640 powder (with L-glutamine and 
4500 mg glucose/L, Gibco) in deionised H2O and add: 
- NaHCO3 (Sigma)     0.85 g 
adjust to pH 7.4  and before sterilizing add: 
- Fetal Bovine Serum (FBS) (Gibco)   50 ml (5% v/v) 
- Horse Serum (HS) (Gibco)    100 ml (10% v/v) 
 
 MEM:Ham´s F12  medium (SH-SY5Y cells) 
1:1 combination of minimum essential medium (MEM) and Ham’s F12 medim. 
 For a final volume of 1 L of deionised H2O add: 
 - MEM 
- Ham´s F12 
- NaHCO3 (Sigma)     1.5 g 
- Na       0.055 g 
- L-glutamine      2 mM 
- Non-essential aminoacids    0.1 mM 
adjust to pH 7.4  and before sterilizing add: 
- Fetal Bovine Serum (FBS) (Gibco)   100 ml (10% v/v) 
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Notes:  
- Prior to pH adjustment add 100 U/ml penicillin and 100 mg/ml streptomycin [10 ml 
Streptomycin/ Penicilin/ Amphotericin solution (Gibco)]. 
- Sterilize all mediums by filtering through a 0.2 µm filter and store at 4 ºC.  
- FBS and HS were heat-inactivated for 30 min at 56 ºC.  
 
 
 PBS (1x) 
For a final volume of 500 ml, dissolve one pack of BupH Modified Dulbecco’s Phosphate 
Buffered Saline Pack (Pierce) in deionised H2O. Final composition: 
- Sodium Phosphate      8 mM 
- Potassium Phosphate    2 mM 
- NaCl                 140 mM 
- KCl                 10 mM 
Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
 
 Complete Neurobasal medium (Cortical primary cultures) 
This serum-free medium (Neurobasal; Gibco, BRL) is supplemented with: 
- B27 supplement (Gibco, BRL)   2% 
- L-glutamine (Gibco, BRL)    0.5 mM  
- Gentamicine (Gibco, BRL)    60 µg/ml  
- Phenol Red (Sigma Aldrich, Portugal)  0.001% 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
 
 Complete Neurobasal medium (Hippocampal primary cultures) 
This serum-free medium (Neurobasal; Gibco, BRL) is supplemented with: 
- B27 supplement (Gibco, BRL)   2% 
- L-glutamine (Gibco, BRL)    0.5 mM  
- L-glutamate (Gibco, BRL)    25 µM  
- Gentamicine (Gibco, BRL)    60 µg/ml  
- Phenol Red (Sigma Aldrich, Portugal)  0.001% 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
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 Hank’s balanced salt solution (primary neuronal cultures) 
This salt solution is prepared with deionised H2O. Final composition: 
- NaCl       137 mM  
- KCl       5.36 mM  
- KH2PO4        0.44 mM 
- Na2HPO42H2O      0.34 mM 
- NaHCO3       4.16 mM 
- Glucose      5 mM 
- Sodium pyruvate     1 mM 
- HEPES      10 mM 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
Cells fixation and Imunocytochemistry 
 1 mg/ml Poly-L-ornithine solution (10x) (COS-7 cells) 
To a final volume of 100 ml, dissolve in deionised H2O 100 mg of poly-L-ornithine (Sigma-
Aldrich, Portugal).  
 
 10 mg/ml Poly-D-lysine stock (100x) (rat primary neuronal cultures) 
To a final volume of 10 ml, dissolve in deionised H2O 100 mg of poly- D-lysine (Sigma-
Aldrich).  
 
 Borate buffer (at primary neuronal cultures) 
To a final volume of 1 L, dissolve in deionised H2O 9.28 g of boric acid (Sigma-Aldrich). 
Adjust to pH 8.2, sterilize by filtering through a 0.2 µm filter, and store at 4 ºC. 
 
 Poly-D-lysine solution (neuronal cells) 
To a final volume of 100 ml, dilute 1 ml of the 10 mg/ml poly-D-lysine stock solution in 
borate buffer.  
 
 4% Paraformaldehyde Fixative solution 
For a final volume of 100 ml, add 4 g of paraformaldehyde to 25 ml deionised H2O. 
Dissolve by gelsolining the mixture at 58 ºC while stirring. Add 1-2 drops of 1 M NaOH 
to clarify the solution and filter (0.2 µm). Add 50 ml of 2X PBS and adjust the volume to 
100 ml with deionised H2O. 
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2. PROTEINS MANIPULATION 
SDS-PAGE 
 LGB (Lower gel buffer) (4x) (1 L) 
- Tris       181.65 g 
- SDS       4 g 
Shake until the solutes have dissolved. Adjust the pH to 8.9 with HCl and adjust the 
volume to 1 L with deionised H2O. 
 
 UGB (Upper gel buffer) (5x) 
Per litre, to 900 ml of deionised H2O add 75.7 g of Tris base. Shake until the solute has 
dissolved. Adjust the pH to 6.8 with HCl and adjust the volume to 1 L with deionised 
H2O. 
 
 30 % Acrylamide / 0.8 % Bisacrylamide solution 
Per 100 ml, to 70 ml of deionised H2O add: 
- Acrylamide      29.2 g  
- Bisacrylamide     0.8 g 
Shake until the solutes have dissolved. Adjust the volume to 100 ml with deionised H2O. 
Filter through a 0.2 µm filter and store at 4 ºC. 
 
 10 % APS (ammonium persulfate) 
In 10 ml of deionised H2O dissolve 1 g of APS. Note: prepare fresh before use. 
 
 10 % SDS (sodium dodecilsulfate) 
In 10 ml of deionised H2O dissolve 1 g of SDS. 
 
 Loading (sample) buffer (4x) (10 ml) 
- 1M Tris  solution (pH 6.8)   2.5 ml (250 mM) 
- SDS      0.8 g (8%) 
- Glicerol     4 ml (40%) 
- β-Mercaptoetanol    2 ml (2%) 
- Bromofenol blue    1 mg (0.01%) 
Adjust the volume to 10 ml with deionised H2O. Store in darkness at RT. 
 
 1 M Tris (pH 6.8) solution 
For a final volume of 250 ml, dissolve 30.3 g of Tris base in 150 ml of deionised H2O, 
adjust pH to 6.8, and adjust final volume to 250 ml.  
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 Running buffer (10x) (1 L) 
- Tris      30.3 g (250 mM) 
- Glycine     144.2 g (2.5 M) 
- SDS      10 g (1%) 
Dissolve in deionised H2O, adjust pH to 8.3, and adjust volume to 1 liter.  
 
 Resolving (lower) gel solution (60 ml) 
7.5%  5%     and     20% for gradient gels 
- H2O     29.25 ml 17.4 ml         2.2 ml 
- 30% Acryl/0.8% Bisacryl solution 15.0 ml 5 ml             20 ml 
- LGB (4x)    15.0 ml  7.5 ml          7.5 ml 
- 10% APS    300 µl  150 µl          150 µl 
- TEMED    30 µl  15 µl          15 µl 
 
 Stacking (upper) gel solution (20 ml)  3.5% 
- H2O      13.2 ml 
- 30% Acryl/0.8% Bisacryl solution  2.4 ml 
- UGB (5x)     4.0 ml 
- 10% SDS     200 µl 
- 10% APS     200 µl 
- TEMED     20 µl 
 
Western Blotting 
 Electrotransfer buffer (1x) 
Per litre, to 700 ml of deionised H2O add:  
- Tris      3.03 g (25 mM) 
- Glycine      14.41 g (192 mM) 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 800 
ml with deionised H2O. Just prior to use add 200 ml of methanol (20%). 
 
 TBS (Tris Buffered Saline) (10x) 
Per litre, to 700 ml of deionised H2O add  
- Tris      12.11 g (10 mM) 
- NaCl      87.66 g (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised H2O. 
 
 
 
 
Aβ biology and its contribution to AD   Appendix 
 
286          Centro Biologia Celular 
                                                                                                                    Universidade de Aveiro 
 
 TBS-T (Tris Buffered Saline + Tween) (10x) 
For a final volume of 1 L, to 700 ml of deionised H2O add  
- Tris      12.11 g (10 mM) 
- NaCl      87.66 g (150 mM) 
- Tween 20      5 ml (0.05%) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised H2O. 
 
 Blocking solution (100 ml) 
- TBS-T stock solution (10x)   10 ml 
- non-fat milk (dry powder)   5 g 
Dissolve in deionised H2O and adjust volume to 100 ml.  
 
 Antibody solution (25 ml) 
- TBS-T stock solution (10x)   2.5 ml 
- non-fat milk (dry powder)   0.75 g 
Dissolve in deionised H2O and adjust volume to 25 ml. Add antibody, mix gently without 
vortex, and store at -20 ºC. 
 
 Alkaline Phosphatase (AP) Reaction Solution (1 L) 
- Tris-HCl (pH 9.5)     12.11 g (100 mM) 
- NaCl      5.85 g (100 mM) 
- MgCl2      1.02 g (5 mM) 
Dissolve Tris base in deionised H2O and adjust solution to pH 9.5 with HCl. Dissolve the 
other solutes and adjust volume to 1 L. 
 
 AP Stop Solution (1 L) 
- Tris-HCl (pH 9.5)    2.42 g (20 mM) 
- EDTA     1.86 g (5 mM)   
Dissolve Tris in deionised H2O and adjust with HCl to pH 9.5. Add EDTA after and adjust 
volume to 1000 ml. 
 
 Membranes Stripping Solution (500 ml) 
- Tris-HCl (pH 6.7)    3.76 g (62.5 mM) 
- SDS      10 g (2%) 
- β-mercaptoethanol    3.5 ml (100 mM)  
Dissolve Tris and SDS in deionised H2O and adjust with HCl to pH 6.7. Add the 
mercaptoethanol and adjust volume to 500 ml.  
      
 
 
 
